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ABSTRACT 
Transient ischaemic attack (TIA) is associated with a high early risk of stroke which can 
be considerably reduced by early initiation of secondary preventive drugs including 
antiplatelets, statins and blood pressure lowering therapy. These treatments are usually 
initiated by a specialist after urgent out-patient review. However, variable access to timely 
specialist services means that initiation of these treatments is delayed for some patients. 
 
The purpose of this thesis was to evaluate the cost-effectiveness of GP initiation of 
treatment following a suspected TIA compared with UK clinical practice. A Markov 
model was constructed to model the cost and effectiveness of urgent initiation of treatment 
following suspected diagnosis of TIA by GPs. In the base-case, GP initiation of treatment 
(followed by specialist review of treatments within a week) was compared with best 
practice, as stated in the National Stroke Strategy (2007).  
 
Strategies involving same-day GP initiation of treatment was found to be highly cost-
effective at willingness to pay thresholds typically applied in the UK.  
 
This study illustrates the usefulness of modelling techniques to use secondary data sources 
to examine a policy relevant question around treatment urgency in a susceptible and 
identifiable group of patients where primary research is impracticable.  
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PREFACE 
 
The theme of this research (that also gives this thesis its title) reflects an identified research 
priority area within the UK NHS, preceding my involvement with the project. In 2006 the 
University of Birmingham’s TIA steering group1 made a successful funding application to 
the NIHR Service Delivery Organisation (SDO) to undertake research into the area. This 
culminated in the publication of an economic modelling project, looking at the role and 
capacity for rapid access clinics within the area. Part of the initial grant included funding 
for a PhD, to develop the research further. I was present in the latter stages of the TIA 
steering group meetings, but not involved in the development or dissemination of the 
results of that economic model. While this piece of work stands alone, it was also prepared 
in response to how that report was received, what recommendations to future research it 
made, and what research gaps it identified. 
  
                                                   
 
1
 The TIA steering group was led by Professor Jonathan Mant, now at the University of Cambridge. The group was 
composed of a clinically trained Professor in Public Health, an academic GP and several Health Economists 
(including Dr Pelham Barton, Reader in mathematical modelling). 
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CHAPTER 1: INTRODUCTION 
 
service innovation: some combination of alternative sites of care or 
caregivers and new care processes, often enabled by new information or 
clinical technologies (The King's Fund, 2013)  
1.1. Outline 
The focus of this thesis is on a service innovation in stroke prevention. This chapter 
provides a précis of what Transient Ischaemic Attack is, how it is managed, and the 
relevance of Economics. Preliminary research questions are identified and the structure of 
the thesis is then described. 
1.2. Background 
Stroke is a major cause of both mortality (about one-third of patients do not survive) and 
morbidity in the UK, accounting for about 11% of all deaths in England and Wales, and 
costing the NHS in England about £2.8 billion per year in direct care costs (Mant et al., 
2004). 
 
It is known that many strokes are preceded by temporary interruptions of the blood supply 
to the brain known as transient ischaemic attack (TIA), which therefore provide an early 
warning signal for stroke (Mant et al., 2004). In particular, the risk of having a stroke is 
especially elevated in the few days (estimated to be up to 10% at 7 days) following TIA 
(Giles and Rothwell, 2007a). However, stroke is increasingly a preventable disease and 
treatments exist to prevent recurrent stroke in populations who have had TIA.  
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General Practitioners play a key role in the management of TIA. Often, they will be the 
first point of contact for patients seeking health care following an event, so being able to 
identify TIA correctly ensures that patients are managed appropriately. Guidance suggests 
that GPs can prescribe low-dose aspirin but the main recommendation is for urgent referral 
to a specialist TIA clinic for assessment and recommendations for treatment (Lasserson, 
2013). This thesis explores the role of GPs in the management of TIA, and considers 
whether the current model by which patients are identified and treated is optimal. The 
economic perspective is instructive in deciding what is optimal. 
 
Economic perspective 
Population growth and pharmaceutical innovation has meant that more people are living 
longer and expect greater and higher quality care from their health care providers. Yet the 
budget for health care (funded in the UK by central taxation) is finite. In the face of 
resource scarcity and increased demand the economic perspective provides a possible 
solution for identifying the most efficient use of resource. 
 
1.3. Thesis structure 
Chapter 2 details the Current approach to stroke prevention in the UK, including the role 
of the GP in the management of TIA. 
Chapter 3 considers the economic impact of stroke and its management. This chapter 
presents an analytical framework for determining the most efficient model of service 
delivery. 
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Chapter 4 provides a critical review of economic modelling studies in the disease area. An 
overview of the modelling methods used in each of the papers is provided in order to 
inform the structure and development of the decision model to be developed. 
Chapter 5 begins by presenting the aims and objectives of the thesis. It then presents the 
methods for structuring and populating the decision model.  
Chapter 6 is a narrative review of the diagnostic accuracy of GP diagnosis in TIA.  
Chapter 7 reports the results from the decision model.  
Chapter 8 provides discussion of this thesis’ contributions, limitations and 
recommendations to future research. 
Concluding thoughts are presented in Chapter 9. 
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CHAPTER 2: CURRENT APPROACHES TO STROKE PREVENTION IN THE 
UK 
2.1. Introduction 
Stroke is a major cause of both mortality (about one-third of patients do not survive) and 
morbidity in the UK, accounting for about 11% of all deaths in England and Wales, and 
costing the NHS in England about £2.8 billion per year in direct care costs (Mant et al., 
2004). However, stroke is increasingly a preventable disease and treatments exist to 
prevent recurrent stroke in populations who have had Transient Ischaemic Attack (TIA) 
(sometimes referred to as a ‘mini’ stroke) and minor stroke. A number of European studies 
recently have reported substantial reductions in stroke recurrence following the 
introduction of rapid access clinics for assessing and treating patients with TIA and minor 
stroke.  
 
It is known that many strokes are preceded by TIA, and as such TIA is often cited as an 
‘early warning signal’ for stroke (Rothwell et al., 2007). In particular the risk of having a 
stroke is especially elevated in the few days (estimated to be up to 10% at 7 days) 
following TIA. As such, optimal prevention requires early initiation of treatment. In the 
UK, guidelines published by the Department of Health in The National Stroke Strategy 
and NICE suggest that patients with suspected TIA assessed as ‘high risk’ should be seen 
by a specialist within 24 hours of presenting symptoms in primary care (Department of 
Health, December 2007, NICE, 2008). However, in terms of current practice, there is little 
to suggest such targets are close to being attained. For instance recent audit of acute TIA 
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and minor stroke services found that the best stroke centres still take longer than 24 hours 
to assess patients (Royal College of Physicians London). 
 
The gulf between the aspirations of guidelines and the results from audit suggest that 
current service delivery as sub-optimal. There are two non mutually exclusive 
explanations. First, the apparently sub-optimal result may arise from underfunding of acute 
TIA services by the NHS. This is supported by a recent, empirically based study 
identifying the under-estimation of demand for TIA services in the UK NHS. Giles and 
Rothwell (2007b) identify a systematic shortfall in the Department of Health’s forecasting 
of demand for TIA services arising from the use of incident-definite TIA rather than TIA. 
In the second case, the model
2
 of service delivery may, in itself, be wrong. This would be 
true if changing the service delivery model could lead to more optimal management of 
TIA patients. This possibility provides the unique focus for the thesis (stated below). 
 
The focus of this thesis is to evaluate alternative models of service delivery in TIA for 
patients presenting in primary care. The primary objective of this chapter is to describe 
Transient Ischaemic Attack (TIA) and its impact in terms of clinical sequelae. The chapter 
will also summarise the evidence of what is current best practice and associated care 
pathways used to manage and treat suspected TIA in the UK NHS. This information will 
be used to inform the structure of an economic model to evaluate the incremental costs and 
                                                   
 
2
 N.B. Here the term ‘model’ refers to the medical management and care of the TIA patients from point of 
presentation through to follow-up. 
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benefits of GP initiation of treatment following suspected TIA compared with current best 
practice (see Chapter 5 for methods relating to the economic model). 
 
2.2. Definitions of Transient Ischaemic Attack 
During the writing of this thesis, the definition of TIA changed. The definition of a 
Transient Ischaemic Attack according to the AHA/ASA definition that is now accepted is: 
‘Transient ischemic attack (TIA): a transient episode of neurological 
dysfunction caused by focal brain, spinal cord, or retinal ischemia, without 
acute infarction’ (Easton et al., 2009). 
 
This tissue based definition of TIA replaced a time based definition: 
‘An acute loss of focal neurological symptoms lasting less than 24 hours’ 
(Matthews et al., 2004).  
 
Previously the time period was chosen to reflect the reversibility of damage, and was set 
arbitrarily. The technical advances in brain imaging meant that the reliability of the 24 
hour rule was questioned, as many TIAs were revealed to have infarcts on scans. The new 
definition reflects the underlying pathophysiology of TIA as a milder event.  
 
The key distinction between TIA (also sometimes called a ‘mini stroke’) and a minor 
stroke is now rests on whether there is damage to the tissue within the brain, which can 
only be known once the patient has a completed clinical work-up that is likely to include 
some form of neuro-imaging. Therefore, the time-based WHO definition might more 
accurately reflect the population presenting in Primary Care who have resolved symptoms. 
Strictly speaking the population for this thesis’ intervention will therefore include some 
resolved minor stroke, which is akin to the time-based WHO definition.  TIA and stroke 
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can result in an array of different symptoms including: motor impairment on one or both 
sides (such as lack of coordination and/or limited ability to make learned purposeful 
movements despite having the physical ability to do so); speech impairment; visual 
disturbances; other sensory and cognitive problems (for instance, confusion); dizziness; 
difficulty swallowing; impaired consciousness and seizures (Mant et al., 2004). The 
management of TIA and stroke is the same in terms of secondary prevention. 
 
2.3. Types of Stroke  
There are a number of different types of stroke that are defined, using the ICD10 coding 
system in terms of the underlying pathology. Understanding the pathological sub-type of 
stroke is important because it influences the choice of secondary prevention and 
management of stroke in the acute phase. 
 
Ischaemic stroke is the most common type of stroke, occurring in 85% of stroke cases. A 
correctly diagnosed TIA is generally a potential precursor of an ischaemic stroke. This 
type of stroke is caused when the blood flow to the brain is disrupted due to a thrombus 
(clot) formed either at the site (thrombotic stroke) or which has travelled from another part 
of the circulation (embolic stroke). The thrombus occludes (blocks) the artery, which 
causes the brain cells to be starved of oxygen, causing cerebral ischaemia. This may cause 
the cells in the surrounding area to die and result in ‘an infarct’ (a macroscopic area of 
damaged tissue). This infarct is sometimes visible if/when brain imaging is done at a later 
stage.  
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Another type of stroke is a haemorrhagic stroke, which occurs when there is bleeding from 
one of the arteries in the brain into the tissue in the brain. The artery bursts usually because 
of arterial disease. This can result in a haematoma (pooling of blood).  It would be unusual, 
but not impossible, for a haemorrhagic stroke to present in primary care as a TIA (TIA 
steering group, 2008). 
 
Sub-arachnoid haemorrhage (SAH) is a sub-type of haemorrhagic stroke, which can arise 
either spontaneously because of underlying arterial disease or physical abnormality in the 
artery, or, as a result of a traumatic brain injury. In a SAH there is arterial bleeding into the 
subarachnoid space between the two meninges (membrane) known as pia mater and 
arachnoidea. Essentially this means that there is bleeding into the skull rather than within 
the brain, which means that SAH is usually considered as a distinct entity from stroke, but 
a SAH may lead on to clinical stroke. SAH typically has a sudden presentation, which 
often includes a severe headache and impaired consciousness. This type of presentation 
means that in practice such a person, if they were to present in primary care, would not be 
considered as presenting with a possible TIA. 
 
There is a further category of patients referred to as stroke or TIA ‘mimics’ because 
immediate symptoms suggest they have experienced a stroke or TIA but subsequent 
evaluation indicates they actually have non-stroke pathology.  
 
2.4. Diagnosis of TIA and minor Stroke 
The focus of this section is on the diagnosis of TIA or resolved minor stroke. 
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There is no ‘gold standard’ clinical test that can be used to diagnose a TIA or stroke. The 
diagnosis is based on the assessment of symptoms and ‘adequate’ investigation by a 
clinician. To be diagnosed as having experienced a TIA stroke a patient must have 
experienced at least one of the symptoms listed in Table 1. Other symptoms sometimes 
accompanying those listed in Table 1 include: dizziness, vertigo, localized headache, 
blurred vision of both eyes, diplopia (double vision), dysarthria (slurred speech), Impaired 
cognitive function (including confusion), Impaired consciousness, Seizures, Dysphagia 
(difficulty swallowing) (World Health Organization, 2006). 
 
In Primary Care, the lack of a gold standard test means that the diagnosis of TIA and 
minor stroke in primary care largely depends on the clinician’s judgement as to whether 
the patient’s symptoms are consistent with TIA or minor stroke. Projections3 from annual 
stroke incidence figures suggest that a GP may only see 1 or 2 TIAs a year so they have 
limited experience by which to make their judgment (Rothwell et al., 2004a).  
 
  
                                                   
 
3
 Based on a standardised community incidence of first-ever stroke of 0.58 per 1,000 patients and assuming a GP 
has an average patient list size of 2,000. 
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Table 1: Symptoms to inform the diagnosis of TIA (Mant et al., 2004) 
 
 
 
In practice, doctors in primary care and A&E may be less well trained compared with 
specialists in how to correctly recognise TIA/stroke symptoms and make appropriate 
subsequent referral. Some evidence suggests that the ratio of genuine TIA (true positive) to 
TIA mimic (false positive) referrals from primary care may be in the region of 1:1 
(Lasserson, 2013). This translates to a greater demand for rapid access clinics than that 
implied by forecasts based on incident-definite TIA. This is well illustrated by findings 
from the most comprehensive study of incidence of TIA or first-ever minor stroke was the 
Oxford Vascular Study (OXVASC). This was a population-based study of some 91 106 
individuals (registered at  9 general medical practices in Oxfordshire, UK) of any age 
experiencing acute vascular events in all arterial territories (but excluding sub-arachnoid 
haemorrhage) with near complete case ascertainment. The resulting crude annual incidence 
rate (95% CI) standardised for the 2005 population of England for all probable and definite 
stroke was 2.13 per thousand population  (1.94-2.31), while the corresponding value for all 
Unilateral or bilateral motor impairment (including lack of coordination), 
Unilateral or bilateral sensory impairment, 
Aphasia/dysphasia (non-fluent speech), 
Hemianopia (half-sided impairment of visual fields), 
Forced gaze (conjugate deviation), 
Apraxia of acute onset (inability to carry out learned purposeful movements), 
Ataxia of acute onset (lack of coordination of muscle movement), 
Perception deficit of acute onset 
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probable and definite TIA was approximately half of this 1.08 (0.95-1.21). Interestingly, 
incident-definite TIA amounted to just 0.54 (0.44-0.63) (Giles and Rothwell, 2007b). 
 
2.5. Clinical sequelae 
The comparative brevity of symptoms in TIA means that the majority of patients make a 
quick recovery within hours (and possibly minutes) of the event. The WHO definition of a 
TIA means that all patients will experience resolution within 24 hours. In contrast, a stroke 
may but does not necessarily result in lasting disability. In reality, as opposed to 
theoretically, the severity of stroke spans a continuum and the 24-hour threshold is 
arbitrary. A stroke tends to be defined in terms of the clinical sequelae and impact on a 
person’s ability to perform usual activities and function independently. A more minor 
stroke has less impact on disability. The Rankin scale is used as a disability index used to 
formally define stroke severity (see Table 2). The Rankin scale has a scale from 0 (perfect 
health) to 6 (representing death). A score of 0 or 1 is usually be defined as a minor stroke.  
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Table 2: The Rankin Scale 
 
 
The following section considers the current management of patients presenting with TIA 
symptoms. This includes predisposing risk factors for TIA. Subsequently, risk modifying 
interventions are considered and the evidence base to support their use. Finally existing 
approaches to the management of stroke are considered with a description of current 
practice in the UK. 
 
2.6. Predisposing risk factors  
There are two key reasons why it is important to identify the predisposing risk factors for 
stroke: policy and patient-level. At policy level, the relative contribution of each risk factor 
Score  Symptoms 
0 No symptoms 
1 
No significant disability. Able to carry out all usual activities, 
despite some symptoms. 
2 
Slight disability. Able to look after own affairs without assistance, 
but unable to carry out all previous activities. 
3 
Moderate disability. Requires some help, but able to walk 
unassisted. 
4 
Moderately severe disability. Unable to attend to own bodily needs 
without assistance, and unable to walk unassisted. 
5 
Severe disability. Requires constant nursing care and attention, 
bedridden, incontinent. 
6 Dead. 
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to the overall burden of stroke can inform stroke prevention initiatives (Mant et al., 2004). 
Secondly, at patient-level it enables a tailored plan of clinical care to be developed by the 
appropriate healthcare professionals which addresses the essentially multi-factorial nature 
of the disease. While some risk factors are modifiable by lifestyle changes alone, others 
may require treatment or a combination of the two. There may also be a genetic 
predisposition to certain risk factors.  
 
  
  
 
1
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Table 3: Predisposing Risk factors for Stroke and evidence 
Category Risk factors  Evidence  
Modifiable  Lifestyle (Diet, 
Exercise, Smoking,  
Heavy alcohol 
consumption) 
 
Hypertension 
(Elevated blood 
pressure) 
 
 
 
 
Diabetes 
 
 
Atrial Fibrillation 
(AF) 
There is strong evidence that smoking is an important independent risk factor for 
stroke, and some evidence that physical inactivity and excessive alcohol 
consumption can raise the risk (Mant et al., 2004). 
 
 
There is strong evidence that hypertension is an important independent risk factor 
for stroke, and that lowering blood pressure confers a reduction in the risk of 
cardiovascular events. (Kjeldsen et al., 1998, Staessen and Wang, 2001) HOT, 
(UKPDS 1998). There is also a growing body of evidence that lowering blood 
pressure in populations who are not hypertensive but at risk of stroke is beneficial 
(Bilous, 1999, Law et al., 2009). 
 
There is established evidence that the diabetes is an independent risk factor for 
stroke (Johnston et al., 2000). 
 
This is a clinical condition causing cardiac arrhythmia or “irregular heart beat”, 
present in approximately 5% of the population over 65). The presence of Atrial 
  
 
1
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Category Risk factors  Evidence  
 
 
 
Carotid Artery 
Stenosis, Ischaemic 
Heart Disease) 
 
 
 
 
 
 
 
 
 
High Cholesterol 
 
 
Fibrillation has a strong association with elevated stroke risk, and in most cases 
can be treated effectively with anticoagulants.  
 
Carotid artery stenosis occurs when the carotid arteries narrow due to the 
formation of artherosclerotic plaque. The need for surgery can be identified from 
carotid imaging (usually Doppler ultrasound), where the degree of narrowing can 
then be measured according to a standardised criteria such as used by the 
European Carotid Surgery Triallists’ study group, (hereafter referred to as ECST 
criteria). Typically, the decision to operate can be taken if the degree of stenosis 
(narrowing) is above or equal to a certain percent value – for the more commonly 
used ECST measure, this is usually 70%. There is strong evidence to suggest that 
patients with severe carotid artery stenosis have a heightened risk of stroke. One 
study found that a sub-group of patients with severe stenosis (ECST 60-99%) 
experience a doubling of stroke risk (ECST 1998). 
 
At present there is little epidemiological evidence to suggest that high cholesterol 
is an important independent risk factor for stroke, but evidence from randomised 
controlled trials suggest that treatment with cholesterol lowering drugs (statins) 
does reduce the risk of major vascular events including all stroke (Mant et al., 
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Category Risk factors  Evidence  
2004).  
Non-
modifiable  
Age  
 
 
 
 
Sex 
 
 
 
 
Ethnicity 
 
 
 
Deprivation 
As can be seen from the age and gender specific incidence table below there is a 
clear trend towards higher event rates in older age groups. Males and females do 
not face equal risks either. Males generally have lower event rates of TIA mimic 
and genuine TIA, and higher rates of major stroke up to the age of 75. 
 
In addition there is some difference in the pathological causes of stroke 
experienced by the sexes. The Oxford Vascular study found that males have a 
higher relative event rate of ischaemic stroke and intracerebral haemorrhage but a 
lower rate of sub-arachnoid haemorrhage (Rothwell et al., 2004a). 
 
Certain populations may be at higher risk of stroke, and evidence suggests that 
West African and Carribbean populations are most at risk, with South Asian, Irish 
and Scottish populations also at heightened risk. 
 
There is evidence that economic deprivation or socio-economic factors at 
childhood are correlated with higher stroke risk (Mant et al., 2004). This may 
explain regional variation in observed UK stroke rates. 
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Clinical features and duration of symptoms (when the patient has had an index TIA or 
stroke) 
There is some evidence that patients whose symptoms include unilateral weakness or 
speech impairment are at higher risk of recurrence, as are patients whose symptoms last 
longer.  
 
2.7. Assessing patient risk - ABCD2 score 
Another way this risk can be assessed by a health service professional is via the use of a 
prognostic instrument such as the ABCD2 score (Johnston et al., 2007). Validated in 
several independent cohorts (Oxfordshire and California) the risk is a point score whose 
calculation depends on the sum of several of the risk factors which enter it additively. 
Together, presence of these features are strongly predictive of the risk of recurrence 
following TIA/minor stroke. Summing to give a total between 0 (lowest risk) and 7 
(highest risk) the score is calculated as follows: 
Age ≥ 60, 1 point 
Blood pressure ≥ 140/90 mmHg, 1 point 
Clinical features: unilateral weakness, 2 points; speech impairment without weakness 1 
point. 
Duration of symptoms: ≥ 60 mins, 2 points; 10-59 mins, 1 point 
Diabetes, 1 point 
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2.8. Secondary prevention of TIA 
These measures relate particularly to strokes and TIA which are identified, or strongly 
suspected to be ischaemic in nature (which as previously identified is the majority of all 
strokes). The clinical management of haemorrhagic stroke is somewhat different and 
beyond the scope of the policy area of this thesis. 
The summary table below (Table 4) shows the agents commonly used in the secondary 
prevention of stroke. 
 
Table 4: Rationale for secondary preventive treatment agents 
Drug Used to: 
Aspirin  Secondary prevention of ischaemic stroke/TIA, 
usually as a loading dose of 300mg daily. 
 
Dipyridamole  Secondary prevention of ischaemic stroke/TIA. 
  
Clopidogrel monotherapy Secondary prevention of ischaemic stroke/TIA 
as alternative to aspirin particularly when the 
heart is thought to be the cause of embolism. 
 
Anti-hypertensives (thiazide diuretic, 
angiotensin-converting enzyme 
inhibitors (ACEIs), angiotensin-II 
receptor antagonists (AIIRAs), calcium 
channel blockers (CCBs), Beta blockers) 
Control blood pressure levels in patients 
suffering from hypertension. Selection of anti-
hypertensive class of drugs depends on 
individual patient factors (e.g. comorbidites 
such as Ischaemic heart disease, ethnic origin), 
tolerability and cost.  
 
Statins Reduce lipid levels, control 
hypercholesteremia.  
Anti-coagulant  Prevent cardiac embolism in patients with 
Atrial Fibrillation. 
 
Lifestyle advice Identify what the patient can do to reduce risk 
of a subsequent event, for instance by measures 
aimed at smoking cessation, diet and alcohol 
approaches, exercise and relaxation. 
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2.9. Evidence for Secondary Prevention 
The objective of this section is to identify and appraise the evidence relating to the 
individual treatment effect in terms of risk of a recurrent stroke outcome. 
 
This involved a search for Medline original research and the following terms “secondary 
prevention” “recurrent stroke” “TIA”. A more focussed search using the previous terms in 
conjunction with one of the following: “aspirin” “antiplatelet” “antihypertensive” “statin” 
“anticoagulation” “carotid endarterectomy”. In addition, the population had to include 
either TIA and/ or minor stroke i.e. patients had to be candidates for secondary prevention. 
When more than one study existed, more weight was given to studies conducted in, or 
including UK populations. Studies had to be published within the last 10 years i.e. January 
2000 onwards.  
 
In spite of a rich evidence base in this area RCT evidence is lacking in the acute phase of 
TIA/stroke with many studies recruiting patients up to six months after the event. With the 
exception of the FASTER (Kennedy et al., 2007)  study, no Randomised Control Trial to 
date has enrolled patients within 24 hours of symptoms suggestive of TIA which means 
that many patients may experience a subsequent event and/or die before they can be 
recruited into a trial (Kennedy et al., 2007). However, given the positive results from 
observational studies in secondary stroke prevention with a focus on early assessment and 
treatment, it may be that the evidence of effectiveness of these drugs from ‘non acute’ 
trials is of some relevance to this area (Giles and Rothwell, 2007a). 
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Evidence for Aspirin Monotherapy 
Since it is both cheap, safe and has some early demonstrable efficacy aspirin is the most 
commonly prescribed agent following TIA/minor stroke. In one study conducted by the 
Antithrombotic Trialists’ Collaboration (Antithrombotic Trialists' Collaboration, 2002) the 
percentage odds reduction in patients with previous stroke/transient ischeamic attack (SE) 
was 22% (4) in patients with a mean 29 months of treatment.  
 
Evidence for Rapid Treatment with dual Antiplatelets 
The European Stroke Prevention Study 2 (ESPS-2) used a 2x2 factorial design which 
investigated the possibility of an interaction between dipyridamole and aspirin, as well as 
in usage as single agents (Diener et al., 1996). While the entry criteria to the trial – TIA or 
ischaemic stroke 3 months prior to study entry – does not allow for easy comparison with 
the decision problem here, the study does demonstrate the significant efficacy of aspirin – 
dipyridamole in combination vs. aspirin alone in the primary outcome of stroke (RR 0.76; 
95% CI: 0.63-0.93). However, there was no significant efficacy for the composite outcome 
of stroke and/or death (RR 0.87; 95% CI:0.75-1.00). 
 
The European/Australasian Stroke Prevention in Reversible Ischeamia Trial (ESPRIT) 
found some evidence to favour dual therapy as compared to mono-therapy in patients who 
had a previous TIA or minor stroke up to six months previously (De Schryver et al., 1999). 
They report evidence of significant efficacy in the primary composite outcome of all 
vascular death, non fatal stroke, non fatal MI and bleeding complications (HR 0.80; 95% 
CI:0.66-0.98). However, while the point estimate appeared to favour the addition of 
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dipyridamole to aspirin for  the outcome of first ischeamic stroke, the confidence intervals 
were too wide to establish significance (HR 0.84; 95% CI: 0.64-1.10).  
 
The Fast assessment of stroke and transient ischaemic attack to prevent early recurrence 
(FASTER) study found evidence to support significant efficacy in clopidogrel vs aspirin in 
the outcome of stroke, and unlike the RCTs comparing aspirin-dipyridamole, the study 
population was recruited within 24h of symptom onset (RR 0.70; 95% CI: 0.3-1.2) 
(Kennedy et al., 2007). A more recent RCT in first recurrent stroke - PRoFESS 
demonstrated similar rates of recurrent stroke with aspirin–dipyridamole to clopidogrel 
and no evidence of superiority in either treatment arm (Diener et al., 2008). Date of 
randomisation was  less than 90 days post ischemic stroke. 
 
Evidence for Rapid Treatment with Statins 
There is some evidence for the use of cholesterol lowering treatments (statins) in the 
prevention of major vascular events. However there is little data showing evidence of a 
clinically significant risk reduction in the acute phase following TIA/minor stroke. One 
such trial which does look at early initiation in the 90 day follow up period following 
ischaemic events was too small and so underpowered to detect a clinically significant risk 
reduction (Kennedy et al., 2007). In the absence, to date, of a clinical trial in the same 
population in the acute phase of illness which uses a protocol that enables the statin 
treatment effect to be distinguished from that of other drugs the best evidence comes from 
meta-analyses of randomised controlled trials not carried out in the acute phase. For 
instance, the Cholestrol Treatment Trialists’ Collaboration identified an overall RR of 0.79 
(95% CI 0.77-.81) per 0.001 per mmol/LDL cholesterol reduction in first major vascular 
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events. In addition, using the same cholesterol reduction, the RR for overall first stroke 
was 0.83 (95% CI: 0.78-.88) (Baigent et al., 2005). 
 
A recent systematic review commissioned by the NHS HTA programme found that statins 
are associated with a significant reduction in the risk of non fatal stroke but not fatal 
strokes (Ward et al., 2007). In addition, in types of study which did distinguish between 
ischaemic and haemorrhagic stroke, it found that a significant reduction in the former. 
Evidence that statins may increase the risk of haemorrhagic stroke (fatal and non fatal) was 
not proven.  
 
Evidence for Rapid Treatment with Antihypertensives  
Results from the PROGRESS study identify the benefits of blood pressure lowering 
(Chalmers, 2003). The interesting result was that following stroke, blood pressure 
lowering reduces subsequent stroke risk irrespective of whether blood pressure was 
controlled or uncontrolled; the implication of this being that further lowering of blood 
pressure may be advisable in all patients with a history of stroke. The circa 28% reduction 
in stroke risk in both these studies applies to a stroke, not TIA population. However, it 
seems conceivable that blood pressure lowering is desirable. Recent guidance on the 
management of hypertension has identified the effectiveness of using a combination of 
antihypertensive drugs over single agents (Williams et al., 2004, NICE, 2011). 
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Evidence for carotid endarterectomy 
The benefit of carotid endarterectomy largely depends on identifying degree of stenosis the 
surgical risks are outweighed by the risk of untreated carotid territory occlusion.  In actual 
fact, this basic relationship is complicated by the fact that carotid imaging is not perfectly 
accurate. This is particularly of relevance if the level of stenosis is less severe than that 
suspected on inspection of the US scan or angiogram because the decision to operate will 
result in excess risk to the patient. Unlike the existence of dual antiplatelet therapy in acute 
stroke populations, carotid endarterectomy has been an area of active research, and the 
wealth of data which includes large multicentre international trials, HTA report and RCT 
evidence. Correspondingly, the results of these are reflected in the National Stroke 
Strategy and NICE guidelines which make recommendation for carotid endarterectomy to 
be carried out within 2 weeks of onset. However, in practice, the delay to receiving both 
assessment and surgery confer a less than favourable risk profile on the patient if surgery is 
indicated by the test alone (Rothwell et al., 2004b, Mehta et al., 2005). 
 
2.10. Investigations commonly used to assess TIA symptoms 
This section considers the standard investigations usually performed to confirm the 
diagnosis of stroke. 
 
Predicting early stroke risk after TIA 
Indeed, the ABCD2 score, now readily accepted as a recognised predictor of early 
recurrent stroke is to be used by practitioner’s to identify high risk patients (ABCD2≥4) 
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presenting in primary care so that they can be treated urgently (Department of Health, 
December 2007). 
 
There is also some evidence that certain risk factors are individually predictive of early 
recurrent stroke. In the acute phase of up to 30 days these may include: motor weakness 
and/or speech impairment lasting greater than 60 minutes as well as carotid artery stenosis 
≥50%. For instance, Rothwell, Giles, Flossman et al. (2005) found that while motor 
weakness and speech disturbance attributed to just 30% of all suspected TIAs, they were 
responsible for 90% of the strokes occurring within 7 days.  
 
Investigations commonly performed following suspected TIA/minor stroke (at the 
point of specialist referral) 
Imaging is carried out to establish the type of stroke, and determine if carotid 
endarterectomy is likely to be effective in cases where surgical intervention is considered 
possible. The first-line test will usually be MRI to establish the type of stroke, plus 
Doppler ultrasound to assess the blood flow of the carotid arteries. Virtually all acute 
stroke units and rapid access clinics have such facilities, although access to them may be 
restricted by a shortage of slots or lack of staffing to provide a 24hr service. In cases where 
symptoms have resolved, brain imaging will only usually take place if there is uncertainty 
about the symptoms being of vascular origin – if a patient’s clinical history is consistent 
with TIA there may be little benefit in scanning, and this may not be effective use of the 
resource. Carotid imaging meanwhile should always be carried out in the case when a 
vascular origin is definite, probable or possible – so long as the patient is a candidate for 
surgery. As is evidenced by the recommendations made by strategy (p.27) and evidence 
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(p.23) it is important that such imaging is timely. Finally, it should be noted that the 
accuracy of brain imaging techniques is not perfect; it depends on the skill of the 
radiographer or specialist stroke physician who interprets the test and the quality of the 
image produced.
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Table 5: Imaging techniques commonly performed following TIA 
Imaging technique/ 
Investigation 
Used to: 
Magnetic resonance 
imaging  (MRI)  
More accurate than a CT due to higher spatial resolution, used if 
there is uncertainty in diagnosis. Non-invasive procedure which 
produces a picture of the brain without the need for ionising 
radiation or iodine. 
Carotid imaging of 
arteries around the 
throat  
Used in the evaluation of TIA and stroke symptoms to identify if 
there is stenosis (narrowing) due to the formation/ulceration of 
artherosclerotic plaque in the carotid artery (usually more than 70% 
ECST criteria). Doppler ultrasound refers to a non invasive test 
which uses high frequency sound waves to determine the extent of 
blood flow through the carotid arteries in the neck. (National Audit 
Office, February 2010). Computed tomography  and a from of MRI 
may be used to confirm the diagnosis and then to establish the 
degree of stenosis.  
Computed 
tomography 
angiography (CT) 
A technique that uses multiple x-ray beams and detectors moving 
around the brain which results in a two-dimensional cross sectional 
image. Typically this requires a contrast material being injected into 
a vein or artery using a needle or cannula. To determine if a stroke 
is ischaemic or haemorrhagic, minimally invasive.  
Echocardiogram 
(ECG) 
An echocardiogram (also known as an echo) uses sound waves that 
echo against structures in the heart to build up a detailed picture of 
the heart.  This test is done to look at the structure of the heart and 
how well the heart functions. Used to detect AF , acute coronary 
syndrome or congestive heart failure (British Heart Foundation, 
2013). Non-invasive. 
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2.11. Optimum management of TIA 
This section outlines the guidance and recommendations made by NICE and the National 
Stroke strategy with regards to the delivery of services for TIA. In terms of the proposed 
management of TIA both sources share a number of common aspirations. Considered 
together, what emerges is NICE’s/ the Department of Health’s notion of a ‘gold standard’ 
for TIA service delivery. By way of contrast, this section also considers the management 
of TIA in practice. This is done by reference to the National Sentinel Stroke Audit (2012) 
and a recent key study evaluating UK TIA services.   
 
Sentinel Stroke National Audit Programme (2012) 
The National Sentinel Stroke Audit is prepared on behalf of the Intercollegiate Stroke 
Working Party (ICWP) by the Royal College of Physicians, London with a remit to 
evaluate the level of practice and service provision across the whole of the patient pathway 
(including rehabilitation services in the case of completed major stroke) in England, Wales 
and Northern Ireland. It is published every two years. A key aim of the audit is always to 
identify areas of progress since the previous (2010) audit ‘against the National Clinical 
Guideline for Stroke’. . The key results with regards to organisational care in TIA reveal 
variation in practice across hospitals, so that overall progress compared to the 
recommendations of the National Clinical Guideline appear modest. For instance, just 36% 
of high risk patients (14% of low risk patients) are seen, assessed and treated on the same 
day, indicating sub-optimal use of resource. 
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National Stroke Strategy (2007) 
In 2007, the Department of Health’s development of a new National Strategy for Stroke 
has a 3-fold purpose: to be a quality framework for the management of stroke; to offer 
guidance to strategic health authorities about the planning of TIA and stroke services and 
to inform expectations of the general public.  
 
Grounded in the evidence basis from which it emerges, the strategy’s core message 
regarding the management of TIA is ‘Time is brain’. Rapid referral, rapid imaging, rapid 
carotid endarterectomy where indicated (defined as an ECST grading of 70% or more) and 
immediate initiation of antiplatelet therapy are key features, as is the triaging of risk by 
ABCD2 score of 4 and above. The specific recommendations are described more fully in 
Table 6 below. 
 
Table 6: National Stroke Strategy Guidelines 
Guidelines following newly diagnosed TIA/minor stroke  
Prevention 
Those at risk of stroke, or who have had a stroke/ TIA are assessed for are given advice 
about risk factors and lifestyle management. Clinical management to follow other 
guidelines such as those for hypertension, statins and diabetes 
Rapid diagnosis and treatment 
rapid referral (within 24 hours) for patients at high risk of stroke ABCD2 ≥4 and urgent 
(≤7 days) for those  with ABCD2<4 
Loading dose of aspirin (300mg) (or other agents as evidence emerges which reinforce the 
findings of the EXPRESS study) (Rothwell et al., 2007). 
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Guidelines following newly diagnosed TIA/minor stroke  
Specialist care - TIA and Stroke 
Rapid MRI (incl. DWI) imaging (within 24 hours) in all patients seen acutely after TIA or 
minor stroke and in next scan slot (in working hours) or within an hour (out-of-hours). 
Carotid imaging at initial assessment not more ≤24h for high risk ABCD ≥4. 
Carotid endarterectomy within 48 hours where clinically indicated. 
Follow up in primary or secondary care within a month of the event. 
Specialist care - Suspected Stroke only 
Patients with unresolved symptoms in the community to be directed to appropriate acute 
stroke unit or hospital providing hyper-acute stroke services by ambulance.  
For patients with suspected stroke, immediate structured clinical assessment (e.g. using a 
tool such as ROSIER) followed by multidisciplinary assessment including a swallow 
screen, and identification of cognitive and perceptive problems if stroke is diagnosed. 
 
While not intended as a clinical guideline and so there is little mention of risk modification 
via different agents (the strategy identifies this to be the remit of other organisations such 
as NICE), the strategy essentially identifies ideal and expedient management. The extent to 
which this is achievable may well vary on whether there is sufficient capacity to be able to 
respond to all suspected TIA and stroke in a timely way. Indeed, there is a clear gap 
between the desirability of carrying out carotid endarterectomy within 48 hours of 
symptoms and the observed typical delays in one Oxfordshire based study of 67 days 
(Mehta et al., 2007). Similarly, the mismatch between the desirability of policy on the one 
hand and limits on service capacity on the other are perhaps most likely to be evidenced by 
future audit of ambulance utilisation and stokes prevented due to thrombolysis. 
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In summary it is evident that the National Stroke Strategy, 2007 is strongly allied to the 
research question of the thesis as a whole in that it takes as its core the question of what 
needs to be done to optimally manage TIA/ minor stroke. However, it does not state how 
to deal with the broader service delivery problem. The ‘evaluation of different models of 
access to TIA services in different settings, e.g. direct access to daily clinics in secondary 
care versus immediate assessment and management in primary care with onward referral 
to secondary care’, it mandates, is one of the top ten priorities for stroke services research  
(National Stroke Strategy, 2007 p.65). 
 
Clinical guidelines, NICE (2008, 2010), SIGN (2008)  
The NICE guidelines (2008) for TIA and acute stroke (developed by the National 
Collaborating Centre for Chronic Conditions) supplements and reinforces the guidance 
from the National Stroke Strategy. In particular, the recommendations are as per the 
National Stroke Strategy with regards to initiation of aspirin at 300mg daily and rapid 
referral for those patients with an ABCD2 of four or above, and weekly for those with 
lower scores or presenting late. Where the guidance makes specific recommendation 
regarding clinical management that is slightly different from the National Stroke Strategy, 
they are outlined below: 
 
i. Crescendo TIA 
The guideline makes a special point about “crescendo TIA”, which it defines as 2 or more 
TIAs in one week as being especially predictive of further stroke, and states that it should 
be treated within 24hours, even if ABCD2 is less than four. 
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ii. Timelines for CE surgery 
The aim for carotid endarterectomy was for assessment within 1 week (if the patient is a 
candidate for surgery) and for surgery, if indicated within 2 weeks of the onset of 
symptoms.   
iii. Ambulance transfer in cases of suspected stroke 
There is no express recommendation that transfer to hospital needs to be by ambulance 
where stroke is suspected in the community, however, there is a recommendation for direct 
admission to an acute stroke unit. 
 
In addition, the document reinforces the National Stroke Strategy on brain imaging (next 
slot and definitely within 1 hour, in this case whichever is sooner). However, it emphasises 
that this needs to be only done where there is uncertainty about the diagnoses of ischaemic 
stroke (e.g. indications for thrombolysis, on anticoagulants, a depressed level of 
consciousness, possible indications for haemorrhagic stroke, or other diagnoses such as 
tumour and migraine).  
 
More recently, the publication of NICE quality standards in stroke “QS2” have heralded a 
potential way forward in terms of optimising the management of patients at key points in 
the care pathway (Stokes, 2013). The current list of statements (standards) is slightly more 
focused on the need for rapid assessment of unresolved neurological symptoms presenting 
in the community (which may be treated as potential strokes) as opposed to resolved 
transient neurological attacks which are the focus of this thesis (NICE, 2010). To date, 
quality standards have particularly emphasised key points on the stroke care pathway. 
Relevant to this thesis’ population is statement 1 which covers the prompt identification of 
 32 
 
 
suspected stroke in the community by the use of a validated screening tool (e.g. FAST, 
ROSIER).  
 
Guidelines produced by SIGN for the management of acute stroke and TIA in Scotland are 
similar to the NICE guidance in most respects (SIGN Scottish Intercollegiate Guidelines 
Network, 2008). However the Scottish guidelines make a recommendation for the 
initiation of dual antiplatelet therapy (aspirin-dipyridamole) following suspected TIA. In 
this respect, the Scottish guidance appears to reflect the favourable evidence for dual 
antiplatelets above aspirin alone. 
 
Guidelines into practice - Resource implications 
Whilst there has recently been a growing consensus of evidence reflected in the above 
guidelines that best practice necessarily demands rapid assessment and treatment, less 
attention has been paid to how services should be organised to achieve this aim. However, 
the development of NICE quality standards may herald a means of measuring the extent to 
which guidelines has been successfully implemented in a measurable way. 
  
While it is perhaps too early to assess the contribution of quality standards, the failure of 
current practice to meet the aspirations of guidance are demonstrated by findings 
documented by that of the National Sentinel Stroke Audit (2012) which identifies a median 
time from event to assessment of 2 days. (Stokes, 2013) Furthermore, the same audit 
identifies that close to 63% of the TIA clinics  audited did not have a same-day rapid 
access clinics in operation.  
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In addition, the demand for rapid access services is another unknown. Giles and Rothwell 
(2007) note that the use of incidence measures arising from the Oxford Community Stroke 
Project results in a serious underestimation of the actual numbers of referrals because the 
service will be the first point of call for TIA mimics, those suffering non disabling stroke 
and recurrent (in addition to incident) TIA. Such projections utilised by the Department of 
Health must therefore be interpreted cautiously – their usage of incident definite alone 
might only capture circa 18% of all referrals to outpatient services. 
 
As a result, Giles and Rothwell (2007) conducted a population based retrospective study of 
all TIA, stroke and suspected stroke events occurring in the Oxford vascular study cohort 
between 2002  and 2005 stratified by in-patient and out–patient services. Based on their 
findings, they estimate a need for clinics in England to cater for some 150,000 referrals.  
 
2.12. Description of current practice 
The objective of this section is to describe current practice in TIA service delivery 
including the associated care pathways in the UK NHS. The identification of current 
practice is important because it has implications for the selection and justification of a 
comparator for the economic model considered later. In addition it helps the formulation of 
the specific research aim and objectives of the thesis. 
 
In describing current practice, the potential for variation (both in terms of process and 
clinical outcomes) across different parts of the NHS is considered. This may arise due to 
restrictions in service capacity (due to the finite budget for healthcare) and/or 
inefficiencies in service delivery, subjects considered in Chapter 3. Both factors result in a 
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divergence between the aspirations set out by the National Stroke Strategy and Department 
of Health documented previously and observed clinical practice. This is most notably the 
case in respect to process outcomes that are collected routinely from TIA clinics as part of 
the Quality and Outcomes Framework (QOF) and National Audit. A prominent example of 
the divergence between best and current practices is evidenced by the delay to timely 
investigation and treatment; in 2007, nationwide audit reported a median delay to 
treatment in TIA of 40 days from onset of symptoms compared with 1 day in the very best 
stroke centres (Rothwell et al., 2007).  
 
In order to characterise current practice, a review of recent evidence on existing 
approaches to the management of suspected TIA was necessary. Table 7 summarises the 
evidence found. Evidence was identified through a variety of methods, including internet 
searches for clinical guidelines, audits and summary data. 
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Table 7: Summary table of evidence 
Title   Author(s) Study Type Purpose  
National Stroke 
Strategy, 2007: 
A new ambition 
for stroke 
 (Department 
of Health, 
December 
2007) 
Strategy document To provide a quality 
framework for local 
services.  
To provide guidance to 
healthcare 
professionals.  
To inform the patient 
expectation of health 
and social care with 
regards to Stroke. 
NICE guideline 2007 (NICE, 2008) Clinical guideline 
(CG38) 
To provide guidance to 
healthcare 
professionals. 
What is the 
optimal model 
of service 
delivery in TIA 
and minor 
stroke?  
2007 (Mant, 2008) Mathematical 
modelling study 
To determine the 
clinical and cost-
effectiveness of 
different strategies 
prepared on behalf of 
the National 
Collaborating Centre 
for Service Delivery 
and Organisation 
(Birmingham TIA 
model). 
 36 
 
 
Title   Author(s) Study Type Purpose  
A transient 
ischaemic attack 
clinic with 
round-the-clock 
access (SOS-
TIA): feasibility 
and effects 
 (Lavallee et 
al., 2007) 
Observational (non 
UK-France): 
prospective cohort 
 
To identify the stroke 
risk following the 
introduction of 24-h 
access hospital clinics 
for patients with 
suspected or identified 
causes of TIA. 
Effect of urgent 
treatment of 
transient 
ischaemic attack 
and minor stroke 
on early 
recurrent stroke 
(EXPRESS 
study) 
2007 (Rothwell et 
al., 2007). 
Observational: 
prospective 
population-based 
sequential comparison 
conducted in two 
phases, (Apr 1, 2002 
to Sept 30, 2004 and 
Oct 1, 2004 to March 
31, 2007)  
To determine the effect 
of more rapid 
treatment after TIA 
and minor stroke in 
patients not admitted 
to hospital. 
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Table 8: Relating process of care and clinical outcomes to policy 
Study Process of care 
components described 
Primary outcome Key policy implication(s) 
EXPRESS 
(Rothwell 
et al., 
2007) 
 Delay to first call to 
medical attention 
from index event 
subsequent delay to 
assessment in study 
clinic.  
 Proportion of 
patients on 
different forms of 
secondary 
preventive 
medications and 
time to carotid 
surgery all assessed 
at 1 month follow-
up. 
 
 
 
 
Stroke rate at 90 
days. Early 
initiation of 
treatment is 
associated with 
an 80% relative 
risk reduction in 
recurrent stroke 
compared to the 
‘before’ phase of 
the study. 
Long delays to assessment 
in TIA clinics are not 
acceptable; initiation of 
secondary preventive 
treatments needs to take 
place in secondary care if 
they have not been initiated 
in primary care; and 
preferably in as soon as 
patients seek medical 
attention (with the 
exception of dual 
antiplatelets) following 
recent TIA. 
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Study Process of care 
components described 
Primary outcome Key policy implication(s) 
SOS-TIA 
(Lavallee 
et al., 
2007) 
 Time to assessment 
following 
telephone call to 
TIA clinic. Number 
of admissions to an 
inpatient stroke unit 
and subsequent 
length of stay.  
 Proportion of 
patients undergoing 
different types of 
imaging. 
 Proportion of 
patients on 
different forms of 
secondary 
preventive 
medications 
prescribed. 
Stroke rate at 90 
days. Early 
initiation of 
treatment is 
associated with 
an 80% relative 
risk reduction in 
recurrent stroke 
compared to 
those rates 
predicted by 
ABCD2 scores. 
 
The implementation of TIA 
clinics with 24 hour access 
to assessment, diagnosis 
and initiation of treatment 
might have implications in 
terms of reduced hospital 
stay and subsequent risk of 
stroke. 
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Table 9: Other studies 
Title (Author/Year) Main process of care 
attributes reported 
Key policy implication 
What is the optimal 
model of service 
delivery in TIA and 
minor stroke? 
(Mant, 2008) 
 Clinic frequency 
 Clinic setting 
i.e.dedicated TIA 
clinics versus 
TIA clinics 
nested within 
other services 
with flexible 
resources. 
 Use of 
ambulance 
transfer 
. 
Implications for service delivery, patient 
and GP education: 
The recommendations for policy 
identified by the report extend to the 
configuration of rapid access clinics, in-
patient admission and the use of 
emergency services. The key result is 
that clinics should ideally allow for same 
day referral (Monday-Friday). If capacity 
is limited, an ABCD2 score of 4 may be 
applied, however, if capacity is more 
restricted than this it is cost-effective to 
refer at the higher thresholds. 
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2.13. Discussion 
The purpose of this chapter was to review current approaches to stroke prevention 
following TIA in the UK. This documented the usual approach for the management of a 
suspected (and resolved) TIA patient presenting in Primary Care.  
 
First of all the diagnosis, prognosis and options for risk modification (including treatment) 
of TIA was described. Where TIA is suspected by a GP, following consideration of the 
patient’s ABCD2 risk score (ABCD2≥4), high risk patients may be fast tracked to a 
specialist for an assessment within 24 hours of the index consultation. Patients with lower 
risk scores should still be seen within one week. In terms of how the delivery of the service 
is arranged, the GP is responsible for making referral to a specialist stroke service and it is 
the specialist who initiates treatment. Providing there is no known contra-indication at this 
stage, this is normally dual antiplatelets (in addition to statins and antihypertensive as 
necessary).  
 
A notable finding was that while the general approach to managing patients appears fairly 
standardized, there is nevertheless considerable variation across the UK in terms of some 
of the process of care measures collated by national audit. A striking example of this is the 
variation in terms of the timeliness of treatment within different service settings where 
median times varied from 1 to 28 days (Royal College of Physicians London, 2012). 
Although causality between expedient treatment and stroke outcomes is established, no 
primary research has suceeded in investigating the potential for same day initiation of 
optimal secondary prevention. A planned pilot trial, RAPID-TIA, recently failed to recruit 
suggesting that primary research in this area is impracticable (Mant, December 2012).  
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CHAPTER 3: THE ECONOMIC IMPACT OF STROKE AND ITS 
MANAGEMENT 
3.1. Introduction 
The objective of this chapter is to describe the economic impact of stroke and its 
management. The chapter begins by describing the budget impact of stroke from different 
perspectives. It goes on to explain the importance of opportunity cost in the context of a 
finite healthcare budget and the need to understand the relative costs and benefits of 
management strategies for stroke with a focus on primary care. The framework for the 
design and conduct of economic evaluations together with the key approaches to designing 
economic evaluations are then described.  
 
3.2. Economic impact of stroke  
Stroke is one of the leading causes of mortality and morbidity in the UK. The financial 
burden of stroke can impact on the economy, the healthcare service and an individual who 
has had a stroke and their family members and carers. It is useful to consider different 
perspectives when describing the economic impact of stroke. The societal viewpoint 
considers the effect on the entire economy. In 2008, the National Audit Office estimated 
that stroke cost the British Economy to be £7bn. This figure includes direct costs of 
informal care and the indirect costs as a result of lost productivity resulting from 
potentially economically active members of society being unable to work. A major impact 
of stroke is the hidden cost of providing informal care for people suffering from the 
sequelae of a previous stroke. There are around 900,000 people living in England who 
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have had a stroke and approximately half of these will be dependent on others for 
performing their daily activities, which results in estimates of informal care costs of 
around £2.4 billion (National Audit Office, 2005). Stroke is not only experienced by older 
people. Around one quarter of all strokes occur in people of working age, with 
productivity losses resulting in annual indirect costs of £1.8 billion (National Audit Office, 
2005). 
 
It is estimated that major stroke costs in the region of £2.8bn in direct hospital care and 
accounts for almost 5% of all health service costs in the UK (Hankey, 2008, National 
Audit Office, 2005). The societal burden of stroke is higher, with one source estimating 
this at £8.9bn (Saka et al., 2009). Stroke has a larger financial burden on the NHS than 
heart disease (Rothwell, 2001). 
 
It is also important to consider the economic burden on the individual whom has 
experienced a stroke. There are a number of potential costs to the individual. First of all, 
there is the direct cost for care and support if the stroke results in a disability that means 
they can not look after themselves or perform day-to-day tasks. Secondly, there may also 
be loss of earnings coupled with a rise in medical care costs resulting from prescription 
charges for medicines and travel costs to attend hospital and GP appointments.  Stroke also 
has an impact on the family and friends of the person who has had a stroke. The family and 
friends are often the ones who provide informal care.  Luengo-Fernandez et al. (2009a) 
estimated an average cost of stroke/TIA per patient of $22,377 US, approximately £15,700 
(using the purchasing power parity exchange rate of £0.70 to 1 US$ (OECD, 2013)). 
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3.3. The budget for health care  
The UK has a publicly funded healthcare system, funded in the most by centralised (UK) 
taxation, which is characterised by a system that is ‘free at the point of use’. The total level 
of funding is therefore determined every year and set by government and civil servants. In 
2012 the budget was £108.8bn (Department of Health, 2012).  
 
Up to April 2013,the annual healthcare budget for England was distributed between 152 
primary care trusts (PCTs) according to population and needs, (Department of Health, 
2012). PCTs had authority for purchasing healthcare from independent providers to meet 
local need. Since April 2013, the PCTs have been replaced by the introduction of clinical 
commissioning groups (CCG) which has granted more powers to GP partners to 
commission the goods and services they want. Healthcare decisions in the rest of the UK 
(Scotland, N. Ireland and Wales) remain devolved and made at country level. Across the 
UK. while funding is not ring-fenced, there are requirements to provide certain treatments 
and services, as well as quality standards (including those relating to the management of 
stroke patients) to try and ensure equality of access. Notwithstanding these attempts, there 
is still regional variation in the patient experiences regionally and nationally.  
 
The potential management options for stroke were previously described in Chapter 2. 
These interventions for the treatment and management of stroke, particularly the use of 
antiplatelet medicines and antihypertensive medicines to control blood pressure, have 
resulted in a steady decline in mortality rates. However, such interventions and 
management options must be funded from a finite healthcare budget. This means that the 
allocation of NHS resources to treat and manage stroke diverts resources from other 
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healthcare treatments (for instance in heart disease, diabetes and cancer as well as less 
prevalent but expensive to treat diseases). Decision makers allocating healthcare resources 
have to make decisions about which interventions represent the most effective use of 
scarce resources.  
 
In the context of stroke these decisions are whether to increase expenditures on (primary 
and secondary prevention) or on acute stroke unit care and rehabilitation. 
 
Treatment versus prevention 
It is estimated that one third of non-fatal strokes result in lasting disability, which imposes 
a significant burden to the NHS and broader economy. However, as Chapter 2 has 
evidenced, the sequelae of stroke could be prevented if patients with TIA were placed on 
appropriate secondary medications or if primary prevention measures were developed to 
detect and treat people with atherosclerosis or if public health measures improved healthy 
lifestyles in cohorts at risk of future stroke. With appropriate planning services could be set 
up to prevent stroke reducing the treatment burden. 
 
3.4. Methods of economic evaluation  
Opportunity cost is a concept that considers choices must be made in the context of a finite 
budget. 
 
When resources are invested in a good or service, the opportunity cost is the benefit 
foregone of the next best alternative use. Within the context of health care, when resources 
are invested in one intervention, the opportunity cost of that choice is the intervention that 
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can not now be funded. The theory of opportunity cost is central to the understanding of 
efficiency in Economics as an efficient outcome is one that secures the most optimal use of 
resources.
4
 
 
Economic evaluation is a framework for comparing the costs and consequences of a health 
care intervention (Drummond, 2005). A healthcare intervention can be a new drug, a new 
device or a new way of managing patients. Typically comparison is made across 
alternatives; nearly always this includes comparison against the existing use of resource. 
 
There are different techniques of economic evaluation.The most commonly used within 
health technology assessment is that of cost-effective analysis (CEA). In CEA benefits are 
measured in natural units (e.g. units of effect, or life years) .A special subset of CEA is 
cost-utility analysis (CUA), which measures benefits (utility) using a summary index 
measure of health status. The majority of cost-utility studies measure benefits using 
quality-adjusted life-year (QALY).  
 
Cost-effective analysis provides a decision maker with an estimate of the value for money 
of one intervention compared with other uses of the healthcare budget. On the assumption 
of a given available healthcare budget CEA provides a basis for maximising health gain 
 
More precisely the cost effectiveness of an intervention, x, is usually stated in terms of the 
expected mean cost of achieving an additional unit of health benefit (either an outcome 
                                                   
 
4
 Within this thesis I use efficien are used interchangeably. 
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based measure such as lives saved, strokes averted or an additional unit of utility). In 
Health Economics utility is normally the health benefit (or detriment in the case of a utility 
loss) that accrues to the patient who receives the intervention.  
 
There are several standardised measures of health status; the most generic across different 
disease areas being the QALY (Briggs et al., 2006). A QALY or quality-adjusted life-year 
considers that life has two dimensions: length and quality of life. One way of thinking 
about this is to consider the value an extra year of life when quality of life is considered: 
one QALY will be equal to one year of life in excellent health, whereas 0.5 QALYs can be 
equal to half a year of life at full health or a year of life with an impaired quality of life, 
quantitatively half of that of ‘full health’. In practice, the way in which QALYs are elicited 
and utilised is one area of uncertainty in the analytical methods used to perform CEA. For 
instance, in Economic Evalation, it is generally held that the quality of life weights should 
capture the preference for being in that health state, versus others. This means that QALYs 
should reflect the individual’s or public’s value for the attributes of health being measured 
(Neumann et al., 2000). 
 
The ICER is defined as the: difference in costs/ difference in consequences. It is 
incremental because it considers the relative difference in costs (per measure of 
consequence) of option 1 vs. option 2. In the case where there are more than two options, 
the calculations are rolled out so that the ICER is calculated for every permissible pair of 
options. Notice that the calculation of the ICER does not make sense in the scenario where 
one option is said to ‘dominate’ another i.e. because it has lower costs and better or 
comparable efficacy than the alternative option. 
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3.5. Types of cost-effectiveness analyses 
There are two main options when performing cost-effectiveness analyses: trial based 
economic or decision models. 
 
Economic evaluations alongside randomised controlled trials 
One vehicle for performing cost-effective analysis is the RCT. In these instances, the trial 
will be the single source of data for the comparative analysis of costs and consequences. 
Advantages of this method are that they provide a reliable estimate of cost-effectiveness 
within the trial and provide patient level data which may be useful for determining 
statistical relationships between events (Petrou and Gray, 2011). However, in 
circumstances where trials would be prohibitively expensive or unfeasible other options 
are needed. An alternative method, which synthesises evidence from a variety of sources, 
is to use a decision model.  
 
Decision Models 
A decision model is a representation of the world constructed to inform a decision. They 
are representations of the world, rather than scientific truth (Weinstein). More formally 
Sculpher et al (2006) see that decision models provide ‘a structure within which evidence 
from a range of sources can be directed at a specific decision-problem (question) for a 
defined population and context’.  
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Decision modelling can be particularly useful in early economic evaluations where there is 
no data on the efficacy/safety of an intervention (Grutters, 2008). Another advantage is 
that they allow for testing of all alternatives (Sculpher et al., 2006).  
 
 
Randomised control trials (RCTs) versus Decision Analytic models 
There are a number of pros and cons of using RCTs evidence for the purposes of economic 
evaluation. The main advantage of RCTs is that they provide an unbiased estimate of the 
treatment effect. Furthermore, an economic evaluation based around a single RCT will be 
a consistent source of evidence, not only for providing an estimate of the treatment effect, 
but potentially for other parameters such as utilities and resource use (so long as this 
evidence was collected as per the trial protocol).  
 
However, recently, there has been some dissent about the use of RCT evidence as the sole 
vehicle for decision making in economic evaluation (Shulpher et al. 2006). A key 
limitation of RCTs is concerned with the applicability of trial based analysis to the 
decision maker’s setting. One reason for this is that there is a failure of RCT based 
economic evaluations to capture all the information that might be relevant to the decision 
maker. Whereas trials examine ‘sub-sets’ of relevant options, clinical practice is 
characterised by a ‘range’ of interventions that might be used in everyday practice in 
‘varying’ degrees (Sculpher et al., 2006). This issue is particularly pertinent to the 
evaluation of the management of TIA patients where interventions are multifaceted. Other 
limitations with trials include the curtailed time horizon and an inadequate dealing with 
uncertainty.  
 49 
 
 
 
Unlike trials, decision models have the ability to incorporate evidence from different 
sources. Since the decision model is an unconstrained framework, the model can more 
properly reflect reality, for instance by capturing all clinically relevant options. In addition, 
the model can capture the full information available to the decision make. The synthesis of 
evidence that this structure accommodates is desirable in that it does not rely on a single 
source of evidence. Providing that appropriate methods of evidence synthesis are used, the 
parameters used within the decision model should therefore be more robust. 
 
The advantage of including all relevant parameters, using an appropriately structured 
decision model has a clear advantage in prospective (or pre-trial) modelling. In situations 
(including this thesis’) where there is no option to use trial evidence, decision modelling 
may be of use in setting research priorities, specifically informing trial design. For 
instance, Sculpher et al. (2006) consider that pre-trial modelling can be used for a ‘rough’ 
estimation of cost-effectiveness of different alternatives, and to identify ‘key’ uncertainties 
in the model.  
 
3.6. Models  
A model is a simplified version of the real world which helps people make a better 
decision (Buxton et al., 1997). Within health care, there are many different types of 
mathematical or computer based models all of which make predictions for different 
purposes (e.g. capacity planning, management of hospital stock inventories, forecasting 
epidemics, mimicking disease progression). Models which estimate the effects of various 
choices are known as ‘decision analytic models’. A basic type of decision analytic model 
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is the decision tree which postulates the outcome of a specific situation with specified 
choices and outcomes. 
 
 
Decision trees 
Perhaps the most common and basic type of model, the decision tree diagrammatically 
represents the probability and valuation (in terms of costs and QALYs) of various 
outcomes occurring (Brennan et al., 2006). It is a convention to represent decision trees 
diagrammatically with square nodes indicating a decision between particular strategies; 
circular nodes indicating points where two or more alternative outcomes are possible 
(Brennan et al., 2006). Particular characteristics of these model which become relevant in 
the later discussion of model selection are that the pathways followed by a particular 
patient is mutually exclusive; patients move along the tree from left to right and that the 
probabilities of an outcome occurring do not vary in a stochastic way.  
 
Decision trees may not be the most elegant way of handling a situation where multiple 
events can occur either concomitantly or in a certain sequential order. Similarly the 
sequential moving of patients from left to right along the tree means that these models 
become laborious when the order in which events occur is not determined. (Related to this, 
these trees do not allow a looping back to earlier event states, so the representation can be 
encumbered by the number of nodes needed to represent possible outcomes). Finally, the 
lack of stochastic variation in outcomes means that this type of tree (unless this assumption 
is relaxed) assumes a homogeneous cohort of patients.  
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Therefore, other types of model are needed. 
 
Markov models 
Markov models are structured around mutually exclusive states rather than along patient 
pathways (Briggs et al., 2006). This potentially allows for a richer modelling of patient 
prognosis because a transition from one disease state to another may be modelled to reflect 
a change in disease progression. The Markov model also allows for a fuller representation 
of time because patient progression is measured in discrete time periods (cycles) which are 
usually of a fixed length. Normally, at the end of a cycle the patient may either move to 
another state (transition to a different state) or remain in the same state. The length of time 
that the patient is in each different disease state before becoming eligible for transition to 
another state therefore becomes an intrinsic part of the model, which is set by the modeller 
who should consider the nature of the disease.  
 
A key limitation of using Markov models is that transitions to other states are 
mathematically independent of the length of time in state. They are therefore 
‘memoryless’. This means that they might not provide a realistic representation of disease 
history if the risk of relapse is non-constant over time or if the risk of relapse is dependent 
on the patient’s former disease history. This assumption can be relaxed by creating 
additional states (‘tunnel states’) that consider the patient’s time in state. These models are 
sometimes referred to as semi-Markov or state-transition. 
  
Chambers et al. (2002) created a semi-Markov model to evaluate the long term care 
options following ischaemic stroke for a hypothetical population based on 30 day 
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survivors of acute ischeamic stroke. The model presented by the authors was in fact 
presented as two linked ‘modules’. The first module (model) was a decision tree detailing 
the treatment options after ischeamic stroke. Key health states included: recurrent stroke, 
on antiplatelet therapy, off antiplatelet therapy and dead. Non-fatal states were further 
stratified according to disability status (disabled or non). Deaths were categorised 
according to cause (acute stroke or other). Efficacy data was identified from trials and 
meta-analyses. Disability status was determined by the proportion of stroke survivors with 
a modified Rankin scale with a score in the range of 0-2 compared with 3-5 within the 
Oxfordshire Community Stroke Project cohort (Rothwell et al., 2005). Health state 
valuations were obtained from direct elicitation of patient’s values (not preferences) for 
post-stroke states (Baruch et al., 2007). Key outcomes were recurrent strokes, costs, life 
years, QALYs and Disability free life years.   
 
Individual sampling models (ISM) 
Individual sampling models (sometimes referred to as patient level simulation models) 
track specific individuals along the path of care that each of them follow (Brennan et al., 
2006). This approach enables the model to accommodate both heterogeneity in patient 
characteristics as well as the unexplained element of variability in patients’ progression 
thorugh the care pathways in the model. Allowing for heterogeneity in patient 
characteristics means that patient attributes may more closely resemble actual patient 
histories which in turn may increase the model’s validity. This might beuseful in the case 
of suspected TIA where different risk factors have been shown to enter additively in a 
prognostic risk score of stroke recurrence (see ‘ABCD2 score’ p. 17). However, this 
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approach might increase the complexity of the model without benefit if the relation 
between patient characteristics and treatment effect is imperfectly known. 
 
Individual sampling models also allow for unexplained variation in the disease 
progression/pathways followed by patients who have same or similar characteristics. The 
accumulation of costs and QALYs depends on the unique pathways experienced by each 
individual, rather than an aggregate approximation for the whole cohort, as in decision 
trees and Markov models.  
 
Brennan et al. (2006) also reported that one key advantage of this type of model is that 
ISM can incorporate ‘time to next event’ rather than being restricted to equal time periods 
as in Markov models.  
 
The ISM can potetially improve the relevance of the model in terms of mirroring the real 
world situation. However, such models require indiviudal patient data, which may not be 
available.  
 
Discrete Event Simulation (DES) 
Discrete event simulation (DES) models are a special type of ISM. As cited by (Barton et 
al., 2004) the key distinguishing factor between ordinary ISM models and DES comes 
down to the issue of interaction between patients, which is useful in modelling the impact 
of treatments or vaccinations for infectious diseases. DES models were first used in 
systems engineering. Unlike the simpler structure of the ISM modelling described in 
section x.x, DES allows for a fuller representation of time. A DES can potentially be 
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designed to count (or simulate) ‘clock’ time, which it does in discrete units determined by 
the model’s next event. There have been several examples of DES in stroke; the majority 
having been produced by the same author (Mant, 2008, National Audit Office, February 
2010). These have been in decision analysis of complex interventions of stroke care, where 
a systems wide approach (i.e. to model competing resources) was needed. The advantage 
of a DES vs. a cohort level would be in evaluating the costs and consequences of initiating 
thrombolytic therapy in acute stroke. While possible in the simpler model, the DES has 
advantages in considering the trade-off between providing a hyper-acute service like 
thrombolysis and other services which might be cut back. 
 
Model selection decision 
In summarising the above model types, it is not possible to identify one as more valid than 
the other. However, certain characteristics might be difficult to implement in the decision 
tree or Markov structures assessed. The taxonomy of model structures by Brennan et al. 
(2006) provides a conceptual representation of the factors that are important to the 
selection decision. One factor that distinguishes between the models is whether time is 
important. Decision trees are essentially timeless, whereas markov models are arranged in 
discrete cycles of time. More sophisticated models such as DES can emulate clock time, 
which is useful if capacity constraints (and specifically the interaction of individuals 
competing for resource) needs to be explicitly modelled (Brennan et al., 2006).  
 
3.7. Guidelines in economic evaluation 
Given the role of economic evaluation in guiding and informing policy decisions, there is a 
need to establish that economic evaluations are of sufficient quality. Economic models that 
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aren’t robust may result in erroneous decisions. In health care policy, the cost of making 
the wrong decision is reflected in the foregone benefits of the best alternative use of the 
resource. This has led to the preponderance of guidelines in the health economics arena for 
research and health technology assessment (e.g. British Medical Journal guidelines, the 
CHEERs statement) to assess the quality of economic evaluations (Husereau et al., 2013). 
 
Areas of Methodological uncertainty regarding model structure  
Aside from the areas previously documented, methodological enquiry is ongoing in certain 
areas of model development (particularly with respect to the early development 
(conceptualisation) stages (Chilcott et al., 2010). This is clearly important since, as 
previously stated, a poorly specified model could lead to a decision rule being applied that 
is sub-optimal/erroneous. 
 
Model parsimony  
This refers to the argument to keep the model as simple as possible without 
oversimplification of the essential elements of the intervention on both the patient pathway 
and disease process (Karnon et al., 2007, Weinstein et al., 2001). However, the precise 
specification of the model is something for the modeller to justify; by its very nature it 
remains subjective and not something that can undergo quality assurance via model 
checklists. 
 
Within the context of the model considered here this may mean ensuring that relevant 
impact(s) of different modelling interventions are fully considered. This may mean that a 
model which accumulates costs and QALYs over its course is preferable to one which 
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relies on estimates of final outcome alone. This implicitly requires the model to consider 
the effectiveness of the timeliness of interventions (i.e. to model the effects of time in 
some way). However, the same approach may not be unnecessary for a disease area where 
time (in terms of time to treatment and time to disease progression) and consequence (in 
terms of costs and utility) do not vary across interventions. 
 
Evidence from different sources/studies 
The synthesis of evidence from different sources requires a systematic approach, and 
possibly the application of epidemiological methods such as meta-analysis. If data is to be 
synthesised from multiple sources then it is important that the effects of different 
populations and outcome measures used is considered as this may introduce bias. In the 
case where data from previously published systematic reviews or meta-analysis are to be 
used it remains important to consider the quality and applicability of these studies to the 
specific research question. 
 
Selection of time horizon 
An area requiring further methodological enquiry identified by Karnon et al (2007) is that 
of the selection of the time horizon. This is largely because the proliferation of models 
using different time horizons (and particularly non lifetime time horizons) may be 
sufficient to turn over policy decision rules. 
 
Treatment of uncertainty 
This requires careful consideration. The model’s treatment of uncertainty will demand an 
understanding of what assumptions the model makes and where the evidence is weakest. 
 57 
 
 
The way in which the model is initially specified and structured is a separate concern to 
the treatment of parameter uncertainty (the precision with which an input parameter is 
estimated) (Briggs et al., 2006). 
 
3.8. Discussion 
This chapter presented economic evaluation as a framework for evaluating the costs and 
consequences of an intervention. A rationale for performing decision analytic models was 
presented. This focussed on the salient features of the intervention being considered within 
this thesis. 
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CHAPTER 4. CRITICAL APPRAISAL OF ECONOMIC EVALUATIONS IN TIA 
4.1. Introduction 
The objective of this chapter is to review systematically and critically, economic models 
that have evaluated the management of acute stroke and/or TIA. This informs the methods 
used to structure and populate this thesis’ economic model (Chapter 4). 
 
To provide valid information for policy decisions, economic models should be based on 
realistic modelling of the health condition. Sculpher et al (2000) make a case for taking 
this further stating that ‘the disease should be the underlying process of any model and 
should drive all decisions about service delivery’. In the context of TIA where symptoms 
have typically resolved by the time of presentation in Primary Care, the important aspect 
of the underlying process would be the risk (particularly the early risk) of a subsequent 
stroke and whether this is mediated by any form of secondary prevention (medical or 
surgical).  
 
While reviews of economic evaluations in stroke exist, the approach and purpose of these 
studies reflects varied purposes for conducting reviews. Jones et al. (2004) undertook a 
systematic review of cost-effectiveness evidence focussing on the medical prevention of 
stroke (exclusively in the agents clopidogrel and modified release dipyridamole). Evers et 
al. (2000) chose to systematically review trial based economic evaluations in stroke 
research (excluding decision analytic models) and Guilhaume et al. (2010) performed a 
qualitative review of stroke management (excluding TIA). Other reviews in specific sub-
sets of stroke prevention and management have also been carried out i.e. imaging 
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sequences prior to carotid endarterectomy, acute stroke treatments and the management of 
stroke in patients with atrial fibrillation (Benade and Warlow, 2002, Earnshaw et al., 
2009); Sandercock et al. (2002).  A de novo search was therefore necessary. The search 
protocol is now outlined. 
 
4.2. Search Protocol 
Search 1: How are models characterised in secondary stroke prevention? 
 
Inclusion criteria 
Population: Patients with TIA or minor stroke 
Intervention: Any form of secondary stroke prevention (i.e. medical, surgical, care setting 
or protocol). Any change to service delivery from patient’s presentation of symptoms 
through to treatment and follow-up. Included interventions will be ‘complex’ health 
service interventions where the term complex follows the convention adopted by the MRC 
as involving ‘several interacting components’ MRC Developing and evaluating complex 
interventions 
Study type: Full economic evaluations (where a full economic evaluation is one 
comparing costs and consequences) published within the last ten years 
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Exclusion criteria: Studies in stroke rehabilitation, in special populations (e.g. atrial 
fibrillation), single technology appraisals.
5
 
 
4.3. Search Strategy 
The keyword search was based on the following strategy (including truncation of terms 
where appropriate): TIA, stroke, prevention, economic evaluation. Filters were not applied 
to isolate complex/policy models; a sift of abstracts was performed to exclude single 
technology appraisals. 
 
In April 2010, five electronic bibliographic databases were searched: MEDLINE; 
EMBASE; Database of Abstracts of Reviews of Effectiveness (DARE); NHS Economic 
Evaluation Database (EED); Cochrane Library. In addition, the ‘grey’ literature was 
searched by exploring the Internet using keywords. The reference lists of idenitfied 
publications were also searched for further relevant modelling studies. In May 2013, the 
search was updated. 
 
4.4. Results  
A flow diagram detailing the selection of economic evaluations is provided in figure 4.1. A 
summary of the cost-effectiveness models included in this appraisal are presented in tables 
1 and 2.  
                                                   
 
5
 Note that a single technology appraisal usually only considers one technology and is therefore not likely to have 
applicability to the policy context of this thesis. NICE. 2004. Guide to the Methods of Technology Appraisal. 
[Online]. Available: http://www.nice.org.uk/niceMedia/pdf/TAP_Methods.pdf. 
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Figure 1: Flow diagram of selection of economic evaluations for service delivery 
models of stroke management 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Total number of abstracts 
identified in literature: 140 
 
     Abstracts studied for 
inclusion: 140 
 
Excluded (non-original models 
and country adaptations): 7 
 
 
 
     Articles included: 8 
 8 = to discuss (one not full CEA) 
 7 = to include 
Additional full text papers 
identified from references 
and other sources: 3 
 
 
Excluded in first instance: 128 
 
 
 
     Full text papers 
studied for inclusion: 12 
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The criteria used to appraise quality were based on published checklists in economic 
evaluation described previously (Husereau et al., 2013, Philips et al., 2006, Drummond, 
2005). The main checklist for this purpose was Philips et al. (2006). 
 
For each included paper, the structure of the model and methods for identifying, analysing 
and incorporating data in models was assessed. In addition, the authors' handling of 
uncertainty and evaluation of consistency was considered. Data was extracted into 
evidence tables in the first instance; these tables informed the design of the summary 
tables and the subsequent discussion  Table 10 and  Table 11).     
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 Table 10: Summary of published economic evaluations 
Author 
(year), 
country 
Comparators Effectiveness Resource use      
(price year) 
Analytic 
approach 
Model outcomes Parameters 
driving cost-
effectiveness  
Chambers et 
al. (2002), 
US 
 
Viewpoint: Societal 
and 3-rd party payer 
Alternatives: ‘new’ 
interventions: dual 
antiplatelet therapy, 
thrombolytic therapy 
and stroke unit care 
(all above compared 
to conventional 
practice). 
 
Analysis of RCT, 
published meta-
analysis cohort 
study for 
treatment efficacy, 
treatment 
discontinuations, 
and death. 
Costs 
presented for 
four 
countries at 
1996 prices, 
primarily 
from 
national 
sources.  
Cost-
effectiveness 
analysis. 
Linked decision 
analytic models – 
decision tree 
(short term); 
Markov (long 
term) 
Time horizon: 
Lifetime  
Uncertainty: Not 
reported. 
Incremental 
cost/QALY in 
addition to 
incremental 
cost/stroke averted, 
incremental cost/life 
year gained.  
ICERs show that 
thrombolysis is cost 
saving, dual 
antiplatelets were 
cost-effective when 
compared to aspirin.  
Stroke incidence, 
efficacy, long-
term care cost, 
service cost 
associated with a 
service to 
diagnose and 
provide 
thrombolysis. 
Sensitivity 
analysis: not 
reported. 
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Author 
(year), 
country 
Comparators Effectiveness Resource use      
(price year) 
Analytic 
approach 
Model outcomes Parameters 
driving cost-
effectiveness  
Moodie et 
al. (2004), 
Australia 
 
Viewpoint: third-
party payer 
Alternatives: current 
practice,thromblytic 
therapy, asprin 
therapy. 
Risk/ risk 
reduction of 
mortality, stroke 
and haemorrhage 
associated with 
therapy. 
Australian 
1997 prices 
converted to 
US $. 
Incremental 
resource use 
only 
identified  
(i.e. 
associated 
with 
reduction in 
beddays). 
Cost-
effectiveness 
analysis. 
Decision analytic 
model (not 
defined) 
Time horizon: 
lifetime 
Uncertainty: 
univariate and 
probabilistic. 
Incremental 
cost/DALY. 
 
ICER: thrombolysis 
is cost-saving. 
Aspirin therapy is 
cost-effective. 
Hospital 
discharge rate, 
access to stroke 
units for 
thrombytic 
therapy. 
Sensitivity 
analysis: no 
reported impact 
on decision. 
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Author 
(year), 
country 
Comparators Effectiveness Resource use      
(price year) 
Analytic 
approach 
Model outcomes Parameters 
driving cost-
effectiveness  
NICE 
(2008), UK 
 
Viewpoint: third-
party payer 
Alternatives: 
immediate access 
TIA clinics, weekly 
clinics, GP 
management (no 
referral). 
. 
Based on 
therapeutic effect 
of dual 
antiplatelets 
(aspirin-
dipyridamole). 
Applied a risk 
reduction to 
baseline stroke 
risk. Authors do 
not state that the 
risk reduction is 
absolute. 
UK 2007 
prices. 
Time horizon: 
Lifetime (based 
on extrapolation 
of outcomes from 
a 90 day model) 
Uncertainty: 
Univariate. 
Extensive testing 
of assumptions 
used to populated 
model. 
ICER: Immediate 
clinics dominate 
weekly clinics. 
Cost/QALY=£3330 
when immediate 
clinics are compared 
to GP management. 
Speed by which 
treatments are 
intiated. 
Sensitivity 
analysis: No 
effect on 
recommendation 
of immediate 
referral for 
patients with an 
ABCD2 score≥4 
PSA not carried 
out. 
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Author 
(year), 
country 
Comparators Effectiveness Resource use      
(price year) 
Analytic 
approach 
Model outcomes Parameters 
driving cost-
effectiveness  
Birmingham 
TIA (2008) 
 
Viewpoint: 3
rd
 party 
payer 
Alternatives: Rapid 
assessment specialist 
clinics with different 
outpatient booking 
systems. 
Regression 
methods applied 
to Oxford 
Vascular data to 
determine the 
recurrent stroke 
risk by ABCD2 
score. 
2007 or most 
recent 
available 
year. Non-
recent years 
were inflated 
using 
relevant 
price index.  
Discrete event 
simulation model 
Time horizon: 
10 years (period 
of ongoing 
patient 
enrolment) with 
1 year of follow-
up. 
Uncertainty: 
deterministically 
tested. 
Stokes averted. 
Cost/QALY 
(approximation) 
 
ICER: £1500/QALY 
for strategies where 
all suspected TIA are 
referred. 
 
Use of 
emergency 
ambulances, 
alternative 
referral rules for 
GPs, improved 
GP diagnosis. 
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Author 
(year), 
country 
Comparators Effectiveness Resource use      
(price year) 
Analytic 
approach 
Model outcomes Parameters 
driving cost-
effectiveness  
Stahl et al. 
(2003), US 
Viewpoint: 3
rd
 party 
payer. 
Alternatives: 
Acute stroke 
treatments delivered 
according to protocol 
vs. routine clinical 
practice (where 
delivery is less 
timely). 
 
Transition 
probabilities for 
recovery or 
worsening of 
functional 
outcome (by 
Rankin scale). 
US $, 2000 
prices. 
Model type: 
Discrete event 
simulation model 
Time horizon: 
lifetime. 
Uncertainty: 
structural 
uncertainty tested 
by varying the  
incidence of 
stroke and costs.  
Incremental cost US 
$/QALY 
ICER: Protocol 
complicant strategy 
was dominant when 
compared with 
current practice. 
Model is 
sensitive to 
numbers of stroke 
and non stroke 
patients 
competing for use 
of imaging 
devices. 
Sensitivity 
analysis: model 
robust unless cost 
of 
implementation 
are prohibitive. 
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Author 
(year), 
country 
Comparators Effectiveness Resource use      
(price year) 
Analytic 
approach 
Model outcomes Parameters 
driving cost-
effectiveness  
Wardlaw et 
al. (2006), 
UK 
Viewpoint: 3
rd
 party 
payer 
Alternatives: 21 
different imaging 
algorithms using 5 
different diagnostic 
tests.  
 
Method used to 
estimate 
effectiveness: 
meta-analysis of 
individual patient 
level data of tests 
used in the 
diagnosis of 
carotid stenosis. 
 
 
UK 2003/4 
prices. 
Model type: 
State transition 
Time horizon: 
20 years 
Uncertainty: 
testing of 
extreme values 
and using this to 
place confidence 
intervals around 
net benefit.  
ICER: less invasive 
tests are cost-
effective (have 
highest net benefit) at 
WTP thresholds of 
£20,000 - £30,000. 
Ultrasound should be 
used first in the 
sequence of tests (as 
the preferred 
strategy). 
Cost of 
endarterectomy, 
time to surgery. 
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Author 
(year), 
country 
Comparators Effectiveness Resource use      
(price year) 
Analytic 
approach 
Model outcomes Parameters 
driving cost-
effectiveness  
NAO (2010) Viewpoint: 3
rd
 parrty 
Alternatives: current 
stroke care pathway 
versus more 
thromoblysis 
perfromed, and 
increased public 
awareness  
Stroke. 
Population-based 
sources (South 
London Stroke 
register, National 
Audit). 
UK 2008 
prices. 
Model type: 
Discrete event 
simulation 
Time horizon:10 
years 
Uncertainty: 
model run 
multiple times to 
test uncertainty. 
Discount rates 
altered. 
ICER: Further 
improvements were 
cost-effective at a 
cost/QALY of £2858. 
Sensitivity 
analysis: 
Rerunning 
scenarios had no 
effect. 
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 Table 11: Summary of key model inputs and assumptions 
 Chambers et 
al.  
 
Moodie et 
al.  
 
Birmingham 
TIA (Mant et 
al.) 
Stahl et al. Wardlaw et al. NICE  NAO 
Method 
for 
modelling 
stroke 
recurrence 
Constant risk 
per 3 month 
cycle. 
Not 
described. 
Parametric 
survival 
function 
(Weibull 
distribution) 
based on 
patient level 
survival data. 
Constant annual 
transition 
probabilities after 1 
year. (Prior to 1 
year the model 
assumes transition 
associated with 
functional 
improvement or 
worsening only). 
Variable cycle 
lengths within the 
model (shortest was 
daily, longest was 
four 
weekly).informed 
by cumulative 
stroke risks. 
Parametric 
survival 
function 
(exponential) 
based on 
patient level 
data. 
Not clear  
how 
probabilities 
(from 
observational 
study evidence) 
were used  
as parameters 
 in the model.  
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 Chambers et 
al.  
 
Moodie et 
al.  
 
Birmingham 
TIA (Mant et 
al.) 
Stahl et al. Wardlaw et al. NICE  NAO 
Data 
source for 
stroke 
recurrence 
Secondary 
sources: 
RCT and 
meta-
analysis of 
RCT data. 
Secondary 
sources: 
systematic 
review and  
RCT data. 
Authors 
analyse 
patient level 
data collected 
in Newcastle 
in the 
emergency 
setting. 
Secondary 
sources:National 
lifetables. Risk 
constant for all 
patients after first 
year in model.  
Relative risks by 
stenosis group used 
to adjust baseline 
risk of cumulative 
stroke in 
observational 
studies. . 
Observational 
study data for 
baseline risk 
adjusted by 
therapeutic 
effect from 
RCT. 
Secondary 
sources: 
observational 
registries. 
  
 
7
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 Chambers et 
al.  
 
Moodie et 
al.  
 
Birmingham 
TIA (Mant et 
al.) 
Stahl et al. Wardlaw et al. NICE  NAO 
Valuation 
of benefits 
Gage et al. 
(1996)  
Direct 
elicitation of 
patient 
preferences 
using 
standard 
gamble and 
time trade 
off. 
Dutch 
disability 
weights 
(2000) 
(Visual 
analogue 
scale and 
Time Trade 
Off)   
Gage et al. 
(1996) 
 (Values used 
in model do 
not match 
valuations 
with 
reference.)  
Multiple published 
sources. 
Method unclear. 
 
Dorman et al. 
(2000) .  
EQ-5D to 
international stroke 
trial participants. 
Dorman et al. 
(2000) .  
 
Van Exel et 
al. (2004)  
Based on 
published 
values. 
Converted 
from the 
Barthel index. 
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This review identifies relatively few (n=8) modelling studies in secondary stroke 
prevention. Most of these studies differed in terms of the precise decision problem(s) they 
were approaching and the interventions they were assessing. In general, all the studies 
suggested that interventions conferring even modest incremental benefit to the patient 
tended to be cost-effective. Comparison of results directly is not possible mainly because 
of differences in the specified populations, the range of alternatives and diseases modelled, 
and the assumptions relating to how the service pathway affects patient outcomes. 
 
4.5. Structure 
All models provided a clear indication of the research question, alternatives, time horizon 
and perspective. Most models adopted the perspective of the 3
rd
 party payer; in a few 
instances, a societal perspective was adopted. The choice of perspective related to the 
purpose and context of the model. 
 
A variety of different model types were used, from simple decision tree to discrete event 
simulation. As might be expected, simulation type models tended to be employed when the 
impact of capacity constraints (e.g. delay to a TIA clinic appointment) needed explicit 
modelling. In these cases, the queue was essentially determined by the inputs to the model. 
However, simple model structures were used to model the impact of assumed delays to 
treatment on service provision. For instance, in an acute stroke treatment model, Moodie et 
al. assume that a delay to investigation restricts the proportion of the population eligible 
for the intervention. A disadvantage of this approach is that, when the proportion of 
patients is arbitrarily set, the relationship between inputs (resource used) and outputs is no 
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longer reflective of actual usage.  A more sophisticated model would consider the capital 
outlay associated with increasing the proportion of patients eligible for this service. 
 
In all cases, the authors presented a “coherent theory of the health condition under 
evaluation”, and explored a range of alternatives (Philips et al., 2006). However, the 
methods for modelling stroke recurrence were strikingly different ( Table 11). Given that 
TIA and minor stroke are both associated with a heightened early risk of recurrence, it 
would seem important that a model capture the attenuation in stroke risk over time. Two 
models reported fitting parametric or semi-parametric curves to patient level data to 
capture this (Mant et al, 2008; NICE, 2008). In two instances, no reference to the methods 
used was made. Stahl et al report that they varied the cycle length within their state 
transition model to allow for an attenuation of risk over time; this suggests that the 
transition probabilities varied in discrete intervals of time. This may reflect the underlying 
data. Phillips et al. caution against allowing data availability to determine the structure of a 
model, but also acknowledge that is reasonable to accept that data availability can limit or 
refine model structure. The use of survival methods, variable cycle lengths and non-
constant transition probabilities all appear to be suitable refinements. 
 
Compared to trials, decision analytic models also have greater flexibility in the extent to 
which they can consider all alternatives. In the context of stoke/TIA prevention, examples 
of this include the mathematical model produced by Wardlaw et al. to test not only 
different imaging strategies but different imaging sequences for carotid endarterectomy. 
Two models appear to be constructed specifically for the purpose of being able to test 
policy interventions. For instance, Chambers et al. combined treatment and prevention 
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modules in their model. This enabled them to make simultaneous recommendations about 
thrombolysis, stroke unit care and aspirin therapy.  
 
4.6. Data 
All eight modelling studies used evidence synthesis from a variety of sources as opposed 
to being primarily based on a single trial. All models reported the data sources used to 
estimate parameters. However, the review methods used to select parameters were not 
always provided, so these studies failed to consider bias. All of the models faced 
challenges in determining the treatment effect associated with the service delivery 
intervention. The treatment effect tended to be determined by multiple inputs; these were 
often from different sources. For example, the NICE acute stroke model compared weekly 
TIA clinics, immediately accessible TIA clinics and an option of GP management alone. 
The treatment effect was determined by: the time when treatments were initiated, which 
treatments were initiated, the patient’s ABCD2 risk score and the level of carotid stenosis.  
 
Table 12 provides the short-term assumptions in the NICE model under each service 
pathway. Sources for the parameter inputs included meta-analysis of carotid surgery trials, 
a RCT of aspirin-dipyridamole versus aspirin alone, a population-based study of stroke 
incidence and secondary analysis of a database of GP prescribing.  
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Table 12: Assumptions (service pathways) made in NICE (2008a) and impacts 
 Assumptions relating to service 
pathways 
Impacts 
Immediate TIA clinic Optimal medical management 
initiated immediately. 
Majority of carotid surgeries 
performed within 2 weeks. 
Immediate clinics more expensive to 
run than weekly clinics. 
Improved efficacy (risk 
reduction applied to baseline 
stroke rate). 
Higher costs associated with 
TIA clinic service. 
Higher drug costs. 
 
Weekly TIA clinic Optimal treatments initiated with 
delay. 
Majority of carotid surgeries 
performed within 2-4 weeks. 
Lower efficacy compared to 
immediate TIA clinic.  
GP management 
alone 
Optimal treatments not offered. 
No imaging or referral for carotid 
surgery. 
Least efficacious but no costs 
associated with running TIA 
service.  
 
 
In the main, the measure of benefit was presented in terms of QALYs. Several modelling 
studies replicated approaches offered in other publications, which might point to 
publication bias. Certainly the methods for valuation of benefits were often not reported by 
the authors (Table 11), it was necessary to check the secondary source. 
 
Typically the cost perspective used included healthcare as a minimum. In three of the 
models, an attempt to capture the long-term costs allowed for a broader representation of 
costs; however the paucity of data on informal care and indirect costs meant they were 
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often excluded. Another simplification was often that resources were assumed to be 
flexible and not capacity constrained. In the main, resources were presented in units, 
alongside costs. Unit costing tends to assume that there are constant returns to scale; it is 
easy to see that this assumption might not hold where the n
th
 additional patient requires 
capital outlay (e.g. opening a new hospital ward). Other commentators have highlighted 
the dangers of the assumption of resource use flexibility and incomplete descriptions of 
costs in economic evaluations of service delivery (Godber et al., 1997, Coast et al., 2000).  
 
4.7. Uncertainty 
All models used some method for dealing with uncertainty. All performed univariate 
analysis as a minimum. To some extent, the model type dictated whether probabilistic 
analysis could be implemented, as this is non-straightforward in simulation based models 
which are typically set up to model patient (as opposed to parameter) variation as a random 
process. One Discrete Event simulation reported re-running its analysis several times for 
all scenarios to check that the results (with respect to randomness) were replicable. 
 
4.8. Consistency 
Five of the studies commented on at least one aspect of model consistency. Four of the five 
studies made reference to the generalisability of their findings, often via direct comparison 
with results in other modelling studies.  Expert opinion appeared to feature highly in 
ensuring that the models had face validity with clinicians, but authors did not report the 
techniques used to achieve this. 
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There was a failure of all but one study to report detail on the checks used to control for 
model error, yet model error is a key risk to the credibility of the model (Chilcott et al., 
2010).  
 
4.9. Strengths and Weaknesses 
The strength of this study is that it appears to be the only study that appraises a range of 
modelling studies in service delivery interventions without exclusion of TIA. The 
weakness is that often the data reporting of analytical methods (within the included 
studies) lacked transparency; this makes it difficult to appraise the suitability of the 
mathematical modelling techniques employed. In one case, the model type was not stated 
and the analytical method used was not otherwise obvious from the description of the 
model’s scope. In general, the methods of pre-model data analysis were poorly 
documented. However, most papers adhered to the quality standards of the Philips’ 
checklist in terms of a clear statement of the research question, detail on model structure 
and data inputs and appropriate methods for dealing with uncertainty.  
 
4.10. Discussion 
In order to inform the methods for structuring and populating a model in the TIA Primary 
Care setting, a critical appraisal of existing models in acute stroke/TIA was carried out. 
Critical appraisal was necessary to inform the selection of model type and the analytic 
methods for modelling in the TIA setting. Models identified within this critical appraisal 
varied from the simple decision tree to more complex discrete event simulations. Selection 
decisions were often not provided by the authors.  
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In terms of results, there was little to suggest that the different model types would result in 
different results. Perhaps unsurprisingly, given the high economic burden of disabling 
stroke, interventions that provided modest benefit to the patient were often cost-effective at 
willingness to pay thresholds typically accepted in the UK (NICE, 2004). Model selection 
decisions seemed to reflect the remit of the policy maker. More complex models tended to 
be used to establish the efficiency of the system of care (of which the intervention is part 
of) as opposed to the efficiency of the intervention per se.  
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CHAPTER 5: METHODS 
5.1. Introduction 
This chapter begins by stating the primary aim and the objectives of this thesis. The 
chapter then describes the methods to be used to address the objectives and involves two 
main approaches. Firstly, the chapter will describe the methods used to build and structure 
an economic model of alternative models of service delivery to manage TIA (see 5.4. 
Structuring the model methods). Secondly, the chapter will describe the methods used to 
identify cost-effectiveness data for use in the model (see 5.6. Identification of Evidence). 
 
5.2. Study Aim 
The primary aim of this thesis is to identify and quantify the incremental costs and benefits 
of GP initiation of treatment following a suspected TIA (hereafter referred to as The GPiT 
strategy) compared with best practice. 
 
5.3. Study Objectives 
The objectives of this thesis are to:  
i. Build and structure an economic model to compare the GPiT strategy with best 
practice.  
ii. Identify and quantify the incremental costs of the GPiT strategy model compared 
with best practice. 
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iii. Identify and quantify the incremental benefits of the GPiT strategy model 
compared with best practice. 
iv. Analyse the incremental costs and benefits of the GPiT strategy compared with 
current practice. 
v. Perform a sub-group analysis to identify the impact of the management of patients 
who present with different clinical characteristics following TIA. 
vi. Identify and quantify the uncertainty around the incremental costs and benefits of 
the GP model compared with current practice. 
vii. Identify the need and type of future research. 
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5.4. Structuring the model methods 
This section provides a specification of the model structure.  
Purpose of the model 
The purpose of the model is to identify and quantify the incremental costs and benefits of 
GP initiation of treatment following a suspected TIA (hereafter referred to as The GPiT 
strategy) compared with best practice (base-case). In the UK there is compelling evidence 
from NICE and the Department of Health to suggest that prompt assessment and treatment 
of suspected TIA in specialist rapid access neurovascular clinics is both effective and cost-
effective (NICE, 2008). One specific point of guidance made by both parties is that 
suspected high–risk TIAs identified in primary care should be seen within 24 hours of 
patient presentation, with the remainder within one week
6
. In spite of these 
recommendations, there is less compelling guidance on how the NHS should arrange and 
deliver its services to ensure that TIA patients are treated in such a timely manner; an issue 
perhaps more pertinent given the results from a UK wide audit of TIA services 
documenting far from timely responses (NICE 2008a, Mant 2008).  
 
                                                   
 
6
 Note that the relevant time interval for patients seeking care in this model is limited to the delay between 
patient presentation and initiation of appropriate treatment. This model does not consider the delay between a 
patient’s experience of symptoms and presentation with symptoms, which can be lengthy for some patients. 
Clearly, both forms of delay increase the risk of early recurrence due to untreated TIA. A natural extension 
of the GPiT model, not considered here, would be to consider delivering GPiT simultaneously with a public 
education campaign aimed at reducing time to patient presentation. Public awareness of symptoms 
suggestive of stroke have already been targeted by FAST, but there may be some reticence about patients 
seeking GP assistance, especially if symptoms are experienced outwith normal GP surgery hours (Lasserson, 
D. S., Chandratheva, A., Giles, M. F., Mant, D. & Rothwell, P. M. 2008. Influence of general practice 
opening hours on delay in seeking medical attention after transient ischaemic attack (TIA) and minor stroke: 
prospective population based study. BMJ, 337, a1569.) 
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Selection and justification of modelled alternatives  
Identification of current practice  
In order to identify current practice for the purposes of the modelled intervention, 
information from national audit was used to determine the timeliness of service provision 
and data from non-urgently treated TIA services was used to estimate risk (Giles and 
Rothwell, 2007a). The studies used for this purpose have been documented more fully 
elsewhere (see Chapter 2). 
 
Identification of best practice 
Giles and Rothwell (2007a) systematic review and meta-analysis identifies the most 
clinically effective TIA services (for which there is evidence) are rapid access, non-
appointment based clinics run by specialists.  The unambiguous finding reported here and 
elsewhere is that more timely specialist treatment very effectively reduces the risk of 
subsequent vascular events (in the region of the observed 80% relative risk reduction at 90 
days documented in the EXPRESS study). In the most clinically effective TIA clinics in 
the UK the care pathways are unchanged from current practice previously documented. 
The crucial difference is that patients are placed on best medical treatment sooner.  
 
Description of care pathways  
The base-case comparison is between the intervention, the GPiT strategy (Figure 2) and 
the comparator, best practice (Figure 3). 
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In both cases, the focus is on what has happened once the patient has presented with 
symptoms to the GP and the GP makes a diagnosis equivalent to ‘suspected TIA’. Patients 
in whom the GP does not suspect TIA are diverted away from the care pathways for TIA. 
Intervention, the GPiT strategy: 
Figure 2 is a diagram of the care pathway associated with the GPiT strategy.  In this care 
pathway, the GP initiates treatment and then refers the patient to a rapid access clinic for 
specialist assessment and review of medication. 
Comparator, best practice: 
Figure 3 is a diagram of the care pathway associated with best practice. In this care 
pathway, the GP does not treat but assesses the patient and refers to a rapid access clinic 
for specialist assessment and initiation of treatment. 
Note that the term ‘care pathways’ adopted here refers uniquely to the patient routing 
associated with the respective strategies.  
 
    
    
 
Figure 2: The patient care pathway associated with the intervention (GP initiation of 
treatment) 
 
 
GP action 
• initiates 
treatment 
Specialist action 
• reviews 
GP action 
• follow-up 
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Figure 3: The patient care pathway associated with the comparator (best practice) 
 
Population 
The population is defined as all presenting patients in primary care in whom the GP 
suspects TIA. In order to reflect the clinical situation, the population includes non-true TIA 
cases which the GP misdiagnoses as suspected TIA (i.e. TIA mimics).  
 
 The proportion of true TIA relative to TIA mimic is set at a level based on results from 
systematic review of diagnostic accuracy studies in primary care (see Chapter 6). Patients 
not presenting to their GP, missed TIA diagnoses (i.e. the false negatives) and those with 
unresolved symptoms at time of presentation (i.e. potential strokes) are excluded for 
reasons previously outlined.  In addition, it is assumed that specialists are perfectly 
accurate i.e. have 100% sensitivity and specificity. 
 
Timing of care pathways (base-case) 
Table 13 details the distinction in the timeliness associated with the care pathways in the 
base-case model. The care pathways and their associated timings allow for a fuller 
description of the alternative models of health service delivery of this thesis’ enquiry.  
GP action 
• refers 
Specialist action 
• initiates 
treatment 
 
GP action 
• follow-up  
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Table 13: Strategies to be compared 
The base-case comparison is between the comparator, best practice, and GPiT. 
Best practice 
Best practice is assumed to be analogous to that exemplified in the 2007 publication of the 
National Stroke Strategy. This means that all patients with suspected TIA who have an 
ABCD2 score of 4 (hereafter high risk) or above are assessed by a specialist within 24 
hours or within 7 days for the remainder (i.e. patients with ABCD2 scores 3 and below 
(hereafter low risk)). Patients who have their diagnosis of TIA confirmed by a specialist 
will be started on a treatment regimen that includes dual antiplatelet therapy (aspirin – 
dipyridamole) in addition to statins and antihypertensives.  
GPiT  
As for the best practice, the alternative model sets to achieve the same standard of care 
regarding the timeliness for referral to a specialist. However, in the baseline analysis, 
treatment is initiated in all patients (i.e. including TIA mimics) on the day they present to 
the GP, i.e. a mean 24 hours sooner (high risk) or up to 7 days sooner (low risk). Patients 
continue to be referred to a specialist for assessment and review of treatment; at this point, 
TIA mimics will have their treatment discontinued. 
 
Identification of the model base-case  
The base-case comparison is GPiT versus best practice. A secondary analysis will compare 
GPiT with the performance of current practice. 
 
The base-case of the economic model assumes that a proportion of all suspected TIAs 
identified by GPs will be TIA mimics. The assumption that GPs are not perfect 
diagnosticians of TIA has been shown to be a very valid one in the findings of several 
population based studies in suspected TIA (Chandratheva et al., 2011). This is unsurprising 
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given the clinical nature of TIA, which has no ‘gold standard’ test in diagnosis. The 
economic model assumes that all patients who see specialists are appropriately imaged and 
receive the correct diagnosis. In addition, the model implicitly knows the true diagnoses 
and ratio of TIA: TIA mimic. 
 
Rationale for choosing intervention/comparator(s) 
The rationale for GPiT is that initiation of treatment at the earliest possible opportunity
7
 
may confer extra benefit to the TIA patient, given the heightened early risk of stroke 
following TIA. However, quantifying this benefit will depend entirely on the accuracy 
with which GPs correctly identify suspected TIA since there is a possible risk associated 
with inappropriate treatment in TIA mimics. (Precisely, this risk will depend on the non-
stroke pathologies that GPs mislabel as suspected TIA). Decision analysis allows for 
quantification of this trade-off in terms of incremental costs and benefits to assess the 
feasibility of a trial. 
 
5.5. The economic model 
The objective of this section is to explain why an economic evaluation has been carried 
out, why CEA is the chosen form of economic evaluation and why a Markov model has 
been selected. i.e. to outline the purpose for the summary description and structure of the 
economic model. 
                                                   
 
7
 For the patient presenting in Primary Care. 
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Summary Description of the economic model 
A Markov (state transition) model was developed in Microsoft Excel (Microsoft 
Corporation) to simulate outcomes following a suspected TIA. The structure of the model 
was informed by current literature and expert opinion (a steering group of clinicians and 
health economists) on the early management of TIA (TIA steering group, 2008). 
 
In the base-case, the model estimates the incremental cost and incremental benefit (in 
terms of QALYS) of GP initiation of secondary prevention agents (relative to the next best 
strategy) at 90 days and via extrapolation of outcomes at 90 days to a lifetime horizon. The 
model also makes a projection about the sequelae of clinical events  (e.g. stroke free 
survival, major haemorrhagic events and carotid surgeries) following TIA up to 90 days.  
 
Within the Markov model, a 90 day time horizon was selected in order to provide a 
projection of the clinical outcomes of a strategy of GP initiation of treatment. This was to 
allow for comparison with published outcomes corresponding to best practice in the 
EXPRESS study 90 days from follow-up (Rothwell et al., 2007). Model predictions that 
coincide with clinical follow-up may have more face validity with clinical experts in the 
field (Briggs and Sculpher, 1998). 
 
As well as estimating the ICER at 90 days, the model also makes a projection about the 
risk of major haemorrhage occurring in the GPiT strategy that is not available elsewhere. 
In the acute phase, the model calculates the number of patients transferring from a state 
where the patient has had a suspected TIA to each of four non fatal health states and five 
fatal states. Table 14 lists these states. 
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 The model employs a fixed cycle of one day. The cycle length chosen was deliberately 
short in order to capture the potential benefit from GP initiation of treatment being at least 
a day sooner. This cycle length was informed by epidemiologic review and modelling on 
the benefit of early treated TIA in terms of recurrent stroke risk.  
 
In the base-case, a hypothetical cohort of 1000 TIA patients with suspected TIA is 
modelled for 90 days. In the initial development of the model, it was assumed that GPs are 
perfectly accurate, i.e that there are no ‘mimics’. In further iterations of the model 
development, this assumption was changed to allow GPs to make false positive TIA 
diagnoses (of suspected TIA). This was on the basis of clinical opinion and the findings on 
a review of the diagnostic accuracy of primary care practitioners in TIA. Note that the 
model does not account for false negatives in the analysis. As discussed in Chapter 2, the 
diagnosis of TIA in Primary Care is essentially clinical, where a diagnosis is essentially 
made by ruling out other conditions rather than ruling out TIA. This means that negative 
cases will not routinely come to light (there is likely to be no record). However, it is 
important to recognise that false negatives represent a susceptible patient group who may 
face a higher risk of recurrence (as they are not identified for timely treatment), and that if 
GPiT was implemented nationally it would be worthwhile to consider investing in an 
appropriate supporting program of clinical education (Lasserson, 2013). 
 
The reference year for costs was 2011/2012. The viewpoint of the analysis is the UK NHS.  
The viewpoint of the analysis is the UK NHS. This perspective is narrower in the sense 
that it does not include the costs associated with personal and social care, which are likely 
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to be a major component of the economic burden of stroke. The rationale for the narrower 
perspective was twofold: 1) the 3rd party healthcare payer needs to be persuaded of the 
healthcare outcomes within its own budgetary domain; 2) estimates of personal and social 
care costs over the remaining lifetime are difficult to obtain and subject to widespread 
variation depending on the methods used to value care costs. 
 
Using the UK NHS perspective is conservative, in that it will be ignoring social care costs: 
if the GPiT model leads to reduced risk of stroke, then the lower social care costs 
associated with fewer strokes will not be incorporated in the final results. Thus, overall, the 
effect will be to under-estimate the cost effectiveness of the GPiT model. 
 
In the acute phase of the model, there is no discount factor. This is because the modelled 
time horizon is only 90 days, which was chosen to reflect the differences in outcome 
following the intiation of antiplatelet therapies. No half cycle correction was applied, again 
because of the very short cycle duration. In the lifetime analyses of the extended model, a 
discount rate of 3.5% per annum on costs and benefits which is in line with that currently 
recommended by NICE methods guidance  (NICE, 2004). 
 
Structure of the economic model 
Table 14 describes the health states used in the model. These health states are: TIA, 
Ischaemic stroke, Haemorrhagic stroke, Carotid surgery, Major haemorrhage, Fatal 
ischaemic stroke, Fatal haemorrhagic stroke, Surgical death, Fatal major haemorrhage and 
other cause death.  Figure 4 shows the possible transitions between health states in the 
Markov model. The boxes are the health states and the arrows represent the possible 
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transitions between them. The circular arrows represent the possibility of remaining in that 
particular state over each cycle. In the initial development of the model complications of 
carotid surgery other than death were not considered; however, extension of the model to 
consider these outcomes was later introduced. This allowed patients to move from the 
carotid surgery states to experience major haemorrhage and haemorrhagic stroke. Within 
the model structure, a simplification was that any death following a major event (stroke, 
major haemorrhage, or carotid surgery) was counted as cause-specific.  
 
Table 14: Description of health states used in the acute phase of the model 
State  Description 
TIA  Patient has had a suspected TIA, and the acute 
symptoms (relating to the TIA) have resolved. All 
patients enter the model in this state, and remain in this 
state so long as they do not have an event.  
Ischaemic Stroke Patient has an ischaemic Stoke  
Haemorrhagic Stroke Patient has a haemorrhagic stroke (includes any 
haemorrhage within the cerebral cortex of the brain?) 
Carotid  surgery Patient undergoes surgery for carotid stenosis 
Major haemorrhage Patient has had a non fatal major haemorrhage 
Fatal ischaemic stroke Underlying cause of death is ischaemic stroke* 
Fatal haemorrhagic stroke Underlying cause of death is haemorrhagic stroke* 
Carotid surgery death Patient dies following surgical complications. Surgical 
deaths include all deaths during or after surgery 
attributable to carotid surgery. 
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Fatal major haemorrhage Underlying cause of death is major haemorrhage 
Other cause death  Underlying cause of death is non-vascular 
† Patients entering these states continue to reside in these states until death or 90 days, 
whichever is the sooner. States therefore include the rehabilitation period post-event. 
*Underlying cause of death is defined as any death within 90 days of a major event 
(stroke, major haemorrhage or surgery) 
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Figure 4: Markov cohort simulation model 
 
The risk of transition from the initial state to each of the other states is determined by 
a unique transition probability associated with that transfer. Patients remaining in a 
particular health state are represented by the circular arrows. 
 
Within the model, the entire population begins in the suspected TIA health state. The 
model assumes heterogeneity in patient’s risk of recurrent vascular events; chiefly patients 
are characterised according to whether they are high or low risk, and these clinical 
characteristics (as ABCD2 scores) are observed by GPs.  
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The model assumes errors in the accuracy of TIA diagnoses by GPs via false positive 
referrals to TIA services. A TIA mimic is defined as a patient who experiences symptoms 
suggestive to the GP as TIA but whose symptoms are the result of another pathology.  The 
main source of evidence for intervention effectiveness is observational study evidence 
derived from the OXVASC cohort, so distribution of risk factors are similar to those 
reported elsewhere (Rothwell, Coull et al. 2004a). In order to reflect the age/gender 
balance nationally (and to make a nationally applicable recommendation to policy) as 
opposed to Oxfordshire alone, the calculation of mean age was adjusted to reflect the UK 
demographic using the methods of Wardlaw et al. (2006). (See also ‘Calculation of life 
expectancy’; Table 15, p.97). 
 
As a simplification, recurrent TIA (within 90 days of patient entry) was not modelled as a 
possible complication following TIA. Patients could only experience one stroke or major 
haemorrhage within the 90 day timeframe. A further simplification was to exclude 
myocardial infarction and other cardiovascular outcomes from the analysis. (Patients with 
previous stroke and MI could be excluded as they should be on treatment). The purpose of 
this model was to determine the cost-effectiveness of GPiT in TIA; extending the research 
question to include cardiovascular diseases would greatly increase the complexity of the 
model. Within the simple model structure here, cardiovascular outcomes are part of other 
cause death. 
 
Following suspected TIA, the risk of transfer to each of the other states is estimated, 
conditional on treatment status. For the case of stroke outcomes, the risk of transfer to any 
stroke state is conditional both on treatment status and the time since presentation with 
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TIA. The transition from TIA to carotid surgery is only permitted if the patient is referred 
to a specialist. 
 
The model incorporates time-dependent probabilities by varying the risk of stroke 
(ischaemic and haemorrhagic) at three discrete time intervals, 0-2 days, 2-7 days and 7-90 
days. The baseline assumption is of constant hazards within these intervals. 
  
The advantage of this relatively simple model structure is that re-parameterisation of the 
transition probabilities is sufficient for exploring variations in the case-mix of patients. 
This extends to variation in the case-mix of patients, including the proportion of true TIA 
relative to minor and serious pathology mimic states. 
  
In the base-case analysis it was assumed that the course of combined secondary preventive 
medications lasted at least 90 days. Patients were assumed to have no known 
contraindication to dual antiplatelet therapy (for instance, on anticoagulation) or any other 
drugs at point of presentation to GP i.e. there would be no reason for the GP not to 
prescribe a combined course. The effect of discontinuations due to minor side-effects and 
or patient adherence were not modelled. It was assumed that certain drugs would however 
be stopped following the patient experiencing one of the life-threatening event represented 
in the model. These included discontinuations of statins and antiplatelet agents following 
haemorrhagic stroke and discontinuation of antiplatelet agents following major 
haemorrhage.  
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Costs are accumulated for each day that the patient spends in any non-fatal health state. In 
addition, there are some ‘one-off’ transition costs associated with the patient moving 
health states (as the patient experiences an event). For instance, the unit cost of a GP clinic 
or an emergency medical procedure in the case of major haemorrhage.  
 
Quality adjusted life days (QALDs) are accumulated for every day that the patient spends 
in each non-fatal health state. The model assumes that the patient experiences static utility 
for the time in state i.e. the model does not attempt to capture the within state fluctuations 
in the health of the patient associated with diurnal variation. It follows that the 
accumulation of QALDS can be divided by 365 to derive the total QALYs for the purposes 
of reporting results in the standard metric of cost/QALY. 
 
While it is common to employ a half-cycle correction when  using a Markov cycle when 
cycle lengths are relatively long (e.g one year), this adjustment was not made on the 
grounds of the daily cycle length used for this model. Patients dying with a cycle were 
only counted as dead in the next cycle, so this leads to a negligible but potential 
overestimation of survival within the 90 day model by up to one day. 
 
Extrapolation to lifetime time horizon 
Costs and benefits of the surviving cohort for the remainder of their lifetime were 
estimated. This was done by a simple extrapolation of outcomes from the 90 day survivors 
for both costs and benefits. In order to establish a measure of benefit, the mean life 
expectancy for the fraction of the original cohort was estimated and multiplied by the 
associated QALY weight associated with that health state. For costs, the direct health 
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service costs to the NHS are again calculated. In addition a discount factor of 3.5% is 
applied to both costs and benefits. The summary measure reported is now the discounted 
cost/QALY, and this reflects the lifetime time horizon. 
 
Calculation of life expectancy 
The average life expectancy for the surviving cohort at 90 days was assumed to be state 
specific. For survivors of TIA, the life expectancy was taken from published UK lifetables, 
adjusted to reflect the age/sex profile of the original cohort (Office for National Statistics, 
Wardlaw et al., 2006). For survivors of stroke (either haemorrhagic or ischaemic) this life 
expectancy was assumed to be half that of patients with TIA, which corresponds to an 
assumption made in the NICE guidance for acute stroke and TIA (NICE, 2008a).  
 
For the other non-fatal model outcomes at 90 days, estimates were guided by rapid review 
(where the general methods for a rapid review have been previously described). Survivors 
of major haemorrhage face a higher risk of all cause death than survivors of TIA, in line 
with evidence on study follow up of survivors of acute GI bleeds (Moukarbel et al., 2009),  
in order to be conservative the life expectancy was assumed to be one third of 10.8 years. 
Patients who had a TIA mimic were assumed to have the same average life expectancy as 
for genuine TIA. Patients who had no complications or events following carotid 
endarterectomy were assumed to have the same average life expectancy as those patients 
with incident TIA.  
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Table 15: Expected number (percentage) of TIAs and minor strokes in a standard 
population of 500,000 people 
  55-64 65-74 75-84 85+ 
male  22.5 (4.6%) 66.3 (13.5% 63.4 (12.9%) 25.7 (5.2%) 
female 30.1 (6.1%) 65.3 (13.3%) 130.7 (26.7%) 86.0 (17.6%) 
 
Table 16: Life expectancy [unadjusted] (median) 2004-06 lifetables 
  55-64 65-74 75-84 85+ 
male  20.81 13.36 7.57 3.10 
female 23.94 15.78 9.03 3.695 
 
Table 17: Life expectancy [adjusted by age of presenting patient] (median) 2004-06 
lifetables 
  Average life expectancy (years) 
Representative cohort 10.53 
male  10.75 
female 10.41 
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Table 18: Model parameters for fatal health states 
Parameter Assumption made in 
model 
Source Basis of estimate 
Other cause death All cause mortality 
minus ICD60-69  
(Calculated as 
49,472 per million) 
Annual probability 
of death = 0.0495 
ONS lifetables 
(ONS 2013) 
Estimate based on 
age and sex profile 
of presenting cohort 
of the OXVASC 
study 
Life expectancy post 
TIA  
As per general 
population 
(calculated as 10.5 
years) 
Birmingham TIA 
model (Mant et al. 
2008) 
Assumes that 
patients will be well 
if no event post 90 
days 
Life expectancy post 
stroke 
Life expectancy half 
as per general 
population (5.25 
years) 
NICE acute stroke 
and TIA guidance 
(NICE 2008a) 
Assume two-fold 
increase in risk of 
death. 
Life expectancy post 
major haemorrhage 
Life expectancy half 
as per general 
population (5.25 
years) 
 Assumes that major 
haemorrhage is 
associated with 
some frailty. (TIA 
steering group, 
2008)  
 
Scenario analysis  
Unlike a trial, decision analytic modelling allows for the testing of a number of different 
strategies with relative ease. The desirability of carrying out a scenario analysis is that it 
allows for consideration of all relevant alternatives and therefore provides a more 
comprehensive analysis of the research question.  
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In the extended scenario analysis, three further strategies were introduced. current practice 
was included (in contrast to best practice). In addition, variations on the GPiT strategy 
were introduced: one with specialist referral limited to high-risk patients; the other 
equivalent to no onward referral. In both cases, all suspected TIA cases are treated. The 
justification for the inclusion of the GPiT alternative strategies was to explore the cost-
effectiveness of alternative configurations of GPiT.  
 
Table 19: Description of strategies considered in Scenario Analysis 
Strategy Patient pathway Service Delivery 
Current 
practice  
GP referral to a specialist 
TIA clinic for imaging, 
assessment and 
treatment. Specialist 
prescribes optimal 
treatment. GP follows-
up. 
Delay to treatment –- currently 
implemented into model via different stroke 
free survival curves derived from Giles et al. 
(2007) systematic review. See assumed and 
projected survival curve below. 
 
Delay to surgery - patients have surgery 
within 2 weeks. The remainder face a delay 
consistent with the findings of Halliday et al. 
on behalf of the RCP Carotid 
Endarterectomy Steering Group (Halliday et 
al., 2009) 
2-4 weeks – 14% 
>4-12 – 34% 
>12 – 30% 
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Strategy Patient pathway Service Delivery 
GPiT 
alternative 
(No 
subsequent 
specialist 
referral) 
GP initiates treatment in 
all patients and then does 
not refer suspected TIA 
patients to a specialist. 
GP follows-up all 
patients. This strategy is 
equivalent to GP 
management of TIA 
patients. 
All patients receive immediate initiation of 
treatment. 
 
GPiT 
alternative 
(High risk 
only referred 
on to a 
specialist) 
GP initiates treatment in 
all/ high risk patients (see 
note above regarding 2 
applications of this 
strategy and then refers 
only patients identified 
as high risk to a rapid 
access clinic for 
specialist assessment 
(including imaging) and 
review of medication. GP 
follows-up all patients. 
High-risk patients face the same benefit and 
risk as those on GPiT. 
Low-risk patients receive immediate 
initiation of treatment, equivalent to GPiT 
alternative (No subsequent specialist 
referral). 
 
 
Sensitivity Analysis 
The model considered the joint uncertainty in the input parameter point estimates. For each 
parameter, an appropriate candidate probability distribution on the basis of the type of data 
was selected following Briggs et al. The model was run 1000 times, as determined to 
minimize Monte Carlo error each time randomly selecting a value for all parameters from 
a respective distribution resulting in 1000 Cost/QALY pairs which provided simulation 
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output in scattergraph plots (Briggs et al., 2006). The model calculated the mean costs and 
QALYs over the 1000 simulations, which averaged resulted in the mean net monetary 
benefit by strategy for different values of the threshold ratio. This allowed the construction 
of cost-effectiveness acceptability curves summarizing the evidence in support of the 
intervention for multiple strategies for different thresholds. 
 
In addition, further sensitivity analysis was carried out to test the underlying assumptions 
of the model. Deterministic analysis (using the point estimates and not probabilistic 
distributions) was initially performed to establish which parameters were most sensitive on 
the results. Parameters judged to be sensitive to the results of the model were then 
subjected to probabilistic testing to further test this, i.e. by re-running the Monte Carlo 
simulation 1000 times for the input parameter and comparing the probabilistic and 
deterministic results. 
 
5.6. Identification of Evidence  
In order to populate the model searches were conducted to identify the best available 
sources of evidence from the literature. A decision about the parameters requiring 
estimation followed from previous decisions regarding the structure of the. The data 
requirements of the model are organized by the nature of input parameter (i.e. Clinical, 
Cost and Resource Use, Utilities and Life Expectancy). 
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Data search methods 
Two types of search/review were performed (rapid review and structured literature 
review). [Here, I use the term rapid review to refer to a quick, restricted and focussed 
search of published evidence.] Compared to the standard structured literature review, the 
rapid search/reviews adopted here were restricted to a single database (Embase) and were 
restricted to high quality systematic review, meta-analysis and RCTs.  The aim was to 
provide a consistent and transparent search that could be replicated by another reviewer.  
 
Justification for a rapid review process  
In the absence of an established convention for a ‘rapid review’ process to populate 
economic models in Health Economics, this section aims to provide a rationale.  
The suitability of performing a rapid review (versus a structured literature review) 
followed pre-defined criteria. Since it is beyond the scope of this thesis to 
comprehensively review all evidence, the aim was again to provide a clear rationale for 
limiting the number of included studies where rapid reviews were performed. Table 20 
reports the criteria for assessing if a rapid review can be justified. 
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Table 20 : Criteria for assessing if a Rapid Review is justified 
A rapid review can be carried out if... 
At least one recent systematic review (or meta-analysis) or RCT has been previously 
carried out in the same population as per this thesis (ideally in a UK population).
8
  
or: 
The results of the model are not likely to be sensitive to this parameter. (Where there is 
doubt, this is to be determined by logical testing of the model, once constructed, by 
allowing the parameter to be at maximal and minimal values and comparing the ICER 
against the commonly applied ceiling threshold in the UK of £20,000-£30,000) 
 
Rapid review  
The rationale for these reviews is to identify the clinical, cost and QALY valuations 
necessary for populating the economic model. The search strategy searched the EMBASE 
database. The search was restricted to published studies in the English language in the last 
10 years, up to 01 Jan 2013. Prior to searching, an explicit statement of the question 
relating to participants, interventions, comparisons, outcomes and study design was 
formed. The search strategy combined free text terms. The search terms used (including 
any limits) and dates searched are reproduced in ‘Appendix 3: Rapid Reviews’. Eligibility 
criteria for included studies were defined a priori.  
 
                                                   
 
8
 Where a similar population was a priori determined to be TIA or minor stroke patients. Preference was given to 
studies that recruited from patients living in the UK. 
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Structured literature review  
In the single case where these criteria in Table 20 (p.104) were not met, a more extensive 
approach was sometimes required. The methods for the structured literature review in 
these instances are documented in the full in the next chapter (see Chapter 6). 
 
5.7. Estimation of Effectiveness 
Clinical transition probabilities 
Patient progression is determined by simulating the movement of the cohort through health 
states, starting with the patient’s presentation with suspected TIA in primary care in cycle 
0; patients then are assigned into other health states based on the probability of the event 
occurring in the next cycle - this is the clinical transition probability associated with the 
event. 
Time dependent transitions for all stroke [combined ischaemic/ haemorrhagic] 
following true TIA 
Survival analysis was used to implement time dependency, using a similar approach to 
NICE (2008). Using the pooled analysis of time to event data at 2,7 and 90 days from the 
Giles and Rothwell (2007a, p.1068) dataset an estimate of the daily stroke rate (h) for 
projected treated and untreated risk
9
 can be made using the following formula: 
h = (-1/t) ln (S/So) 
                                                   
 
9
 Strictly speaking, untreated (‘Proj. no Rx’ on graph) risk is non-optimally treated risk. The time to event data for 
the projected no treatment curve corresponds to the pooled result for ‘ population based, face to face follow-up’; 
the projected early treatment curve corresponds to the ‘pooled specialist stroke service’ (Giles, M. F. & Rothwell, 
P. M. 2007a. Risk of stroke early after transient ischaemic attack: a systematic review and meta-analysis. Lancet 
Neurol, 6, 1063-72. 
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where t is the number of days follow-up since the TIA, S=the number of patients who 
survived the follow up period without a stroke and So=the number of patients in the group. 
 
The technique for determining the baseline stroke rate and effects of treatment initiation 
are next considered graphically. A technical summary is provided at the end of this 
chapter. These calculations result in the projected early (‘Proj Early’) and projected 
untreated (‘Proj no Rx’) curves in Figure 5 and Figure 6, which illustrates modelled stroke 
free survival.  
 
Figure 5: Modelling stroke free survival following TIA 
The blocked squares relate to the observed data points within specialist stroke clinics. 
The blocked triangles relate to the observed data point within less urgently treated 
TIA. The proportion of the cohort remaining event free (stroke free survival) subject 
to treatment status is shown by the dotted curves joining the data points. 
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It was assumed that constant hazards applied within the intervals from 2-7 and 7-90 days. 
Inspection of Figure 6 reveals that extrapolation of the daily stroke rate as applied within 
the interval of 2 to 7 days back to day zero underestimates the true risk of events since 
Stroke free survival for both curves is less than one (as indicated by the y axis intercepts). 
A correction was therefore applied such that survival is maximum and equal to 1 at time 
zero, equivalent to the assumption that everyone in the cohort is alive at the point of 
presentation to the GP. 
 
To do this, assumption of a constant daily stroke rate was made to extrapolate the survival 
data backwards from day two to the start (time zero) where survival is at a maximum and 
consequently equal to one. The resulting assumed early treatment curve (solid line) 
between days 0 to 2 in Figure 6 accounts for the excess risk within the hyper-acute period, 
before treatment is initiated. 
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Figure 6: All stroke survival by strategy (first 8 days) under the strategy of best 
practice. 
The blocked squares relate to the observed data points within specialist stroke clinics. 
The blocked rhombus shape relate to the observed data point within less urgently 
treated TIA. The proportion of the cohort remaining event free (stroke free survival) 
is shown by the solid line curve. 
 
In turn, the modelled risk associated with the ‘assumed early treatment curve’ (solid 
dashed line) can be modified by the initiation of secondary preventive agents. Therefore, if 
treatment commences at the beginning of cycle 2, the daily stroke rate calculated from the 
‘specialist stroke clinic’ data is immediately applied, modifying the underlying stoke risk. 
The benefit of treatment at day 2 is therefore shaded area between these curves. The 
‘assumed early treatment curve’ in this instance corresponds to the model’s strategy of best 
practice. 
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Note that while the lines appear to be straight line, a distribution using the exponential 
model was fitted. In addition the graphs have been truncated at 8 days for presentation 
purposes.  
 
The technique allows for the initiation of treatments at different time points along a 
continuum. In all cases the baseline stroke risk is associated with the ‘assumed no Rx’ 
curve and treatment initiation modifies risk by applying a reduction in the daily stroke rate 
at the point of treatment initiation. Notice that at present this modelling assumes that all 
treatment is initiated uniformly either at day 1 (GPiT), day 2 (best practice) or day 7 
(current practice) and that the benefit of treatment is instantaenous. 
 
All stroke survival by date of treatment initiation  
The estimates for all stroke survival for the first 10 days for by date of treatment initiation 
are shown in table x below (full 90 days for all strategies in technical appendix). 
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Time (in days)  (day 1) 
[values used 
in GPiT] 
 (day 2) 
[values used 
for base-case 
analysis best 
practice] 
 (day 7)  
[values used 
in current 
practice] 
0 1 1 1 
 1 0.984481 0.984481 0.984481 
2 0.983943 0.969203 0.969203 
3 0.983406 0.968674 0.954162 
4 0.982869 0.968145 0.939354 
5 0.982333 0.967616 0.924777 
6 0.981796 0.967088 0.910425 
7 0.98126 0.96656 0.896296 
8 0.981131 0.966432 0.896178 
9 0.981001 0.966305 0.89606 
10 0.980872 0.966178 0.895942 
 
Adjustment by ABCD2 scores 
The time dependent risks of stroke were then adjusted to accommodate the heterogeneity 
in the data with respect to ABCD2 scores. This was to enable important differences in the 
treatment effect across sub-groups to be interpreted at a policy level. 
 
 The incidence rates for high and low ABCD2 scores from the Johnston et al (2007) study 
were pooled. The stratified relative risk of these rates was then calculated. This allowed for 
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disaggregation of the combined stroke risk curve by high and low risk sub-groups. The 
pooled analysis in Table 25 suggests that the relative risk in the low risk (relative to high 
risk) population might be relatively constant over time, and was therefore set at 0.2 in the 
base-case. Given that the underlying relative risk is affected by the incidence of patients 
with ABCD2 scores of 4 or above in the study population, disaggregation assumed that the 
proportion of patients with ABCD2≥4 was =0.5 (corresponding to a  proportion of patients 
with ABCD2≥4 = 0.5). This is in line with the proportion of high risk cases observed in 
the Oxford cohorts used to derive and validate the ABCD2 score (Johnston et al., 2007). 
 
Table 21: Strokes experienced by time point and ABCD2 score. 
 (Observed frequencies within both clinic and validation cohorts are combined to increase 
sample size) 
ABCD2 score by day 2   by day 7 by day 90 
0-3 incidence (n=1628) 17 20 40 
4+ incidence (n=3171) 171 246 391 
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Table 22: Pooled analysis – relative risk of stroke for low risk populations  
(Johnston et al. 2007) 
ABCD2 score by day 2   by day 7 by day 90 
0-3 incidence rate (a) 0.0104 0.0123 0.0246 
4+ incidence rate (b) 0.0539 0.0776 0.1233 
relative risk (a/b) 0.1936 0.1584 0.1993 
 
Mathematically, the disaggregation of stroke free survival followed from solution of a pair 
of simultaneous equations where L is the stroke free survival rate in the low risk sub-group 
and H is the stroke free survival rate in the high risk subgroup and S(t) is  the Stroke free 
survival rate. 
On the assumption that 70% of the cohort are low risk: 
0.7L+ 0.3H = S(t)         (1) 
Using the incidence rate (where the proportion of the population at risk is given as 1-S(t)) 
gives the relative risk approximation of 0.2: 
(1-L)/(1-H) = 0.2         (2) 
Rearranging: 
(1-L) = 0.2 (1-H) 
L=0.8 + 0.2H          (3) 
Substituting (3) into (1) gives: 
0.7(0.8 x 0.2H) + 0.3H = S(t) 
Solving provides the rule for disaggregating S(t) 
H=(S(t) – 0.56)/0.44 
Application of this result can then be viewed on survival plots (next section). 
 113 
 
 
 
 
Figure 7: Stroke free-survival following TIA by risk group: initiation of treatment 
following GPiT 
 
Figure 8: Stroke free-survival following TIA by risk group: corresponding to 
initiation of treatment following best practice 
0.5
0.6
0.7
0.8
0.9
1
0 20 40 60 80 100
St
ro
ke
 f
re
e
 s
u
rv
iv
al
 
Days since Primary Care TIA diagnosis  
Low risk
High risk
Aggregate
0.5
0.6
0.7
0.8
0.9
1
0 20 40 60 80 100
St
ro
ke
 f
re
e
 s
u
rv
iv
al
 
 
Days since Primary Care TIA diagnosis 
Low risk
High risk
Aggregate
 114 
 
 
 
Figure 9: Stroke free-survival following TIA by risk group: corresponding to 
initiation of treatment following current practice 
 
Table 23: Disaggregated survival by date of treatment initiation 
Days since 
TIA 
Low risk: 
Day 1  
High risk: 
Day 1 
Low risk: 
Day 2  
High risk: 
Day 2  
Low risk: 
Day 7  
High risk: 
Day 7 
1 0.984587 0.922936 0.984587 0.922936 0.984587 0.922936 
2 0.984347 0.921737 0.969697 0.848485 0.969697 0.848485 
3 0.984108 0.920539 0.969465 0.847327 0.955312 0.776558 
4 0.983868 0.919341 0.969234 0.846169 0.941414 0.707071 
5 0.983629 0.918144 0.969002 0.845012 0.927988 0.639939 
6 0.98339 0.916948 0.968771 0.843855 0.915017 0.575084 
7 0.98315 0.915752 0.96854 0.8427 0.902486 0.512428 
8 0.982936 0.914679 0.968333 0.841663 0.902311 0.511553 
9 0.982507 0.912535 0.967918 0.83959 0.901961 0.509804 
10 0.982434 0.912169 0.967847 0.839236 0.901901 0.509505 
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Type of stroke experienced 
In the model base-case, it was assumed that the proportion of ischaemic to haemorrhagic 
strokes experienced following TIA was 1.42/0.010 (Antithrombotic Trialists' 
Collaboration, 2002). This proportion was considered to be constant across all populations, 
i.e. for true TIA and mimic states, as well as for high and low risk individuals. 
 
5.8. Mortality and risk of events (acute model) 
Table 24: Model parameters for true TIA 
 Data Unit of 
data 
Daily transition 
probability (where 
applicable) 
Assumption 
Probability of 
all stroke (at 
2, 7 and 30 
days) 
Time and treatment dependent. See separate 
survival analysis 
Pooled event rate data 
from specialist study 
clinics. (Giles and 
Rothwell, 2007a) 
Relative risk 
of all stroke 
for low risk 
populations 
ABCD2<4 
compared 
with 
ABCD2>-4 
(at 2,7, and 30 
days)  
 Estimated to 
be constant at 
0.2 
Relative 
risk 
N/A Pooled analysis of 
data (Johnston et al., 
2007). 
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 Data Unit of 
data 
Daily transition 
probability (where 
applicable) 
Assumption 
Proportion of 
haemorrhagic 
strokes (as 
proportion of 
all stroke) 
Incidence per 
1000 per year 
Primary 
Intracerebral 
Haemorrhage/ 
Incidence per 
1000 per year 
Ischaemic 
stroke = 
0.10/1.42 
Ratio N/A Calculated as a 
proportion of time 
dependent transition 
probabilities for 
stroke, 
Antithrombotic 
Trialists' 
Collaboration (ATC), 
(2002). 
Probability of 
major 
haemorrhage 
(at 90 days) 
Treated: 2.42% 
per annum 
Untreated: 
0.10% per 
annum 
Rate 0.0000671 ActiveW 2006 
(Connolly et al., 
2006) and 
ATC (2002). 
 
Probability of 
other cause 
death 
Age and sex 
dependent  
Risk (Standardised 
mean=) 
0.0001608 
UK lifetables 
(adjusted for mean 
age and sex of 
assumed cohort) with 
within model stroke 
and major 
haemorrhage deaths 
excluded. 
Conditional 
probability of 
fatal 
ischaemic 
stroke (given 
ischaemic 
6%  Ratio 0.0029926 Based on Lothian 
stroke registry 
(Counsell et al., 
2002), reporting of 
outcomes at 6 months 
(2-10% with the risk 
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 Data Unit of 
data 
Daily transition 
probability (where 
applicable) 
Assumption 
stroke) of fatality increasing 
in age deciles) and 
ATC 2002.  
Conditional 
probability of 
fatal 
haemorrhagic 
stroke (given 
haemorrhagic 
stroke) 
15% Ratio 0.0039552 Based on the above 
sources (Lothian 
stroke register was for 
all stroke), but with 
the assumption that 
prognosis tends to be 
worse. Birmingham 
TIA model had 
conditional 
probability of death at 
20%. 
Conditional 
probability of 
fatal major 
haemorrhage 
(given major 
haemorrhage) 
0.17% per 
annum 
7 0.0000047 ACTIVE W trial (for 
dual antiplatelet arm). 
 
Complications of carotid surgery, risk at 30 days 
Expert opinion obtained within a model steering group meeting suggested that the risk 
modification (other than surgical death at 30 days) of carotid surgery could be explicitly 
modelled. A pragmatic decision was taken to not add in additional non fatal health states 
post complication (e.g. cranial nerve palsy). Data transitions from carotid surgery to 
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ischaemic, haemorrhagic stroke and major haemorrhage were allowed. Data was obtained 
to see how surgery modified the risk of events, both at 30 days, and for the lifetime 
horizon. It was a model assumption that only symoptomatic stenosis of 70% or more 
would be treated, as this is the level that corresponds to current recommendation.  
 
The risk of events post carotid surgery are provided as conditional probabilities in the 
literature. These were converted these to daily transition probabilities using an exponential 
model (see general formula under ‘mortality rates’ p.138) 
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Table 25: Model parameters for carotid surgery  
 Data Statistic 
type 
Daily 
transition 
probability 
% 
Assumption 
Conditional probability of 
haemorrhagic stroke given 
carotid surgery (30 days 
from surgery) 
0.018 Ratio 0.0597 Rothwell et al., 
(2004b), 
proportion 
ischaemic (2/3) 
Conditional probability of 
ischaemic stroke given 
carotid surgery (30 days 
from surgery) 
0.036 Ratio 0.1205 Rothwell et al., 
(2004b), 
proportion 
ischaemic (2/3). 
Conditional probability of 
major haemorrhage given 
carotid surgery (30 days 
from surgery) 
Assumed to be 
unchanged 
from treated 
TIA, not 
considered a 
significant 
outcome in the 
carotid 
triallists’ 
collaboration 
Ratio - Randomised  
trial of 
endarterectomy 
for recently 
symptomatic 
carotid stenosis: 
final results of 
the MRC 
European 
Carotid Surgery 
Trial (ECST, 
1998). 
Conditional probability of 
surgical death given carotid 
surgery (30 days from 
surgery) 
0.09 Ratio 0.3096 Rothwell et al. 
(2003) 
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Model parameters for TIA mimic  
This table presents the parameters estimated for the TIA cohort presenting who are false 
positive, with a relatively minor other diagnosis. From the review of diagnostic accuracy, 
the likely explanation for this are likely to include: vertigo and dizziness, migraine, 
syncope. It was therefore felt that such sequelae were benign and would not be harmed by 
the initiation of inappropriate treatment. It was felt that this cohort might show some 
modest benefit from initiation of antiplatelet therapy. 
Table 26: Model parameters for TIA mimic 
 Data Daily 
transition 
probability, 
% 
Assumption 
Probability of all stroke 
(90 days) 
sum of 
haemorrhagic 
and ischaemic 
stroke  
N/A - 
calculation 
see below 
Probability of ischaemic 
stroke (90 days) 
Treated: 80% 
CI reduction in 
the risk of all 
stroke in a 
population 
aged 55-64  
 
Untreated: 
standardised 
incidence per 
thousand per 
year 1.42. 
Treated risk 
reduction = 
0.00008 
 
 
Untreated: 
0.00039 
Assumed same as per primary 
prevention populations of 
similar age to cohort. 
Treated: Wald and Law 
(2003); Untreated: Rothwell 
et al. (2004a). 
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Probability of 
haemorrhagic stroke (90 
days) 
All stroke – 
ischaemic 
stroke cases 
N/A - 
calculation 
Treated: Wald and Law 
(2003)  
Untreated: Rothwell et al. 
(2004a)  
Probability of major 
haemorrhage (90 days) 
Treated: 
Excess risk 
expressed as a  
prevalence per 
100 people 
2.3%  
0.00027 From meta analysis of aspirin 
trials, Wald and Law (2003). 
This does not confer an 
excess risk of fatal major 
haemorrhage (prevalence per 
100 people was -0.01 (0.07-
0.05) 
Probability of other cause 
death (90 days) 
Age and sex 
dependent 
Not varied UK lifetables (adjusted for 
mean age and sex of assumed 
cohort) with stroke outcomes  
(ICD60-69) excluded 
 
Transition probabilities for mortality 
These rates were then converted to daily transition probabilities assuming constant hazards 
applied. Since no patients started in any of these states, the constant hazards were 
calculated on the basis of mean length of time in state using: 
risk = 1-exp 
(-rate)
 
rate= -ln (1-risk) 
 
 Data  Daily transition 
probability 
Sources 
Conditional probability of 
fatal ischaemic stroke 
(given ischaemic stroke) 
0.25 (at 90 
days) 
0.0030 ECST (1998); 
Rothwell et al., 
(2004b). 
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Conditional probability of 
fatal haemorrhagic stroke 
(given haemorrhagic 
stroke) 
0.40 (at 90 
days) 
0.0040 Estimate based on 
Mant et al., (2004). 
Conditional probability of 
fatal major haemorrhage 
(given major haemorrhage) 
0.15 (at 90 
days) 
0.000005 Conservative 
assumption based on 
low fatality rate, 
ACTIVE-W 
 
5.9. Estimation of Utility Data 
The main outcome  for the modelwas the QALY. The estimates provided were based on 
the Dorman et al. (2000) which elicited the quality of life in 867 UK patients who were 
participants in the International Stroke Trial using the EQ-5D. This study assessed health 
states by dependent 0.31 (95% CI 0.29-0.34), independent  0.71 (95% CI 0.68-.84) and 
fully recovered health states 0.88 (95% CI 0.84-0.92). Since all patients in this trial had 
had a minor stroke, not a TIA, the figure of 0.88 may under-estimate the utility of a patient 
in the TIA health state. In addition, as the Dorman study classified stroke according to the 
level of disability, there was no mean measure for Stroke. This was calculated by assuming 
that one third of all strokes are disabling (resulting in dependent health states), and the 
remainder non disabling (resulting in independent health states) i.e. 1/3 (0.31) x 
2/3(0.71)=0.443 QALDS. This is the same assumption as applied in the NICE model. 
(NICE, 2008a). 
 
The Dorman study did not report health states specific to carotid surgery and major 
haemorrhage. In addition, to date there appears to be no referencable single source of 
utilities for the health states included within the economic model.  For these states (which 
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affect small numbers of the population) estimates were made about the health status (in 
QALDs) and plausible range. This followed from a search of the Centre for Reviews and 
Dissemination and PUBMED using the key word terms (i. carotid surgery or carotid 
endarterectomy, ii. major heamorhage, Quality of life, utility, EQ-5D) allowing for 
possible truncations to inform the estimate.  
 
As the population moves through the 90 day acute model, patients accumulate QALDs as 
they remain in or transit to other health states. The assumption was made that patients who 
die within the 90 day period experience accumulate QALYs in the cycle in which they die. 
In the absence of a half cycle correction, this might lead to a negligible over-estimation of 
total QALDs in all arms (by a maximum 1 QALD per patient). 
 
Table 27: Quality of life values used in the model 
 Data Plausible 
range 
Sources 
Post confirmed TIA 0.88 0.84-0.92 Dorman et al., (1997). 
Stroke  0.44 0.33-0.55 Estimate obtained from 
Dorman with the 
assumption that 1/3 of all 
strokes are disabling i.e. 
1/3(.31) x 2/3 (.71)=.443 
Major haemorrhage 0.31 0.29-0.34 Assumption, TIA steering 
group, (2008). 
Post carotid surgery 0.71 0.68-0.84 Assumption (as per 
dependent stroke). 
Non stroke mimic (benign) 0.88 0.84-0.92 Assumption (as per TIA). 
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Non stroke mimic 
(serious) 
0.31 0.29-0.34 Dorman et al. (1997). 
 
An alternative source of QALYs commonly used in models of stroke that has been argued 
to have more face validity with clinicians, are those provided by van Exel et al. (2004). 
These utility values are based on direct comparison of proxy report on functional status 
(using the Barthel index) and self-report (by EQ-5D) in 598 stroke patients in the 
Netherlands.  The authors found evidence in support of a stable relationship between the 
Barthel Index and EQ-5D. From this, it is possible to make a projection about the HRQoL 
on the basis of stroke severity. The values from the linear regression are shown in Table 
28. 
 
Table 28: Utility values by Barthel index, van Exel (2004) 
Health status (Barthel index) Utility  s.d. 
independent ( 20) 0.75 0.00 
mild (15-19) 0.63 0.07 
moderate (10-14) 0.36 0.07 
severe (5-9) 0.11 0.07 
very severe (0-4) -0.15 0.06 
s.d. = standard deviation 
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5.10. Estimation of Cost and Resource Use data 
Identification of cost and resource use estimates had three components. First, a rapid 
review of the costs of TIA and stroke in the UK was carried out. This identified one recent 
critical review on the cost of stroke in developed world countries, which reported the mean 
cost of stroke from 27 UK studies as US $22 377, the median as $15,720 and the range as 
$5026-107,860 (Luengo-Fernandez et al., 2009a). Adjustment using the appropriate 
purchasing power parity index for the year in question, the amount in US dollars equates to 
a mean in the region of £15,000. The Luengo-Fernandez study did not provide evidence on 
the cost of TIA, or non Stroke health states.  
 
Second, the results from the included studies in this thesis’ critical review of models 
following TIA in Chapter 3 were re-analysed. For each included model, the costing 
methods were appraised using quality criteria established by the Philips et al. (2006). Data 
was extracted in the following fields: 
 Perspective and costing principles  
 Resource use included in analysis 
Finally a costing exercise was carried out to identify the most recent costs of capital and 
drugs from standard sources. (Department of Health, November 2012, British National 
Formulary, March, 2013).
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Table 29: Data searches undertaken – Cost and Resource Use 
Costs of care 
GP clinic (per patient clinic) 
Specialist daily clinic (per patient clinic) 
Specialist weekly clinic (per patient clinic) 
Mean length of inpatient stay and associated cost for all modelled outcomes: 
ischaemic, haemorrhagic, major haemorrhage, CE surgery 
Capital expenditure by NHS associated with change in strategy 
Medication costs based on prescribing (by strategy)  
Pack price, dosage of medications used in the EXPRESS study drug algorithm (by 
class) 
Length of course (by drug class) 
Mean cost /per person/ per day (combined medication) for each alive state in model 
 
Costs  
Costs are calculated assuming an NHS perspective, inflated using the 2011 hospital pay 
and price index information from the PSSRU as necessary (Curtis, 2012). The main costs 
relate to the time in hospital, surgical procedures, and drug costs. A basic cost for a high-
dependency hospital bed in a stroke unit, and the cost of in-hospital costs associated with 
carotid endarterectomy were obtained from the latest available NHS reference costs 
(2009/2010). The costs of medication were obtained from the British National Formulary 
2011, and are summarised in Table 30.  
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Table 30: Drug costs included in the model 
  Dose/ day           
Drug costs  (mg) pack price tabs/ pack tabs/ mg Cost/ mg cost/ day 
aspirin  75  £       0.85  28 75 0.0004 £0.03 
simvastatin 40  £       1.17  28 40 0.0010 £0.04 
dipyridamole 400  £       2.87  84 100 0.0003 £0.14 
lisinopril 10  £       0.95  28 10 0.0034 £0.03 
bendrofluazide 2.5  £       0.81  60 2.50 0.0054 £0.01 
Total estimated cost      £0.26 
 
For simplicity the model assumed a standard drug regimen was applied, based on the most 
commonly prescribed statins and blood pressure lowering agents. The model assumed that 
all patients would be suitable for treatment of cerebrovascular risk factors with the full 
regimen (i.e. dual anitplatelets, blood pressure lowering agents and a statin). 
 
This results in a combined cost of aspirin, dipyridamole, blood-pressure and lipid lowering 
drugs of £0.26 per patient per day. This combined cost, as well as those associated with GP 
and Rapid Access visits, inpatient stays, and carotid endarterectomy are those reported in 
Table 31. In the base-case analysis it was assumed that the course of secondary preventive 
medications was continued over the patient’s remaining lifetime, however, current UK 
guidance is not explicit in recommending the duration of treatment with respect to dual 
antiplatelets. At the time of writing there appears to be no recommendation from the Royal 
College of Physicians on the optimal length of antiplatelet therapy for TIA and stroke, and 
NICE recommends that treatment should continue unless there is joint agreement on the 
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appropriateness of stopping (NICE, 2005). The model therefore assumes that the course of 
treatment would continue for 90 days; this corresponds to the length of follow-up in a 
number of trials and cohort studies of dual antiplatelets in TIA/stroke populations (NICE, 
2005). The additional costs associated with the capital expenditure as the intervention was 
felt to be potentially resource saving. However, it is possible that such an intervention 
might shift the balance of care from specialty stroke services to GP providers of care. 
Resource Use 
GP follow-up identical in all scenarios, and is assumed to occur once within the 90 day 
model.
 
Table 31: Unit costs in the GPiT strategy model 
 
Data 
Plausible 
range  
Sources 
Acute costs (90 days) 
   
Cost of secondary 
prevention medicines 
(combined/day) 
£0.26 Not varied BNF, price year 2012 
Cost of GP clinic £43.00 Not varied PSSRU, 2012 (Curtis, 2012) 
Cost of specialist clinic 
(daily/weekly) 
£246.00 Not varied NHS reference costs, year 2011/12 
Cost of carotid surgery £4,017.00 Not varied NHS reference costs, year 2011/12 
Lifetime costs 
   
Dependent after a stroke 
at 90 days 
£57,378 
(43,033-
71,722) 
NICE (2008a), inflated to current 
year using the Hospital and 
Community Health index (HCHI) 
(Curtis, 2012). 
Independent after a stroke 
at  90 days 
£8,415 
(6,312-
10,519) 
NICE (2008a), inflated using HCHI 
Recovered (GP follow-
up) at 90 days 
£887 (665-1109) NICE (2008a), inflated using HCHI 
Recovered (specialist 
follow-up) at 90 days 
£1475 
(1106-
1844) 
NICE (2008a), inflated using HCHI 
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5.11. Model assumptions 
The objective of this section is to outline the methods relevant to the service delivery 
aspects of the model. Whereas the previous section was concerned with the derivation of 
transition probabilities for clinical patient progressions within the model (for the 2 patient 
populations: True TIA, TIA mimic) this section considers how the alternative TIA 
management strategies* impact on clinical patient progressions.  
* i.e. best practice, current practice, GPiT (baseline), GPiT (high risk referral only) and 
GPiT (no referral).  
 
 
Table 32: Assumptions for the base-case model 
 Data (used in 
model) 
Plausible 
range 
  
Sources 
Prevalence of true TIA in a 
primary care population 
suspected of having TIA 
0.60 0.4-0.8 Estimated by review of 
diagnostic accuracy 
Proportion of cohort with 
ABCD2 scores > 4 or above 
0.30 - From a prospectively 
identified cohort in the 
OXVASC study (Rothwell 
et al., 2004a) 
Proportion of true TIA 
requiring carotid surgery 
0.05 0.01-0.10 Estimated from (Wardlaw 
et al., 2004) Assumed 80% 
of people eligible will have 
surgery  
Proportion of false positive 
TIA requiring carotid 
surgery 
0.00 Not varied Definition of benign TIA 
excludes patients with 
occlusion 
Positive predictive value of 
a GP 
0.50 0.3-0.7 Review of diagnostic 
accuracy (Chapter 6) 
Positive predictive value of 
a stroke specialist 
1.00 Not varied Assumption 
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5.12. Sensitivity analysis for increased risk of major haemorrhage  
An additional threshold analysis was carried out (for the base-case comparison, GPiT vs. 
best practice) to determine the robustness of the model to an increase in the rate of major 
extracranial bleeding in the TIA mimic population. This was intended to test the 
uncertainty surrounding the harm of inappropriate treatment in a population with 
misdiagnosed TIA in Primary Care. An analysis was performed in Excel by holding the 
other parameters within the model constant, and varying the daily transition probability 
TIA-major extracranial haemorrhage such that a maximum ceiling ratio of £20,000 per 
QALY was attained.
10
 This provides detail of the maximum acceptable rate of major 
haemorrhage at which GPiT remained cost-effective. 
 
Sensitivity analysis for poor prognosis in carotid surgeries foregone   
An additional sensitivity analysis was carried out to adjust the model results for carotid 
surgeries foregone in the alternative GPiT strategies involving no referral for specialist 
assessment. This was to examine the impact of medical management of patients with 
significant stenosis. This adjustment applies to the GPiT alternative strategy with no 
subsequent referral and the alternative strategy with partial referral by ABCD2 risk score. 
In the latter case, carotid surgeries are only foregone in patients in the low risk group. No 
adjustment was made to the current practice scenario as the average treatment effect with 
                                                   
 
10
 Formally this was done by using the EXCEL add-in ‘goal seek’. 
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current practice is likely to already reflect poor prognosis as a result of delayed carotid 
surgeries. 
 
Wardlaw et al. (2007) identify the cumulative risk of recurrent stroke as 29% at 90 days in 
the affected sub-group with carotid stenosis (defined as 70% occlusion according to ECST 
criteria). The equivalent rate in the period of 90 days to three years was 48%. The above 
figures suggest that in a cohort of 1000 suspected TIA cases, of which 500 are true 
positive, and 25 (5% of 500) are candidates for surgery. If no surgeries were offered, this 
would suggest that there would be approximately 7 recurrent events at 90 days and a 
further 5 events at 3 years, i.e. 12 recurrent events. These results do not indicate the excess 
risk of stenosis over and above patients without significant stenosis but the absolute risk. 
However evidence presented to date indicates that the risk is low in those without 
significant stenosis and on optimal medical management. There is an issue of which data 
source to use to control/adjust for a population without stenosis as there are problems with 
data reporting stroke rates stratified by degree of artery occlusion. Wardlaw et al. pool 
results for patients with no stenosis with those of complete artery occlusion (Wardlaw et 
al., 2006). The excess risk up to 90 days was therefore assumed to be the stroke rate from 
the best performing stroke clinics, and equivalent to the aggregate risk estimated using 
survival methods. i.e. about 0.2%.  To be conservative, a sensitivity analysis was carried 
out on the short and long-term model predictions when the proportion of the cohort with 
stroke was assumed to increase by 7 (at 90 days) and 12 (for the lifetime horizon). The 
corresponding increases for the GPiT strategy with referral of the high risk cases only 
assumed that the excess risk of medically treated stenosis were 1.4 at 90 days and 1 at 
lifetime. 
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5.13. Technical summary: Stroke free survival 
Stroke free survival rates (proportion of the original cohort who are alive) at t=2, t=7 and 
t=90 (i.e. from the figures above 0.93, 0.90 and 0.83). In addition, it can be assumed that 
the entire cohort is alive at t=0 (i.e. where survival is at a maximum i.e. 1) 
 
To calculate the proportion of the cohort free from stroke between the intervals of 2 and 7 
days you need the stroke free survival rates (proportion of the original cohort event free) at 
t=2, and t=7 (i.e. from the figures above, using notation S(t2)=0.93 and S(t7)=0.90). 
In order to estimate the proportion of the cohort event free at other points in time (ti) 
within the interval for which we have data (i.e. ti=2,3,…≤90 etc.) one option is to calculate 
and apply survival methods. 
 
An exponential function was used to implement time dependency in the model. It would be 
possible to use other functional forms here but the rationale for using this function was 
suggested by the clinical evidence on recurrence. To calculate this, the natural log of the 
ratio of the above survival rates is used to calculate the hazard or (instantaneous event rate) 
for any timepoint within the interval. In this case, t evaluates to 5  (the interval, in days, 
corresponding to the follow-up period relating to the data)  
ht= -ln(0.90/0.93)/(5) = -0.0066. 
(Note this evaluates to a constant hazard rate for all time points within the above interval) 
i. The above four steps were repeated (substituting in for S(t90) and S(t7)) to 
estimate the hazard rate between 7 and 90 days. 
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ii. Therefore the relation between the hazard rate and the survival function can 
be used to calculate continuous (stroke free) survival rates for the TIA 
population for any Si within the interval for which data is required by the 
model, i.e. for days 2-90. 
iii. To estimate points earlier in time, the above steps (i-ii) were repeated for 
the interval 0 and 2 where the stroke free survival rates were S0=100% and 
S2=0.93%. (Note that t=0 is taken to be the point at which the patient 
presents to the GP).  
iv. This provides the modelling method for the non-urgently treated TIA. 
v. This exercise was repeated for specialist study clinics initiating optimal 
secondary prevention agents urgently to derive the hazard rates under 
optimum service delivery. 
vi. The two curves were used to implement treatment status. Patients faced the 
non-urgently treated TIA curve until treatment is initiated. At this point, the 
hazard rate from urgently treated TIA is applied. 
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Table 33: Cumulative event free survival: by strategy (first 9 days) 
Time (days) GPiT 
(corresponds to 
treatment on day 1) 
Best practice 
(corresponds to 
treatment on day 2) 
Current practice 
(corresponds to 
treatment on day 
0 1 1 1 
1 0.984481 0.984481 0.984481 
2 0.983943 0.969203 0.969203 
3 0.983406 0.968674 0.954162 
4 0.982869 0.968145 0.939354 
5 0.982333 0.967616 0.924777 
6 0.981796 0.967088 0.910425 
7 0.98126 0.96656 0.896296 
8 0.981131 0.966432 0.896178 
9 0.981001 0.966305 0.89606 
 
Discussion 
This chapter has outlined the methods for the identification and application of data to build 
and structure the GPiT strategy model. In one area, GP diagnostic accuracy, the need for a 
more structured literature review was necessitated. This is the focus of the next chapter. 
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CHAPTER 6: NARRATIVE REVIEW OF STUDIES ASSESSING THE 
DIAGNOSTIC ACCURACY OF GPS IN THE DIAGNOSIS OF TIA 
 
6.1 Introduction  
The rationale for this narrative review is to establish the accuracy of GPs in making the 
diagnosis of TIA. Previously, Chapter 5 identified GP accuracy as an important model 
parameter requiring a more structured and in-depth review.  The need for a review on this 
subject was also highlighted in the discussion of the published Birmingham TIA report 
(Mant, 2008). The review question that the review is seeking to consider is ‘What is the 
accuracy of GP diagnosis in patients with first-ever TIA?’  The question is further refined 
by inclusion/exclusion criteria (section 6.2). 
 
Given that the diagnosis of TIA is essentially clinical, a strategy of GPiT will correspond 
to an increase in unnecessary prescribing (one extra patient treated) for every false positive 
GP diagnoses made. It therefore follows that the ability of the GP to identify and treat just 
the true positives could be a key driver of the cost-effectiveness of the intervention 
strategy.  
 
A linked aim of the review is that it will also record what the final diagnoses of non true 
TIA are, i.e. those diagnoses suspected by the GP as TIA but ultimately receiving non-
stroke diagnoses. The clinical outcomes of the false positive diagnoses will be important in 
identifying the potential harm of early initiation of GP treatment. From the answer to the 
review question it will be possible to determine the number of false positive diagnoses in a 
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hypothetical population. Additional information on the underlying pathologies of stroke 
mimics will enable judgements to be made on the harms posed by treatment. 
 
One contribution of this review is therefore that it will help define the profile of patients 
receiving the GPiT intervention. This is of clear import to policy makers. Methods for the 
review are provided overleaf, starting with the search questions. 
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6.2 Methods 
Search 1a: What is the accuracy of the primary care doctor’s diagnosis in patients TIA? 
 
Inclusion criteria:  
 Studies reporting details of diagnostic accuracy of TIA/minor stroke 
(ischaemic or all stroke)  
 Studies reporting diagnostic accuracy of clinicians in Primary or pre-
hospital care 
 Study design: any original research papers or secondary reviews of 
diagnosis of stroke in the community 
 Year 2000 onwards 
 Reference standard: usually specialist diagnosis (will include and report 
other methods of verification) 
 
Exclusion criteria: 
 Studies designed only to test accuracy of a diagnostic instrument (for 
instance screening tool) where no evidence on the accuracy of the clinician 
is provided 
 Studies which do not include strokes or TIA first triaged in Primary or pre-
hospital care 
 Studies with incomplete or missing description of the methods for verifying 
diagnosis  
 Studies which do not quantify accuracy (or allow for quantification of 
accuracy), for example by not reporting sensitivity, specificity, positive 
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predictive or negative predictive values (or allowing them to be calculated 
from detail provided) 
 
Seach 1b: What differential diagnoses occur in TIA/mini stroke first assessed in Primary 
Care? 
Inclusion criteria: 
 Studies reporting details on differential diagnoses where TIA is initially 
suspected  
 Quantification of differential diagnoses must be provided, for instance in 
percentage terms or absolute frequencies 
 Any setting (preference to Stroke/TIA presenting in Primary or pre-hospital 
care) 
 Study design: original research or secondary reviews 
 Year 2000 onwards 
 
Documentation of search strategy 
As evidenced above and by the search strategy reproduced in Appendix 2 (p.210). Where 
possible, standardised subject terms were used with additional keyword searches. A review 
of the papers identified in the earlier Birmingham TIA report with a focus on index words 
informed this process. The specific search words included the following (allowing for 
possible truncations) “Diagnostic accuracy”, “Predictive Value of Tests” “Sensitivity” 
“Specificity” and  “Transient Ischaemic Attack”.  
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The Embase/Medline databases were searched on 02/06/2009 and were too limited to 
those published between 1989-2009 week 19 (initially), updated to 2013 week 12. In 
addition a review of the Cochrane Library (including DARE database) and MEDION 
database was conducted to identify any additional studies in diagnostic accuracy of 
TIA/stroke. None were found. References of included studies were also checked. 
 
 
201 identified studies  
 
201 abstracts for first review 
 
n =11 for main search (includes information on accuracy) 
Of which n=5 (information on alternative stroke diagnoses) 
 
Figure 10: Study flow 
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Table 34: Study methods 
Author (year) 
[country/ study 
type] 
Study population and 
size 
Index test Reference standard Verification method 
(Fischer et al., 
2008)  [Denmark/ 
retrospective 
cohort ] 
All (n=583) patients 
classified as having 
acute cerebrovascular 
accident at a mobile 
emergency care unit. 
 
Physician trained in 
advanced life support 
but with no specialist 
training in neurology. 
Diagnosis applied was the 
primary diagnosis at point 
of discharge from hospital. 
Screening of hospital information 
systems at 6 hospitals. Non 
randomised comparison of consistency 
between all referred medical records 
and hospital information system at the 
study author’s hospital.  
(Mant et al., 2003) 
[UK/ retrospective 
cohort] 
All registered 
participants (n=5801) 
at participating GP 
practices.  
GP Study authors. Confirmed 
TIA. 
Authors applied a set of reference 
criteria to decide if the TIA or stroke 
was substantiated based on the 
evidence. TIA diagnosis required a 
record by the GP corroborated by the 
specialist and Stroke diagnosis was 
only made where there was evidence 
from 2 sources (or 1 source and patient 
record). 
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Author (year) 
[country/ study 
type] 
Study population and 
size 
Index test Reference standard Verification method 
(Gibbs et al., 
2001) 
[UK/ prospective 
cohort] 
 
 
Random sample 
(n=60) of patients 
referred to TIA clinic. 
GP Specialist Case note review. (Random but 
limited sample of referred TIA and 
stroke suspects was selected (n=60) 
from General Practice Research 
Database for case note review). 
(Harbison et al., 
2003) [UK/ 
prospective 
cohort] 
All (n=487) patients 
referred to the stroke 
unit, of which 
(n=216) were referred 
from Primary Care. 
Primary care physicians, 
A&E doctors and 
ambulance staff using 
the Face Arms Speech 
Test. 
Specialist. (Time based 
definition for TIA). 
Independent review of medical records 
by two study authors (neurologists in 
training). Areas of disagreement were 
discussed with lead study neurologist. 
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Author (year) 
[country/ study 
type] 
Study population and 
size 
Index test Reference standard Verification method 
Tomasik et al. 
(2003) [Poland/ 
GP survey] 
N/A (survey, n=100 
GPs). 
GP Two GPs with special 
interest in vascular 
diseases. (Not indicated 
whether there was 
independent verification by 
two study authors for each 
questionnaire. If this was 
not the case study may lack 
agreement between 
verifiers). 
GPs with special interest in vascular 
diseases identified if proposed 
diagnosis/management was: 
i. correct ii. probably correct or  iii. 
Incorrect. 
McNeill (2008) 
[UK/ prospective 
cohort] 
Patients admitted to 
the stroke unit (n=72) 
on the basis of 
primary care doctor’s 
referral letter. 
Primary care doctor. Admissions doctor at stroke 
unit (Senior House 
Officer). 
Hospital notes and study author’s 
opinion. It is not stated explicitly that 
the study author and the admitting 
Senior House Officer were the same 
person. 
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Author (year) 
[country/ study 
type] 
Study population and 
size 
Index test Reference standard Verification method 
Kidwell (2000) 
[US/prospective 
cohort] 
Consecutive transfers 
(n=1298) to a 
medical centre 
Paramedic (using the 
Los Angeles Prehospital 
Stroke Screen) 
Specialist Medical review and case discussion by 
two neurologists. 
Bos et al. (2007) 
[Netherlands] 
[prospective 
cohort]. 
Population based 
(n=6062) in those 
without disease with 
no relevant prior 
comorbidities 
(stroke/MI/ 
dementia).  
 
 
Not directly applicable. 
Study objective was to 
identify the incidence 
and prognosis of 
different types of 
transient neurological 
attacks. Study therefore 
aimed to ascertain all 
transient neurological 
attacks within 
community. 
Not directly applicable. 
Study classified transient 
neurological attacks into 3 
categories: focal (i.e. 
equivalent to TIA), non-
focal and  mixed (for TIAs 
with focal and non-focal 
symptoms). 
Electronic linkage of data sources 
from General practices, Mental health 
outpatients and face to face survey 
methods. 
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Author (year) 
[country/ study 
type] 
Study population and 
size 
Index test Reference standard Verification method 
Fonseca et al. 
(2011) [Portugal/ 
prospective 
cohort]] 
Cohort of consecutive 
referrals (n=578) 
[suspected TIA time-
based definition] 
patients attending a 
once weekly TIA 
clinic.  
GP or A&E diagnosed 
TIA, referred to clinic. 
Specialist diagnosis. Data collected on neurological, 
laboratory and imaging exams. Two 
independent observers classified 
patients into groups: TIA, Mimic, 
TNA: difficult to classify). Kappa 
statistics showed good inter-observer 
agreement (k=0.89, 95% CI: 
0.8509.93). 
Magin et al. (2013) 
[Australia/ 
prospective 
cohort] 
All referrals with 
suspected TIA [time-
based definition] 
(n=344) from GP or 
Emergency 
departments.  
Referred to TIA clinic. Specialist stroke physician. 
Most cases informed by 
MRI. 
Clinico-radiological assessment. 
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Author (year) 
[country/ study 
type] 
Study population and 
size 
Index test Reference standard Verification method 
Cameron et al. 
(2011) [UK/ 
prospective cohort: 
with suspected 
TIA] 
Consecutive referrals 
(n=3553) to acute 
access TIA clinic. 
Referred to TIA clinic 
(source not discussed). 
TIA was not further 
defined. 
Clinical diagnosis of 
cerebrovascular (TIA). 
Authors acknowledge 
outcome includes some 
minor stroke.  
Standardised assessment verified by 
senior stroke physician. 
Murray et al. [UK] 
(2007) 
All new referrals 
(n=813) to TIA 
clinics.  
Referred to TIA clinic. Specialist diagnosis. Not discussed. 
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Table 35: Summary of results 
Note: These tables detail summary data. A detailed view of the data extracted with a view to the graphical presentation of results are tabulated 
in  Table 47 and Table 48 (p.212-214). 
Author 
(year)  
Study purpose Estimate of clinician accuracy Estimates of other diagnoses (accounting for 
>5% of non-stroke diagnoses) 
Fischer et 
al. (2008)   
To calculate the proportion of 
patients admitted with a suspected 
stroke who had a final diagnosis at 
hospital discharge of ‘acute 
cerebrovascular incident’. 
Positive predictive value of initial 
diagnosis of stroke = 30.1% (95% CI 
26.3-34.1).  
 
Unclear reporting. Specific diagnoses not 
detailed. Authors refer to non-stroke 
neurologic disease, systemic and non-systemic 
disease without further explanation. 
Mant et 
al. (2003)  
Comparison of three different 
methods for identifying prevalent 
cases of cerebrovascular disease in 
the community: GP database 
systems; population surveys and 
hospital information systems. 
Sensitivity of GP (the GP database 
records) = 80%, specificity = 97% and 
the positive predictive value = 70% (95% 
CI: not reported).  
 
 
Not provided. 
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Author 
(year)  
Study purpose Estimate of clinician accuracy Estimates of other diagnoses (accounting for 
>5% of non-stroke diagnoses) 
Gibbs 
(2001) 
 
 
Stated aim ‘to establish the 
difference in burden of 
cerebrovascular disease across the 
different health regions of the UK 
and to determine the initial 
management of new cases of stroke 
and TIA was uniform across the 
UK’. 
Of those (n=30) cases coded as TIA on 
the General Practice Research Databasen 
(GPRD), 48% were confirmed as correct 
by specialist. A further 18% of TIA 
diagnoses received a stroke diagnosis. Of 
those coded as stroke 64% were correct 
and 16% were given a final diagnosis of 
TIA. These suggest an overall GPRD 
PPV of approximately 48% (66% if all 
CVA) and 64% (80 if all CVA). (CI: not 
reported). 
Limited information due to small study size 
(n=60). No non-stroke diagnoses were 
observed in more than 5% of patients.  
Harbison 
(2003) 
To assess the diagnostic accuracy of 
stroke referrals from Primary Care 
and Emergency Room physicians, 
and ambulance staff using the Face 
Arm Speech Test? 
Primary care physicians had a PPV = 
71% (95% CI: 65-77%). 
Information on non strokes and other 
diagnoses recorded by primary care doctors 
with a greater than 10% incidence were: 
infections and sepsis 14%, malignant tumour 
11%; seizures 10% and deteriorating dementia 
10%. 
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Author 
(year)  
Study purpose Estimate of clinician accuracy Estimates of other diagnoses (accounting for 
>5% of non-stroke diagnoses) 
Tomasik 
(2003)  
How competent are Polish primary 
care physicians in diagnosing and 
managing patients with transient 
ischaemic attacks in the carotid 
territory? 
Standard test statistics not reported or 
calculable. 
(Authors state that proportion of patients 
receiving correct diagnosis ranged from 
20-78%: this includes true positives and 
true negatives. Incorrect diagnoses 
occurred in 3-42% of cases: this includes 
false positives and false negatives). 
Not applicable. 
McNeil 
(2008)  
How accurate are primary care 
referral letters for presumed acute 
stroke? 
Standard test statistics not reported or 
calculable. 
Author’s state ‘Primary care doctor’s 
diagnosis was correct in approximately 
30% of cases’.  
Identified as falling mainly into 2 groups: 
elderly patients which typically have general 
medical conditions such as sepsis or delirium 
and present with features such as: 
confusion (16%), falls/poor mobility (12%) 
and vertigo (7%). Second group: patients with 
functional neurological disorders (detail not 
provided) displaying focal neurological signs.  
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Author 
(year)  
Study purpose Estimate of clinician accuracy Estimates of other diagnoses (accounting for 
>5% of non-stroke diagnoses) 
Kidwell 
(2000)  
To validate an instrument used by 
paramedics to detect ischaemic 
stroke, currently symptomatic TIA 
and intracerebral haemorrhage. 
Paramedics trained in a screening 
instrument 
(non adjusted for documentation errors) 
resulted in sensitivity=91% (95% CI: 71-
98), specificity=97% (95% CI: 93-99), 
PPV=86% (95% CI: 70-95) NPV=98% 
(95% CI: 95-99). 
Not reported. 
 
Bos 
(2007) 
 
To incidence and prognosis of focal 
Transient neurological attacks 
(TIA), non focal Transient 
Neurological Attacks (TNA) and 
mixed Transient Neurological 
Attacks. 
Standard test statistics not reported.  
282 of the 554 (51%) Transient 
Neurological Attacks (TNA) that 
occurred were TIA, 228 were non-focal 
and 38 were mixed. 12 TNAs did not fit 
into any category. This study had higher 
ascertainment of TIA in the community 
(i.e. false negative TIA was detected) due 
to the use of survey methods. 
Underlying pathologies for non-focal and 
mixed TNA not reported, but the long-term 
prognosis was assessed by Kaplan-Meier 
survival analysis. There was a high risk of 
vascular death and dementia in non-focal 
TNA. 
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Author 
(year)  
Study purpose Estimate of clinician accuracy Estimates of other diagnoses (accounting for 
>5% of non-stroke diagnoses) 
Fonseca 
et al. 
(2011)  
To classify patients with transient 
neurological attacks (TNA) and 
identify frequent problems in 
establishing diagnosis. 
PPV (TIA or possible TIA)= 65.2% 
PPV (confirmed TIA with recent 
ischaemic lesion on imaging)= 19.7% 
Not reported. 
Magin et 
al. (2013)  
To establish paths and care for 
patients referred by GPs and 
emergency departments to an acute 
access TIA clinic. 
PPV (all referrals to clinic, TIA) = 52%  
 
Not reported. 
Cameron 
et al. 
(2011)  
To describe long-term outcome 
following attendance at a TIA clinic. 
PPV (all referrals to clinic, TIA)= 52% Not reported. 
Murray et 
al. (2007) 
To describe profile of referrals to 
TIA clinic. 
PPV (all referrals to clinic, TIA)= 26.8% 
PPV (all referrals to clinic, composite 
stroke)= 47.3 
PPV (GP referrals, TIA)= 28.2% 
PPV (GP referrals, composite stroke)= 
49.7%  
Migraine 8.9%, syncope 7.7%. 
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6.3. Quality Assessment of Studies 
The QUADAS-2 checklist for the purposes of assessing the quality of primary diagnostic 
accuracy studies was used to inform the rigour and validity of the review process (Whiting 
et al. 2011). 
 
Since assessing the accuracy of GP diagnosis is distinct from the usual test accuracy 
studies for which the checklist was developed, some of the QUADAS-2 criteria were less 
applicable to the specific review considered here. These items were omitted, and the 
descriptive tool is therefore not included either.  
 
It is nevertheless interesting to consider the ways in which this test accuracy studies 
considered in this review are different from the traditional test accuracy studies (Table 36). 
 
Table 36: Differences between GP clinical accuracy studies, and more standard 
studies of test accuracy 
Inclusion of test characteristics 
Full results on the accuracy of the test were often not presented, as there was no follow-up 
on participants receiving a negative diagnosis. This excludes all but the potential to report 
the proportion of people with a positive test who have the condition (positive predictive 
value, hereafter PPV). It would, in fact, be interesting to have information on false 
negatives and true negatives (to enable sensitivity and specificity to be calculated),  
Index test  
As stated in Chapter 2, the diagnosis of TIA is essentially clinical, unless supported by 
facilities for imaging and interpretation. These services are not currently available for 
mainstream use in the UK NHS, so the diagnosis of TIA in Primary Care is entirely 
clinical. 
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Reference standard 
Although specialists have access to imaging, the reference standard still rests on a clinical 
diagnosis which may not correctly identify true positives. In addition, the reference 
standard might be more prone to vary across studies, as there may be disparity in how 
studies classify/define TIA (as it is currently unclear if there is concensus on the ‘new’ 
tissue-based definition of TIA) and whether they consider a stroke misdiagnosed as a TIA 
as incorrect diagnosis. 
Sequence of tests 
It follows from the above point also that the reference standard is only routine in patients 
with a positive diagnosis, therefore the diagnostician in the reference case can not 
(normally) be blind to the results of the index test. 
Appropriacy of meta-analysis 
Meta-analysis is useful in generating an overall measure of tendency from multiple studies, 
by quantitatively pooling results from individual studies. While it may be appropriate to 
meta-analyse estimates of sensitivity and specificity from diagnostic accuracy studies, the 
same is not conventionally undertaken in studies of positive and negative predictive 
values. This is because the latter measures are heavily influenced by the prevalence of 
disease in the population, and therefore meta-analysis in these cases would be of limited 
value, unless the studies were all drawn from study populations with the same prevalence 
of TIA. Given the essentially clinical diagnosis of TIA, it seems unlikely that studies will 
be able to discriminate between true and false negative cases that would be required to 
determine sensitivity and specificity. (For one thing, in routine clinical practice, it is 
unlikely that the negative cases would come to light). For this reason, no attempt to meta-
analyse PPVs (or any other aspects of diagnostic accuracy) will be made, however, Forest 
plots will be used to indicate the 95% CI ranges corresponding to the point estimates of 
effect size. 
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6.4. Results 
The search identified 201 studies. Of these, 11 met the eligibility criteria (Figure 6.1 flow). 
 
The majority of the studies were conducted in the UK, one in each of Portugal, the 
Netherlands, Australia, Denmark and Poland. Of the included studies recruiting patients, 
the smallest study size was 72 in a prospectively identified TIA clinic cohort, the largest 
6062 in a prospective, population-based cohort of participants with no history of TIA. 
 
However, the majority of studies used a prospective cohort. Usually the cohort would be 
composed of consecutive referrals to a TIA clinic (to avoid bias); so the index test was the 
GPs clinical evaluation of the patient resulting in referral. The study would then compare 
the results of the index with the reference standard (typically specialist diagnosis). This 
study design is therefore analogous to how diagnoses are made in practice, and would 
appear applicable to this thesis’ review question. 
 
In the main, patients were recruited on the basis of having TIA clinic referrals for 
suspected TIA or stroke. Exceptions to the rule included a study looking at the rapid 
transfer of patients to hospital by ambulance, a population-based study of the incidence of 
TIA in the community and a study designs looking at the consistency in different methods 
of record linkage. One postal survey of GPs asked them to consider their diagnosis in 
response to a series of vignettes.  
 
Three studies focused on pre-hospital emergency setting whereas others focused on TIA 
and stroke in the community. This suggests that there may be have been differences in the 
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way the diagnosis was made. For instance, paramedics attending a TIA may use a specific 
screening tool to establish patient’s risk (Kidwell et al., 2000). Across these 2 groups it 
would also be likely that there would be some differences in the acuteness and severity of 
the patient’s symptoms. It seems plausible that the condition be more severe in the former, 
but also the presence of non-TIA diagnoses may be different. As these factors could 
account for plausible differences in test statistics presented, descriptive presentation of 
results was restricted to settings which were predominantly composed of suspected TIAs 
identified in Primary Care. Full details of all studies is provided in ‘Appendix 4: Data 
extracted on Diagnostic accuracy and alternative stroke/TIA diagnoses’ (p212). 
 
The proportion of study participants with a suspected TIA and a final diagnosis of TIA 
ranged from 4% to 57% (figure 1). The proportion of study participants with a suspected 
TIA and a final composite outcome of TIA or stroke ranged from 20% to 86% (figure 2). 
These results appear to be symptomatic of the heterogeneity in the selection of participants 
and the method by which the reference diagnosis was established.  Note that a full results 
table is provided in the appendix.  
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Figure 11: Positive predictive values of GP diagnosis in TIA‡ 
‡ Where not reported in the primary paper, 95% confidence intervals were estimated using 
the estimate of standard error for a proportion (Bland, 2000). 
 
With a final diagnosis of TIA:
0 10 20 30 40 50 60 70 80 90 100
PPV, %
Magin et al, 2000
Bos et al, 2007
Murray et al, 2007
Cameron et al, 2011
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Figure 12: Positive predictive values of GP diagnosis in TIA or stroke‡ 
‡ Where not reported in the primary paper, 95% confidence intervals were estimated using 
the estimate of standard error for a proportion (Bland, 2000). 
 
The linked aim of this review was to record the diagnosis of the false positive TIA cases. 
Only 5 of the studies reported on the final diagnoses received by patients (Gibbs et al., 
2001). Of these, the study by Fischer et al was excluded from analysis (but not extraction) 
because it did not identify alternative TIA/Stroke diagnoses in Primary Care, and inclusion 
would therefore bias results. The details of all non TIA/stroke diagnoses were tabulated 
using the author’s classification system initially. Following this, diagnoses were sorted by 
pathological cause, and results were pooled to provide the mean incidence. 
 
With a final diagnosis of TIA or Stroke:
0 10 20 30 40 50 60 70 80 90 100
PPV, %
Magin et al, 2000
Murray et al, 2007
McNeil et al, 2008
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The most common alternative diagnoses are presented in Figure 13. Few alternative 
diagnoses would be worsened by the initiation of secondary preventive drugs. Clinical 
Knowledge summaries (NICE) identify no specific contraindications for dipyridamole and 
that the risk of bleeding is no greater than with low dose aspirin alone (NICE, 2013). For 
this reason, the main contraindication would be active pathological bleeding. Therefore, 
Figure 19 presents detail on the alternative circulatory diagnoses. Full detail on all 
alternative diagnoses are presented in Appendix 4: Data extracted on Diagnostic accuracy 
and alternative stroke/TIA diagnoses.
 
Figure 13: Alternative pathological cause in false positive GP diagnosed TIA (n=185) 
(NOS = not otherwise specified.) 
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Figure 14 Percentage of all non-stroke diagnoses† observed in at least 0.5% of the 
sample 
† Excludes [ICD-10 60-64 inclusive and TIA]; Psychological/psychiatric also includes 
dementia.  
 
Within these studies, there were some characteristic differences in the way the alternative 
diagnoses were defined. For instance, in some cases the diagnoses seemed to relate to 
well-known category codes used in hospitals, whereas in others the authors seemed to have 
grouped diagnosis together. There were pitfalls of both methods. The first method resulted 
in a myriad of alternative diagnoses such that no diagnoses was recorded in more than 5% 
of participants whereas the second resulted in a loss of precision. An unexpected finding 
was that two studies (identified for this test accuracy review) used longitudinal follow-up 
to examine the prognosis of false positive TIAs, but did not report the alternative diagnosis 
causing the TIA  (Bos et al., 2007).  
 
However, half of the non-stroke diagnoses were explained by an underlying neurological 
or circulatory pathology (Figure 13) and over a third were explained by either seizure, 
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syncope, hypotension or mental, behavioural or neurodevelopmental disorders (such as 
dementia, see Figure 14). There was therefore limited evidence to suggest a heightened 
risk of adverse events under the GPiT strategy. 
 
6.5. Discussion 
Summary of key findings 
A review of studies in the diagnostic accuracy of TIA found that the majority of studies 
did not identify/report on negative cases. This review has therefore focussed on reviewing 
the positive predictive values presented in primary studies. Quality assessment suggested 
there was substantial concern about the risk of bias and applicability when comparing test 
statistics obtained in different settings and study designs. 
 
A stratified analysis (presented using descriptive forest plots) was performed to 
demonstrate the positive predictive values in two instances:  i. GP referred TIA receiving a 
final TIA diagnosis ii. GP referred TIA receiving  a diagnosis of TIA or stroke. Meta-
analysis was not performed for fear that the underlying prevalence of TIA could bias 
results.  
 
A subsidary aim of this review was to identify the typical diagnoses in fase positive TIAs 
in a subset of studies identified within the main search. Common alternative diagnoses 
(defined as occuring in at least 5% of TIA or combined TIA/ minor stroke referrals) 
included syncope, dementia and migraine. In the main, this is consisent with the generally 
reported finding that most false positive TIAs had other neurological or vascular 
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explanation. In two studies looking at outcomes over a longer period of follow-up, there 
was more convincing evidence that false positive TIA are associated with poor prognosis 
in terms of cardiovascular and neurological outcomes.  
 
Limitations 
There was a general question over the applicability of test-accuracy review methods to the 
accuracy of diagnoses made by GPs. This review did not provide the level of information 
to inform estimates on the precision of the positive predictive values, nor did it provide 
any robust information on the numbers of false negatives. The latter is of interest to policy 
makers as missed diagnoses constitute a susceptible group of patients that warrant the 
intervention but are missed in all the modelled scenarios. In practice, it might be that the 
GPiT intervention could also include some training of GPs to better recognise the 
symptoms of TIA. There may also be more attention given to training the public to better 
recognise symptoms and take appropriate action. Of course, both these measures will only 
be effective if they ensure that more of the target population are identified for treatment 
and remain to be tested in TIA. 
 
Recommendations to future research 
It may have been insightful to consider the accuracy of GPs in other conditions more 
generally as part of this research question. It might be interesting to compare referrals for 
chest pain or asthma, for instance. This might provide some guidance on how susceptible 
patients are identified in other disease areas where there is a similar speed of onset and 
opportunity for effective treatment. It was not possible to apply standard test accuracy 
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appraisal methods to primary studies which, in the main, restricted the reporting of results 
to PPVs. The methods used within the diagnostic review here, and elsewhere, offer 
possible approaches (Shapley et al., 2010, Astin et al., 2011). 
 
Implications for the model 
In conclusion, this review suggests a significant proportion (at least 50%) of suspected 
TIA cases identified by GPs ultimately receive some other (non-stroke) diagnosis, and 
therefore represent the broader population for a service delivery intervention in Primary 
Care. In addition, this review has highlighted something possibly unexpected: potentially 
high vascular risk (and so a likely benefit from treatment) in the false positive cohort.  
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CHAPTER 7: RESULTS OF THE COST-EFFECTIVENESS ANALYSIS 
7.1. Introduction 
The objective of this chapter is to present the results of the model based economic 
evaluation. The overarching aim of this thesis is to examine the cost-effectiveness of GPiT 
when compared to existing strategies based on current clinical practice and guidelines. 
Along with the key summary-level information (incremental costs and benefits), data is 
also presented on the sequelae of clinical events (e.g. stroke-free survival, major 
haemorrhagic events and carotid surgeries) following TIA at 90 days. 
 
7.2. Approach 
As discussed in Chapter 2, the budget for healthcare is finite. In order for healthcare 
purchasers to maximize health gains from a limited resource, the framework of economic 
evaluation was used to compare the costs and consequences of GP initiation of treatment 
versus strategies based on existing clinical practice. A decision-analytic Markov type 
model was developed to make a projection about the cost-effectiveness of GPiT relative to 
existing options. The main comparison compares GPiT to: i. best practice (base-case) ii. 
current practice (this is a “secondary” analysis).  Comparisons are made at 90 days and 
over a lifetime time horizon. The chapter concludes with a summary of findings. 
 
7.3. Clinical outcomes 
The following outcomes are presented for a cohort of 1000 people with suspected TIA at 
90 days: number of non-fatal or fatal ischaemic stroke, haemorrhagic stroke, major 
haemorrhage and carotid surgery events. In addition, figures 15-17 plots the event status 
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over the 90 days corresponding to the Markov model time period. These categorise the 
number of persons according to event status: well (for TIA and recovered carotid surgery 
states); non-fatal major event (for non-fatal stroke and major haemorrhage states) and 
dead. The contrast between strategies appears in the gradient of the curve for major events 
in the first 10 days of the model corresponding to differences in timings of treatment 
initiation over this period. 
 
For reference, in the model time period of 90 days, the number of strokes anticipated in the 
best performing Oxford Vascular study cohort would be 6 per 1000; compared with 104 
per 1000 in less urgently treated cohorts (Rothwell et al., 2007). Furthermore, assuming 
that 5% of the population are eligible candidates for surgery and the proportion of the 
population with true TIA is 50%, a maximum of (0.05 x 50=) 25 carotid surgeries could be 
anticipated (Wardlaw et al., 2006, Sudlow and Warlow, 2009). 
 
The base-case model projections for rate of stroke (17.4 per 1000) in best practice are 
higher than the rate observed in the best performing stroke clinic, but the projections are 
within the anticipated bounds of other rapid access stroke clinics. Comparison of the 
number of strokes experienced at 90 days under best practice with that of current practice 
reveals a 75% reduction in the stroke rate which is also consistent with evidence on rapid 
access stroke clinics reviewed (Luengo-Fernandez et al., 2009b, Lavallee et al., 2007).
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Table 37: Model health state occupancy at 90 days per 1000 cases of suspected TIA 
presenting in Primary Care 
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  Non-
fatal 
Fatal Non-
fatal 
Fatal Non-
fatal 
Fatal Non-
fatal 
Fatal  
GPiT 953.59 11.90 2.78 0.08 0.03 14.47 0.05 2.96 0.00 14.14 
Best 
practice 
945.65 17.44 4.47 0.11 0.04 15.32 0.06 2.87 0.00 14.04 
Current 
practice 
918.73 44.12 12.26 0.29 0.11 8.37 0.03 2.52 0.00 13.56 
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Figure 15: Event status by time point within the Markov model for a notional 
population of 1000 suspected TIA cases, best practice 
 
Figure 16: Event status by time point within the Markov model for a notional 
population of 1000 suspected TIA cases, GPiT 
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Figure 17: Event status by time point within the Markov model for a notional 
population of 1000 suspected TIA cases, current practice 
 
7.4. Cost-effectiveness outcomes  
The base-case comparison presents results from the pair-wise comparison of GPiT versus 
best practice. Total and incremental costs and effects are reported in addition to 
cost/QALY (where applicable). The secondary analysis reports the findings from a pair-
wise comparison of GPiT vs. current practice. For both analyses, results are presented over 
two time points: 90 days and lifetime. 
 
Table 38 presents the findings from the base-case comparison at 90 days from the 
deterministic analysis. The results suggest no difference between GPiT and best practice. 
Table 39 presents the results when the modelled outcomes are extrapolated to a lifetime 
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horizon. These results show that the incremental QALY gain is now approximately 0.0538 
and the cost saving is £551.
11
 
 
Table 38: Results of the base-case analysis (pair-wise comparison of GPiT vs. best 
practice) [90 day time  horizon] 
  
Total 
QALYs/ 
patient 
Total cost/ 
patient  
(£) 
Incremental 
QALYs 
Incremental 
cost  
(£) 
Cost/QALY 
(£) 
Best practice 0.2100 £190 - - - 
GPiT 
0.2108 £187 0.0009 -£3 No 
difference 
 
Table 39: Results of the base-case analysis (pair-wise comparison of GPiT vs. best 
practice) [lifetime horizon] 
  
Total 
QALYs/ 
patient 
Total cost/ 
patient  
(£) 
Incremental 
QALYs 
Incremental 
cost  
(£) 
Cost/QALY 
(£) 
Best practice 9.1439 £1,477 - - - 
GPiT 9.1977 £926 0.0538 -£551 Dominant 
 
                                                   
 
11
 Results for QALYs are expressed to 4 decimal places; results for costs are presented correct to the nearest 
integer. Incremental cost/QALYs presented may reflect rounding. 
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Table 40 and Table 41 present the secondary comparison for the 90 day model and the 
lifetime horizon respectively. The direction of results are similar to that of best practice, 
but as might be expected the magnitude of the effect gains and cost savings are greater.  
 
Table 40: Results of the secondary analysis (pair-wise comparison of GPiT vs. 
current practice) [90 day time  horizon] 
 
  
Total 
QALYs/ 
patient 
Total cost/ 
patient  
(£) 
Incremental 
QALYs 
Incremental 
cost  
(£) 
Cost/QALY 
(£) 
Current practice 0.2053 £293 - - - 
GPiT 0.2108 £187 0.0055 -£107 Dominant 
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Table 41: Results of the secondary analysis (pair-wise comparison of GPiT vs. 
current practice) [lifetime horizon] 
  
Total 
QALYs/ 
patient 
Total cost/ 
patient  
(£) 
Incremental 
QALYs 
Incremental 
cost  
(£) 
Cost/QALY 
(£) 
Current practice 8.8870 £2,055 - - - 
GPiT 9.1977 £926 0.3107 -£1,129 Dominant 
 
In order to examine the robustness of these results to parameter uncertainty, probabilistic 
sensitivity analysis (PSA) was performed. Results of the 1,000 Monte Carlo simulations of 
the model are presented on cost-effectiveness scatter plots. Each point within the scatter 
plot corresponds to an incremental cost/effect pair resulting from random sampling of the 
inputs. Additionally, comparison of the mean outcome of the probabilistic modelling 
(mean incremental costs and QALYs) were compared with the incremental estimates from 
the deterministic analysis. Results appeared to be similar and are considered further in 
A.6.2. Scenario analysis for the base-case comparison.  
 
The mean incremental QALYs and costs (of GPiT relative to the comparator) from PSA 
were calculated as part of the approach for constructing cost-effectiveness acceptability 
curves (CEAC). The CEAC curve shows the probability of a positive net benefit over a 
continuum of threshold values for different values of the ceiling ratio. 
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Specifically this is calculated as: 
Net benefit  =  λ Q – C 
Where Q  is the incremental QALY gain of the intervention 
And C is the incremental cost 
And λ  is the ceiling ratio of the ICER 
 
Figure 18 shows a cost-effectiveness scatter plot and generated cost-effectiveness 
acceptability curve of GPiT vs best practice for the 90 day Markov model. The CEAC 
shows that GPiT is the preferred strategy in all simulations, at WTP conventionally 
adopted by NICE. All points within the scatter plot are associated with a net incremental 
QALY gain suggesting that GPiT is the more effective option. The results show 
considerable uncertainty as to the incremental cost. At the highest plausible gain of 0.0007 
QALY an incremental cost of 0.0018 × £20,000 = £36 is the maximum acceptable 
incremental cost with a threshold ICER of £20,000/QALY. However, all points lie inside 
of the south east quadrant, indicating that GPiT appears to have a small but consistent 
benefit over and above GPiT. This result is likely to reflect the structuring of the GPiT 
strategy which is essentially identical to best practice, albeit with earlier initiation of 
treatment. Averaged over a cohort of individuals, the benefit appears somewhat modest 
and it is therefore difficult to identify if the margin of difference amounts to clinically 
significant difference in effect. 
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Figure 18: Cost-effectiveness scatter plot and cost-effectiveness acceptability curve at 
90 days, GPiT vs. best practice 
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Cost-effectiveness results at lifetime 
Figure 19 shows a CEAC scatterplot for GPiT compared to best practice when a lifetime 
horizon is adopted. The CEAC shows that GPiT has the highest probability of being cost-
effective in all simulations over the continuum of ceiling ratios. As before, all points 
within is the scatter plot show an incremental benefit, however, now the mean plausible 
gain is approximately 0.05 QALY per suspected TIA case. 
 
 
Figure 19: Cost-effectiveness scatter plot and cost-effectiveness acceptability curve 
when a lifetime horizon is adopted, GPiT vs. best practice 
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Figure 20 and 21  provide the second pair wise comparison within the base-case: GPiT vs. 
current practice for the 90 day and lifetime time horizons respectively. Inspection of the 
cost-effectiveness plane in Figure 20 shows that there is no uncertainty as to the 
effectiveness of GPiT but some uncertainty about the cost-savings. This is consistent with 
the CEAC which shows that GPiT is the preferred strategy in approximately 80% of 
simulations.  
 
 
Figure 20: Cost-effectiveness scatter plot and cost-effectiveness acceptability curve at 
90 days, GPiT vs. current practice 
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Figure 21: GPiT vs. current practice: Cost-effectiveness scatter plot when a lifetime 
horizon is adopted 
 
The CEAC associated with points in the scatter plot shows that 100% of simulations are 
cost-effective at WTP according to thresholds conventionally adopted by NICE i.e. the 
CEAC associated with this scatter-plot would look identical to Figure 18 and is not 
reproduced for this reason. 
 
7.5. Scenario Analysis: Other options for GP initiation of treatment 
For the scenario analysis, results are presented in terms of the net benefit statistic. As 
discussed in Chapter 3, when considering multiple strategies (scenarios) the net benefit 
option allows for the direct comparison of options, without having to consider strict or 
extended dominance. As previously stated, the net benefit was calculated as 
NB = λ Q – C 
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Where Q  is the incremental QALY gain of the intervention  
And C is the incremental cost 
And λ  is the ceiling ratio of the ICER 
   
Scenarios tested: a reminder 
In addition to the main comparison of the three strategies, a scenario analysis was 
undertaken to evaluate the cost-effectiveness of alternative routing of patients after the GP 
has initiated secondary prevention. Different configurations of GPiT are now examined to 
explore different options for implementation, for instance, including strategies based on 
part or no onward referral (i.e. alternative GPiT 1: high risk group only referred and 
alternative GPiT 2: no subsequent referral). Findings are summarised in terms of 
incremental costs and effects relative to current practice, [where choice of comparator has 
been chosen for presentational purposes]. Preferred strategies were identified on the basis 
of (mean) expected net benefit for each comparison at ceiling ratio of the ICER at £20,000, 
computed from incremental costs and QALYs (Table 42). Using expected mean net 
benefit, the preferred strategy at both 90 days and for the lifetime horizon was GP 
initiation of treatment with no subsequent follow-up. These correspond to the scenarios 
preferred when the model is run deterministically. 
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Table 42 Comparison of main results: deterministic and probabilistic output 
  
Incremental QALYS vs current 
practice 
Incremental costs vs current practice 
(£) 
Maximum 
incremental net 
benefit at a 
ceiling ratio of 
(£20,000) 
Most CE 
strategy 
(corresponding 
to strategy 
maximum 
incremental net 
benefit) 
 Best 
practice 
GPiT GPiT 
refer 
only 
high 
risk 
GPiT 
no 
subsequ
-ent 
referral 
Best 
practice 
GPiT GPiT 
refer 
only 
high 
risk 
GPiT 
no 
subsequ
-ent 
referral 
Base-case 
(probabilistic):  
90 days 
0.0046 0.0055 0.0059 0.0063 -95 -99 -115 -131 257 GPiT no referral 
Base-case 
(determinisitic):  
90 days 
0.0047 0.0055 0.0059 0.0062 -104 -107 -120 -134 257 GPiT no referral 
Base-case 
(probabilistic): 
lifetime 
0.2573 0.3113 0.3118 0.3126 -560 -1115 -1109 -1115 7366 GPiT no referral 
Base-case 
(determinisitic): 
lifetime 
0.2569 0.3107 0.3112 0.3109 -578 -1129 -1123 -1130 7354 GPiT no referral 
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The probabilistic modelling also presents the results in terms of multiple cost-effectiveness 
acceptability curves at 90 days (Figure 22) and over the lifetime horizon (Figure 23). As 
before, each curve shows the probability that each intervention is most optimal; which has 
a slightly distinct interpretation from basis of mean net benefit above (Table 42). At 
typically applied ceiling ratios, Figure 23 shows that GPiT with no subsequent referral is 
associated with the greatest probability of each simulation/run being cost-effective (96% of 
model runs at a WTP threshold of £20,000/QALY). This finding is consistent with the 
recommendation on the basis of maximising expected mean net benefit; i.e. identifying 
GPiT with no subsequent specialist referral is the most cost-effective option at 90 days. 
 
 
Figure 22: Cost-effectiveness acceptability curve for multiple strategies (90 days) 
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When the analysis horizon becomes lifetime, results from extrapolation of model outcomes 
suggest that the alternative GPiT with no subsequent referral is preferred (has a higher 
probability of being cost-effective) for all credible ranges of the ceiling ratio shown 
(Figure 23). Again, this is consistent with the preferred strategy on the basis of expected 
mean net benefit  
Table 42). 
 
 
Figure 23: Cost-effectiveness acceptability curve for multiple strategies (lifetime)
 
7.6. Sensitivity analysis 
Additional one-way sensitivity analysis was undertaken to further test the uncertainty 
within the model with respect to both the uncertainty in the data inputs (parameter 
uncertainty) and the methodological/structural assumptions. While parameter uncertainty 
has been tested by probabilistic modelling by allowing for variation around the point 
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estimates, it was desirable to test the robustness of the model results (in terms of preferred 
strategies) to alternative assumptions other than which the base-case model was founded. 
Following this, it was possible to re-run the probabilistic analyses for the alternative 
assumptions. A summary of the results from the sensitivity analysis is provided in Table 
43. For information on total as well as incremental costs and QALYs, and net benefit at 
various thresholds, tables are provided in Appendix 6: Model results (Detailed view). 
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Table 43: Overview of results from sensitivity analysis (deterministic analysis results): note other assumptions relating to model 
remain unchanged, and as per the base-case. 
Assumption 
Incremental QALYS (vs. current 
practice) 
Incremental Costs, £ (vs. current 
practice) 
Incremental net 
benefit 
(corresponding 
to most CE 
strategy) 
Most 
CE 
strategy 
12
  Best 
Practice 
GPiT 
GPiT 
high 
risk 
referral 
GPiT: no 
subsequent 
referral 
Best  
Practice 
GPiT 
GPiT: 
high 
risk 
referral 
GPiT: no 
subsequent 
referral 
Standard 
model 
assumptions 
90 day 0.0047 0.0055 0.0059 0.0062 -104 -107 -120 -134 257 
GPiT 
no 
referral 
Lifetime 0.2569 0.3107 0.3112 0.3109 -578 -1129 -1123 -1130 7354 
GPiT 
no 
referral 
                                                   
 
12
 On the basis of net-benefit at a WTP of £20,000. 
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Assumption 
Incremental QALYS (vs. current 
practice) 
Incremental Costs, £ (vs. current 
practice) 
Incremental net 
benefit 
(corresponding 
to most CE 
strategy) 
Most 
CE 
strategy 
12
  Best 
Practice 
GPiT 
GPiT 
high 
risk 
referral 
GPiT: no 
subsequent 
referral 
Best  
Practice 
GPiT 
GPiT: 
high 
risk 
referral 
GPiT: no 
subsequent 
referral 
Variation in 
accuracy of 
GP diagnosis 
(PPV =75%) 
90 day 0.0070 0.0083 0.0088 0.0093 -155 -160 -181 -202 387 
GPiT 
no 
referral 
Lifetime 0.3854 0.4661 0.4674 0.4659 -867 -1474 -1471 -1475 10823 
GPiT 
no 
referral 
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Assumption 
Incremental QALYS (vs. current 
practice) 
Incremental Costs, £ (vs. current 
practice) 
Incremental net 
benefit 
(corresponding 
to most CE 
strategy) 
Most 
CE 
strategy 
12
  Best 
Practice 
GPiT 
GPiT 
high 
risk 
referral 
GPiT: no 
subsequent 
referral 
Best  
Practice 
GPiT 
GPiT: 
high 
risk 
referral 
GPiT: no 
subsequent 
referral 
Variation in 
accuracy of 
GP diagnosis 
(PPV=25%) 
 
90 day 
 
0.0023 0.0028 0.0030 0.0031 -52 -53 -60 -67 128 
GPiT 
no 
referral 
Lifetime 0.1285 0.1553 0.1550 0.1558 -289 -784 -775 -784 3892 
GPiT 
refer 
only 
high 
risk 
Increased risk 
of major 
haemorrhage 
90 day 0.0047 0.0055 0.0059 0.0062 -104 -107 -120 -134 257 
GPiT 
no 
referral 
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Assumption 
Incremental QALYS (vs. current 
practice) 
Incremental Costs, £ (vs. current 
practice) 
Incremental net 
benefit 
(corresponding 
to most CE 
strategy) 
Most 
CE 
strategy 
12
  Best 
Practice 
GPiT 
GPiT 
high 
risk 
referral 
GPiT: no 
subsequent 
referral 
Best  
Practice 
GPiT 
GPiT: 
high 
risk 
referral 
GPiT: no 
subsequent 
referral 
in TIA mimic 
population 
Lifetime 0.2569 0.3106 0.3106 0.3106 -578 -1129 -1123 -1130 7343 
GPiT 
no 
referral 
Adjustment 
for poor 
prognosis in 
medically 
treated severe 
carotid 
stenosis 
90 day 0.0047 0.0055 0.0059 0.0062 -104 -107 -120 -134 258 
GPiT 
no 
referral 
Lifetime 0.2569 0.3107 0.3228 0.3132 -578 -1129 -1100 -1015 7472 
GPiT 
no 
referral 
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Assumption 
Incremental QALYS (vs. current 
practice) 
Incremental Costs, £ (vs. current 
practice) 
Incremental net 
benefit 
(corresponding 
to most CE 
strategy) 
Most 
CE 
strategy 
12
  Best 
Practice 
GPiT 
GPiT 
high 
risk 
referral 
GPiT: no 
subsequent 
referral 
Best  
Practice 
GPiT 
GPiT: 
high 
risk 
referral 
GPiT: no 
subsequent 
referral 
Variation in 
utility values 
used (van Exel 
et al.) 
90 day 0.0022 0.0026 0.0029 0.0030 -104 -107 -120 -134 195 
GPiT 
no 
referral 
Lifetime 0.1817 0.2197 0.2201 0.2207 -578 -1129 -1123 -1130 5537 
GPiT 
refer 
only 
high 
risk 
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Assumption 
Incremental QALYS (vs. current 
practice) 
Incremental Costs, £ (vs. current 
practice) 
Incremental net 
benefit 
(corresponding 
to most CE 
strategy) 
Most 
CE 
strategy 
12
  Best 
Practice 
GPiT 
GPiT 
high 
risk 
referral 
GPiT: no 
subsequent 
referral 
Best  
Practice 
GPiT 
GPiT: 
high 
risk 
referral 
GPiT: no 
subsequent 
referral 
Variation in 
lifetime cost of 
stroke (50% 
increase in all 
long-term care 
costs) 
Lifetime 0.2569 0.3107 0.3112 0.3109 -1156 -2258 -2246 -2260 8484 
GPiT 
no 
referral 
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Assumption 
Incremental QALYS (vs. current 
practice) 
Incremental Costs, £ (vs. current 
practice) 
Incremental net 
benefit 
(corresponding 
to most CE 
strategy) 
Most 
CE 
strategy 
12
  Best 
Practice 
GPiT 
GPiT 
high 
risk 
referral 
GPiT: no 
subsequent 
referral 
Best  
Practice 
GPiT 
GPiT: 
high 
risk 
referral 
GPiT: no 
subsequent 
referral 
Varying the 
discount rate 
(costs and 
benefits) 
 
0% 
discount 
rate, 
lifetime 
horizon 
0.3070 0.3713 0.3719 0.3715 -686 -1341 -1334 -1342 8780 
GPiT 
no 
referral 
6% 
discount 
rate, 
lifetime 
horizon 
0.1920 0.2322 0.2326 0.2323 -513 -1002 -997 -1003 5654 
GPiT 
no 
referral 
† This analysis is outlined in the following section, ‘Sensitivity analysis’ p. 101
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The most conservative estimate from the analysis of the acute model suggested that GPiT 
would still be the preferred strategy if a daily transition probability of 0.14% was not 
exceeded. This is approximately equivalent to a 40% annual probability of an extracranial 
bleed, i.e. a four-fold increase in the annual rate of bleeding compared with the base-case 
assumption. The maximum  rate of bleeding that was cost-effective at lifetime was 
considerably higher, probably due to the impact on cost savings from a reduction in the 
risk of recurrent stroke.
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Table 44: Outcomes following adjustment for poor prognosis in medically managed 
patients with carotid stenosis who would otherwise have been eligible for carotid 
surgery (90 day time horizon) 
  
Total 
QALY/ 
patient 
Total 
costs/ 
patient 
Inc. 
QALYS 
vs. best 
practice 
Inc. 
costs vs. 
best 
practice 
Net 
benefit 
at a 
£10,000 
ceiling 
ratio 
Net 
benefit 
at a 
£20,000 
ceiling 
ratio 
Net 
benefit 
at a  
£30,000 
ceiling 
ratio 
Current 
practice 
0.2053 £293 -0.0047 £104 -£150 -£197 -£243 
Best 
practice 
0.2100 £190 
     
GPiT 0.2108 £187 0.0009 -£3 £12 £21 £29 
GPiT 
refer 
only 
high risk 
0.2112 £173 0.0012 -£17 £29 £41 £54 
GPiT no 
referral 
0.2115 £159 0.0015 -£31 £45 £60 £75 
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Table 45 Outcomes following adjustment for poor prognosis in medically managed 
patients with carotid stenosis who would otherwise have been eligible for carotid 
surgery (lifetime time horizon) 
 Total 
QALY/ 
patient 
Total 
costs, £ 
/patient 
Inc. 
QALYS 
vs. best 
practice 
Inc. 
costs vs. 
best 
practice 
Net 
benefit 
at a 
£10,000 
ceiling 
ratio 
Net 
benefit 
at a 
£20,000 
ceiling 
ratio 
Net 
benefit 
at a  
£30,000 
ceiling 
ratio 
Current 
practice 
8.8870 £2,055 -0.2569 £578 -£3,147 -£5,717 -£8,286 
Best 
practice 
9.1439 £1,477           
GPiT 9.1977 £926 0.0538 -£551 £1,089 £1,626 £2,164 
GPiT 
refer 
only 
high risk 
9.2002 £955 0.0563 -£522 £1,085 £1,648 £2,211 
GPiT no 
referral 
9.2098 £1,040 0.0659 -£437 £1,096 £1,755 £2,415 
 
 
7.7. Expected value of perfect information (EVPI) 
For the base-case analysis, the uncertainty surrounding the decision whether or not to 
implement GPiT resulted in an individual EVPI of £2,251 at a WTP of £20,000. 
Implementing GPiT affects the entire population with an index (first in a lifetime) TIA or 
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resolved minor stroke presenting in Primary Care; this equates to a total ‘effective’ 
population of 208,761 when the intervention is rolled out for 10 years. The calculated 
population EVPI is therefore £470 million at a WTP of £20,000. This value equates to the 
upper bound of eliminating all uncertainty within the model. The population EVPI at 
different values of the ceiling threshold is presented in Figure 24. The EVPI curve is of the 
expected shape
13
, given that GPiT dominates the comparator in the mean analysis but there 
is uncertainty about which strategy is more costly (so non-zero EVPI at zero WTP) and 
also uncertainty about which strategy is more clinically effective (so EVPI remains 
positive at large WTP values). 
 
 
Figure 24: Population EVPI at different levels of the ceiling threshold
 
 
                                                   
 
13
 i.e. positive values of EVPI and no sharp point where the ‘a priori’ decision changes. 
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Additionally it would be desirable to explore the EVPI for subsets of parameters, for 
instance, around the effectiveness of the intervention, utilities, costs and important to this 
model, parameters relating to the safety of care: in particular, the positive predictive value 
of GP diagnosis of TIA and the risk of adverse events. This would inform which 
parameters were most valuable to further research. In particular, if the partial EVPI 
associated with safety parameters is low, this would potentially allow for a case to be made 
for implementation of GPiT based on current evidence.  
 
7.8. Summary of results  
Results from the base-case analysis at 90 days demonstrate that in comparison with best 
practice, GPiT is both more effective and less costly. When outcomes at 90 days are 
extrapolated to a lifetime horizon, there is an increase in both incremental cost savings and 
QALYs gained. Secondary analysis shows that the magnitude of benefit is greater when 
GPiT is compared to current practice. Comparison of deterministic and probabilistic 
results suggests that the results of the model are robust to parameter uncertainty. 
 
Results from scenario analysis identify that the alternative GPiT strategies (with fully or 
partially restricted specialist follow-up) are also cost saving and beneficial when compared 
to both best and current practice. At both 90 days and over a lifetime horizon, ‘GPiT: no 
subsequent referral’ was preferred.  However, an observation was that the difference in net 
benefit between all three GPiT strategies was small. Furthermore, univariate sensitivity 
analysis showed that these findings hold under the structural/methodological sensitivity 
analysis performed.  
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The next chapter considers the model implications in more detail. Limitations of the 
approach used and recommendations to future research are also made. 
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CHAPTER 8: DISCUSSION – GP INITIATION OF TREATMENT IN THE CASE 
OF SUSPECTED TIA 
8.1. Introduction 
This chapter discusses the implications of the model results. Finally, it considers the 
implications of these results in terms of recommendations for clinical practice and 
research.  
 
8.2 Interpretation of results 
Findings from the model show that a strategy based on GP initiation of treatment (and 
subsequent referral) is less costly and more effective compared with strategies based on 
existing practice. This result appears robust for the range of sensitivity analysis performed. 
In terms of budget impact, the model suggests that GPiT strategies could save NHS 
resources in the long-term by reducing the economic burden of stroke and its sequelae. In 
terms of the population of England with suspected TIA, the model predicts total long-term 
savings of between £14 - £30 million per annum depending on the current level of service 
provision.
14
  The only exception was if the adverse effects of inappropriate treatment in the 
TIA mimic population are considerably higher than conjectured. Threshold analysis 
suggests that this risk could be up to four times higher and GPiT would still be preferred. 
                                                   
 
14
 Estimate based on incidence of TIA from the TIA commissioning guide for England (0.05%) and cost-
savings predicted in the long-term model (NICE 2008b). Range presented corresponds to the anticipated cost 
saving for current practice (£1,129) versus optimised (scenario referred to as best practice in the model) 
(£551) and correspond to the steady state prediction associated with long-term roll out of GPiT. Note that the 
projected savings in the first year of implementation alone will be significantly lower than these projections. 
However, the 90 day model suggests that the effect on the budget should be no worse, and possibly a little 
more favourable (cost-saving), than best practice in this time period. All analysis assumes that GPiT is 
associated with no additional staffing or other costs of implementation. 
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In addition, scenario analysis performed identified that there may still be a question with 
respect to the most efficient configuration of a service involving GP initiation of 
treatments, as results are sensitive to the time horizon. The finding that GPiT ‘no 
subsequent referral’ was most cost-effective at 90 days is not surprising given the cost-
savings (TIA clinic and carotid endarterectomy surgeries) in secondary care. When the 
perhaps more relevant (since it considers the sequelae of stroke) lifetime horizon is 
considered, the preferred strategy remains GPiT ‘no subsequent referral’ but the difference 
in net benefit between other configurations of GPiT (‘GPiT’ base case) and GPiT: refer 
only high risk was small. 
 
One implication of this service innovation is that if ‘GPiT: refer only high risk’ is 
preferred, the purpose for which the ABCD2 score is used changes. Currently the ABCD2 
threshold of four and above is used to identify the population at highest risk of recurrence 
for expedited treatment. However, under a strategy of GPiT, where everyone is treated 
irrespective, ABCD2 appears to have a role in identifying more of the population with 
severe carotid stenosis. As might be expected, the maximum (lifetime) benefit from carotid 
endarterectomy occurs with (the main GPiT) ‘refer all’ strategy but ‘GPiT refer only high 
risk’ appears to have application in cost-effective identification of those most likely to 
have stenosis. 
 
If either GPiT or ‘GPiT: subsequent referral high risk group only’ are  preferred strategies, 
this would suggest that the role of the TIA clinic becomes more about diagnosing as 
opposed to treating, a view also put forward by Mant et al. (2007, p.121). Furthermore, as 
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patients with genuine TIA will be on the correct treatment, the benefit of the strategies 
which still refer to clinic would also appear to be due to the potential for providing an 
alternative diagnosis. In the model developed here, only the effect of treatment 
discontinuation in TIA mimics was operationalised. However, over and above the direct 
treatment effects (beneficial or harmful) there is also a diagnostic dimension to be 
considered. It is not implausible that the TIA mimic cases may significantly benefit from 
attending a specialist TIA clinic, as the investigations might prompt the correct 
diagnosis.
15
 If this is the case, results here underestimate the benefit of GPiT with 
subsequent referral.  
 
Results would appear to indicate that it is difficult to form a recommendation on which 
GPiT strategy is optimal (especially as the difference between strategies, in terms of net 
benefit, is small). However, over a lifetime horizon, the base-case GPiT strategy may be 
the most efficacious assuming there is a benefit to carotid endarterectomy and getting the 
right diagnosis. If this strategy would place too great a burden on the health system, in 
terms of additional demand for specialist clinics, GPiT (refer high risk) or even GPiT 
(refer none) would also appear to be good options.  However, the latter strategy means that 
there is no referral at all for carotid endarterectomy which might not be well accepted by 
health professionals or patients. 
 
                                                   
 
15
 Indeed, this would seem to especially apply to TIA which is typically diagnosed by ‘ruling out’ other differential 
diagnoses. 
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8.3 Generalisability 
In trying to structure a model around current and best UK practice, there was widespread 
variation in TIA practices across the UK and that current practice was difficult to 
characterize. However, the model’s characterization of current practice was based on the 
findings of clinical audit into TIA services, and other parameters from the model (utilities, 
drug and long—term care costs) were drawn from UK sources. In addition the modelling 
of best practice drew on the EXPRESS study, a high quality before and after nested cohort 
study within the Oxford Vascular population, in Oxfordshire, UK. 
 
The results of the model appear to show good external consistency. For instance, as 
previously discussed, the number of strokes anticipated by the strategies appear to be 
consistent with the projections based on individual patient data on stroke recurrence. It is 
also not unusual for a stroke prevention intervention to be identified to be both less costly 
and more effective than comparator in the long run. This is largely because of the 
significant economic burden and poor health outcomes following stroke. However, there is 
an important contrast between this and the other modelling studies reviewed previously 
(Chapter 4). All these models considered service developments that would be likely to 
require an increase in TIA clinic capacity. Initially, these interventions result in cost 
increases. In contrast, GPiT potentially allows for some specialist resources to be released, 
and is therefore cost-saving. 
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The only study that has examined a similar strategy to GPiT was the Birmingham TIA 
model. This model considered a strategy analogous to GPiT (no subsequent referral) but 
no strategy directly analogous to the base-case GPiT strategy.
16
 The strategy based on no 
subsequent referral identified that referring all suspects was the most effective strategy and 
was potentially the most cost-effective (ICER £35,000 per major stroke averted). It is 
possibly inappropriate to make a direct comparison of the outcome (clinical/ cost-
effective) of this study with the model developed in this thesis. First of all, the models had 
different methodological/structural assumptions, these included: notable differences in the 
modelling of the treatment effect; choice of parameters within the model and the time 
horizon adopted. Nevertheless, in terms of the recommendations made across models 
recommendations are similar. For instance, both models suggest that if GPs are better at 
correctly identifying stroke, a strategy of partial referral (high risk group only) may be 
preferred, depending on the value of the ceiling ratio adopted.  
 
8.4 Model limitations 
Findings are preliminary, based on limited evidence in relation to the introduction of a new 
role for GPs in the management of TIA.  
 
Limitations of the model structure include the failure of the Markov model to consider 
repeat or co-morbid events. In addition, cardiac events are not modelled. All are clinically 
                                                   
 
16
 The name given to  this is ‘optimal management by GPs’. Mant et al. p.102. 
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significant events with obvious impacts in terms of costs and QALYS, so the reasons for 
exclusion need to be considered a little more.  
 
First of all, expanding the model to include more outcomes might have improved its face 
validity with clinicians. However, a more comprehensive model is only a better model if it 
succeeds in offering a more realistic modelling of the disease process (Philips et al., 2006). 
In recent years, the recommendations of a stroke costing model commissioned by the NAO 
have been questioned on the basis of a lack of transparency in the model methods and 
overly optimistic benefits relating to thrombolysis treatment (Sudlow and Warlow, 2009, 
National Audit Office, 2005). In the field, this has resulted in some discussion about 
whether hyper-acute services following stroke have been wrongly prioritised.  
 
Secondly, it is plausible that extending the model to include cardiac events would provide 
more support in favour of the intervention if GP initiation identifies and treats more people 
with high general vascular risks, so the exclusion of cardiac events in this instance should 
be conservative, or neutral in terms of the benefit of the intervention. 
  
A challenge faced in the development of any model is in the identification of data to 
populate the model. As this model is testing a strategy that has not been trialled or tested 
elsewhere, it was necessary to estimate the treated and untreated risk of stroke. Estimates 
of the risk of recurrent stroke were based on the results of a high-quality systematic review 
of clinical studies with longitudinal follow-up. In order to estimate the hyper-acute risk of 
stroke following TIA a method of extrapolation to points earlier in time using an 
exponential function was used. It might be that other functional forms better describe the 
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natural course of risk in TIA, or that other longitudinal follow-up studies of TIA cohorts 
provide data at more time points to preclude the use of such an assumption. 
 
This model succeeds in providing a simple description of the disease process, but the 
caveat with this is that this description is not as comprehensive as it might be. The 
extrapolation of outcomes from the 90 day model used an aggregate life table approach to 
estimate the life years gained for the general population, and expert opinion/literature to 
estimate the assumed reduction in expectancy for each of the non-TIA states. This is quite 
a blunt measure, but not an uncommon one. Several other models reviewed in the critical 
appraisal used similar techniques (e.g. NICE 2008a).  
 
Finally, while the joint uncertainty of all model inputs using probabilistic sensitivity 
analysis was tested, this does not negate the chance that the model might be incorrectly 
structured. For instance, estimation of long-term outcomes follows from a simple 
extrapolation of the outcomes of the 90 day model. This was a simplifying assumption 
justified on the basis that the clinically relevant time horizon for the effects of the 
intervention (which might just involve earlier initiation by a day in some patients) was 90 
days. A lifetime time horizon was used to capture the enduring disability of the 90 day 
outcomes which have important economic consequences beyond the relevant clinical 
timeframe. The assumption is that post 90 days the treatment of patients would essentially 
be the same such that the patient risk profiles should be identical. Introducing a 
probabilistic Markov model for the entire lifetime would introduce random fluctuation into 
the estimates of intervention effects and would greatly increase the data requirements of 
the model (for instance, it would also be preferable to consider recurrent stroke) under this 
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methodology. Note that it is usual for economic models to restrict their consideration of 
costs and consequences to those attributable to the intervention, and other models reviewed 
in Chapter 4 have used similar methods of extrapolation to make projections over a 
lifetime horizon (e.g. NICE 2008a, the Birmingham TIA model 2008). 
 
Clear guidance on how to perform decision analytic modelling of service delivery 
interventions is currently lacking, but the selected model structure (Markov) might over-
simplify the complex interplay of doctors-patients and treatment decisions.  
 
Furthermore the costing approach within the model used costs reflect average costs 
associated with current service provision, and it is foreseeable that some of these costs may 
change post intervention (Coast et al., 2000). It is usual for CEA to assume that resources 
and costs have a linear and monotonic relationship (such that doubling the quantity 
doubles the cost) but this assumption has been questioned for service delivery 
interventions (Godber et al., 1997, Coast et al., 2000). This was a problem also evident 
from the review of other models (Chapter 4), and is not reflected in good practice guidance 
for performing economic evaluations.  
 
 
8.5. Future research 
Recommendations to clinical practice 
This thesis provides an important de novo health economic analysis of an important 
clinical question that was not addressed in the NICE (2008a) guidance or elsewhere. It is 
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hoped that the evidence presented as part of this model should be considered when the 
guidance for acute stroke and TIA is formally revised. It remains the work of the 
appropriate Guideline Development Group to consider the merits of the model of service 
delivery in the light of a lack of evidence relating to the risk of adverse events in patients 
incorrectly suspected of having a TIA and therefore being inappropriately treated.  
 
Recommendations for research 
The cost-effectiveness of GPiT could not be assessed reliably mainly because of the 
imprecise estimates relating to efficacy. A large scale RCT would be desirable to 
determine the risk of TIA in the appropriate population, however, a pilot trial similar in 
nature to the intervention could not recruit, making a future RCT impracticable (Mant, 
December 2012). This suggests that the intervention might need to be piloted in practice. 
Prior to this additional research needs to be performed to quantify the risk of haemorrhagic 
events in incorrectly diagnosed TIA. It may also be appropriate to consider the risk of 
haemorrhagic events in TIA cases where there are comorbid conditions as the guidance of 
when, what and who should prescribe needs to be tailored to these different needs. If the 
efficacy of the intervention can be demonstrated, qualitative research could inform on the 
acceptability of the intervention to GPs and public. 
 
A logical extension to the existing decision-analytic model presented might consider 
further application of analytical methods (known as ‘Value of Information’) for assessing 
the need for and type of future research. These methods look at the opportunity loss 
associated with deferring today’s decision in the face of uncertainty (Briggs et al., 2006). 
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At the time of writing, there are also some more general recommendations to research 
from a commentator within Primary Care. Lasserson (2013) identified that current NICE 
guidance is based on decision analytic models in service pathways that have typically not 
considered the subsequent management of false positive TIA patients. This view might 
question the brief provided by the SDO, that is also the title of this thesis. In other words, 
shouldn’t the question for policy makers be, ‘What is the optimal model of service delivery 
in transient neurological attack?’ In the model developed here, the approach has begun to 
consider the downstream outcomes of people with likely differential diagnoses. 
Nevertheless, this study presents preliminary findings when false positives are treated in 
error and not by design. More empirical evidence is needed to determine the net benefit of 
both treatment and assessment in this population, who have also been evidenced as having 
poor vascular prognosis (Bos et al., 2007). 
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CHAPTER 9: CONCLUDING THOUGHTS 
9.1. Introduction 
This chapter draws together the key findings from the thesis. It discusses the contribution 
made by the thesis overall as well as the limitations. Lastly, there are some concluding 
thoughts. 
9.2. Key findings and contributions 
The thesis’ overarching contribution is primarily in the development and application of a 
decision-analytic model to conduct an economic evaluation of GP initiation of treatment 
versus best practice. It has addressed a number of research questions towards this main 
aim: 
 
i. What informs the decision to develop a decision-analytic model? 
ii. Subsequent to this, and if modelling is appropriate, what informs the type of model 
used in a service delivery intervention? 
iii. What is the effectiveness and cost-effectiveness of initiation of treatments in the 
hyper-acute phase of TIA? 
 
Other areas of contribution fit broadly within this thesis’ main objective but also stand-
alone, these are now considered. 
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Model methods: Moving from a model developed from operational research purposes 
to a Markov model 
This thesis grew out of a body of work commissioned by the NIHR SDO which 
culminated in a published report in 2007 (Mant, 2008). The main report (having the same 
title as this thesis) explored policy questions linked to the provision of services including 
the scheduling of specialist clinics and the emergency transfer of suspected TIA patients to 
hospital for rapid assessment. The report documents a simulation model evaluating the 
cost-effectiveness of various service delivery options. The Birmingham TIA model 
developed reflects the existence of capacity constraints in the provision of services (for 
instance, if TIA clinics were only offered once a week, this would result in patients waiting 
longer for the next available consultation) so the type of model is quite complex (discrete 
event simulation), with origins in operational research.  
 
While initially this thesis was intended to pursue the research questions arising from the 
Birmingham TIA model, potentially using a similar simulation based structure, my 
research training suggested that I could ‘pare down’ the existing model subject to certain 
caveats. The major caveat was whether the model needed to consider capacity constraints 
affecting the provision of services such as waiting lists. At first, this seemed quite 
important, but as my research questions developed I felt that these could potentially be 
answered with a simpler decision model (a Markov model). I felt that while I was still 
concerned with timeliness, waiting lists did not need to be explicitly modelled to determine 
the cost-effectiveness. 
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In addition, there could be advantages to developing a simpler model. Compared to 
simulation models, Markov models might be more transparent and easier to validate; they 
also typically allow for a more comprehensive treatment of uncertainty (Briggs and 
Sculpher, 1998). Developing a model from the position of an existing model may also 
have advantages. Many of the models being developed now are the result of an iterative 
process of adaptation and change, and it is possible to see that each iteration/model has a 
role in the evolution of a process towards what might be a more applicable model. In the 
case of this intervention – and indeed for other complex interventions – understanding the 
mechanisms which impact on patient outcomes has been important, and it is hoped that 
this model might lead policy-makers, modelers and clinicians to identifying other potential 
mechanisms (Grutters et al., 2008). 
 
Policy options: Conceptualising and then modelling a number of alternative 
GP management strategies which might be impractable in clinical study settings 
Unlike the controlled clinical study setting, modelling can test alternate models of service 
delivery without prohibitive cost (Buxton et al., 1997, Sculpher et al., 2006). Testing an 
array of options (for instance in a modelled scenario analysis) can inform which strategies 
are more effective and cost-effective either for trial in clinical practice or for 
implementation into policy. A further benefit is that there is no requirement to undergo 
ethical approval.  
 
In addition to scenario analysis, decision modelling can inform on ‘what if’ scenarios that 
can not realistically be tested in the trial setting (sensitivity analysis). In other words, while 
a clinical trial can really only assess the impact of one (or two) interventions for one 
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population, in a model one can explore the impact of multiple variants of the intervention 
in several different populations.  For instance, this model can examine the robustness of 
the ICER to different states of the world. Typically these include varying the model input 
parameters in isolation or simultaneously. In the context of the GPiT model, an interesting 
state of the world to test is one in which GPs are better diagnosticians. This leads into the 
third area in which the PhD has made a contribution. 
 
Addressing uncertainty: re-examining and updating the data on the accuracy of GP 
diagnosis in TIA to reduce the uncertainty with this model input 
The effectiveness of the GPiT strategy is likely to be sensitive to the false positive rate of 
GPs making the initial diagnosis of suspected TIA, which is why this rate is such an 
important input for the economic model. More evidence on this input will increase the 
external validity (generalisability) of the model to clinical practice where regional services 
have local information on accuracy of GPs making these decisions.  
 
Several studies have compared the false positive rate of GPs in referred TIA with final TIA 
diagnoses and appear to lend support to a PPV of 50% (Lasserson, 2013). However, 
regardless of the estimated or assumed PPV, there is an ensuing difficulty in quantifying 
the risks and benefits of inappropriate treatment in the misdiagnosed. Patients with false 
positive TIA diagnoses may be a disparate group with a myriad of potential alternative 
diagnoses. This makes quantification of the benefits and risks of inappropriate treatment 
difficult without considerable assumptions. In the model, this was made operable by 
considering the proportion of the cohort who might face an increased risk of haemorrhagic 
events relative to the base-case assumption. 
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9.3. Limitations  
Finally, there are limitations in the way this research has been conducted as a process.  
This thesis reflects a period of experiential learning, and decisions regarding the methods 
and data sources used to structure and build the model might not reflect the approach that I 
would use in future.  
 
Since commencing this thesis, there have also been some notable additions to the 
literature. One challenge I faced was to produce an up-to-date report when the evidence 
base – which is also experiential – was also shifting. Indeed, over the course of this thesis 
the definition of TIA itself changed. This results in a potential biases when attempting to 
compare test-statistics across studies which have used alternative reference standards.  
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9.4. Concluding Thoughts 
Overall, this thesis illustrates the application of a decision model to examine a policy 
relevant question around treatment urgency in a susceptible group of patients. Results 
suggest that GP initiation of secondary preventive agents dominates (i.e. is less costly and 
more beneficial) a comparator which was characterised on the basis of the best performing 
UK TIA clinics in the UK. It is therefore unsurprising that the direction of these very 
positive findings (with respect to GPiT) were unchanged and magnified when comparison 
with a strategy based on nationwide audit of clinical practice. 
 
However, there is considerable uncertainty associated with a number of key inputs of the 
model, particularly in relation to the accuracy of diagnosis and, related to this, the dangers 
of inappropriate treatment in those misdiagnosed as TIA by GPs. While the model’s results 
appear to robust to extreme values of these unknowns, there remains a risk of serious 
events in a few.  
 
Economic evaluation only informs on the efficiency criterion. The acceptability of the 
intervention to health care providers, professionals and the public remains to be 
considered. 
 
 209 
 
APPENDIX 1: CRITICAL APPRAISAL OF MODELLING METHODS  
 
Table 46: Embase search strategy for critical appraisal of economic modelling studies 
 Citations identified 
1. (“prevent$” or service delivery or “health care 
delivery”).mp. [mp=title, abstract, subject 
headings, heading word, drug trade name, 
original title, device manufacturer, drug 
manufacturer, device trade name, keyword] 
1447735 
2. 1 and (“decision support techniques decison 
tree$” or “computer simulation” or “cost benefit 
analysis” or “cost effective analysis” or “cost 
utility analysis”).mp. [mp=title, abstract, subject 
headings, heading word, drug trade name, 
original title, device manufacturer, drug 
manufacturer, device trade name, keyword] 
12777 
3. (“stroke/” or “TIA/”).ti. 76076 
4. (“Cerebrovascular Accident/” or “Isch$ 
Attack, Transient/”).ti. 
696 
5. 3 or 4 76755 
7. 2 and 5 140 
8. 1 and 7 140 
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APPENDIX 2: MEDLINE/EMBASE SEARCH STRATEGY FOR DIAGNOSTIC 
ACCURACY REVIEW 
1. diagnosis/ or diagnosis.ab.  
2. predictive value of tests.sh.     
3. primary health care/ or primary health care.mp. or “general prac$”/ or “community 
care”.mp. or “emergency care”.mp. or “clinic”.mp. or “hospital”.mp.     
4. (“Isch$ attack, transient/” or “tia” or “stroke”).ti.     
5. sensitivity.kw.     
6. specificity.kw.     
7. (diagnostic adj accuracy).kw.     
8. (predictive adj value).kw.     
9. (general practice or gp$).mp. [mp=ti, ab, sh, hw, tn, ot, dm, mf, dv, kw, nm, kf, ps, rs, 
ui]     
10. referral/     
11. 2 or 5 or 6 or 7 or 8 or 10     
12. 3 or 9     
13. 11 and 12 and 4 
Cochrane, NHS Economic Evaluation Database search 
stroke [ti ] or tia [ti] and  
accuracy [ti] or ppv [ti] or referral [ti] or test [ti] or gp [ti] or diagnosis [ti] or diagnose [ti] 
 
MEDION search 
“Signs and symptoms” and “neurological” 
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APPENDIX 3: RAPID REVIEWS 
Cochrane database 
Search terms used to identify effectivenss of dipyridamole/clopidogrel 
ID Search Citations identified 
#1 dipyridamole or clopidogrel  2461 
#2 systematic review and #1  0 
#3 meta-analysis and #2  26 
#4 stroke prevention:ti  1551 
#5 #1 and (#2 or #3) and #4  12 
 
Search terms used to identify safety associated with dual antiplatelet therapy  
safety and (dipyridamole or clopidogrel or dual adj 
antiplatelet) and secondary prevention and stroke 
84 
“prevention/” and (“stroke or Tia”) AND (haemorrhage or 
bleed*) 
46 
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APPENDIX 4: DATA EXTRACTED ON DIAGNOSTIC ACCURACY AND 
ALTERNATIVE STROKE/TIA DIAGNOSES 
Table 47: Extracted data (stratified by referral route) for clinician accuracy
17
 
Study Type 
Positiv
e cases 
Total, 
N 
PPV, %  
(95% CI) 
Main 
referral 
source 
Reference 
diagnosis 
Magin et al, 
2000 
Prospective 
validation 29 127 
0.23 
 (0.16-0.39) GP TIA 
Magin et al, 
2000 
Prospective 
cohort 9 231 
0.04  
(0.01-0.06) 
GP/ 
A&E TIA 
Gibbs et al, 
2001 
Prospective 
cohort 13 27 
0.48  
(0.29-0.67) GP TIA 
Murray et al, 
2007 
Prospective 
cohort 217 811 
0.27  
(0.24-0.30) 
GP/ 
A&E TIA 
Bos et al, 2007 
Prospective 
cohort 282 538 
0.52  
(0.48-0.57) Any TIA 
Harbison et al, 
2009 
Prospective 
cohort 25 216 
0.12  
(0.07-0.16) GP TIA 
Fonseca et al, 
2010 
Prospective 
cohort 259 458 
0.57  
(0.52-0.61) 
GP/ 
A&E TIA 
Kidwell et al, 
Prospective 
cohort 31 36 
0.86  
(0.75-0.97) 
Parame
dic CVA 
Magin et al, 
2000 
Retrospective 
population-
based 50 127 
0.39  
(0.31-0.48) GP CVA 
                                                   
 
17
 Where there is more than one data entry for a single study this reflects that the study reported outcomes relating 
to either different reference diagnosis (e.g. TIA, or a composite outcome of all stroke (including TIA). 
 213 
 
Study Type 
Positiv
e cases 
Total, 
N 
PPV, %  
(95% CI) 
Main 
referral 
source 
Reference 
diagnosis 
Magin et al, 
2000 
Retrospective 
population-
based 46 231 
0.20  
(0.15-0.25) 
GP/ 
A&E CVA 
Gibbs et al, 
2001 
Prospective 
cohort 18 27 
0.67  
(0.49-0.84) GP CVA 
Mant et al, 2003 
Retrspective 
cohort 376 524 
0.72  
(0.68-0.76) Any CVA 
Murray et al, 
2007 
Retrospective 
cohort 383 811 
0.47  
(0.44-0.51) 
GP/ 
A&E CVA 
Fischer et al, 
2008 
Retrospective 
cohort 168 558 
0.30  
(0.26-0.34) Other CVA 
McNeil et al, 
2008 
Prospective 
cohort 22 72 
0.31  
(0.20-0.41) GP CVA 
Cameron et al 
2011 
Prospective 
cohort 1890 3533 
0.53  
(0.49-0.58) Any TIA 
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Table 48: Clinical diagnoses recorded by authors in suspected TIA cases identified in 
Primary Care (frequency by study, pooled totals and percentage of alternative 
diagnoses attributed) 
Clinical diagnosis 
G
ib
b
s 
n
=
9
 
H
ar
b
is
o
n
 
n
=
6
4
 
M
cN
ei
l 
n
=
3
4
 
F
o
n
se
ca
 
n
=
8
4
 
T
o
ta
l 
n
 
%
 
Alcohol/drugs 
 
3 
  
3 2.8 
Aneurysm 1 
    
0 
Arrhythmia 
     
0 
Asymptomatic stenosis carotid 
artery 
    
1 0.9 
Atrial fibrillation 
  
1 
 
3 2.8 
Bell's palsy 
  
3 
 
0 0 
Brain tumour 
    
2 1.9 
Cardiac dysrhythmia 2 
   
5 4.7 
Cardiovascular collapse 
 
5 
  
4 3.7 
Cervical spondylosis 
 
1 3 
 
7 6.5 
Delirium 
  
7 2 0 0 
Dementia 
 
6 1 
 
1 0.9 
Depression       1 0.9 
Epilepsy 1 
   
3 2.8 
Hypoglycaemic collapse 
 
1 
  
0 0 
Hyponatremia and collapse 
 
3 
  
22 
20.
6 
Iatrogenic 
   
1 3 2.8 
Infections/sepsis  
 
9 13 
 
7 6.5 
Labyrinthine disorders 
 
3 
  
1 0.9 
Malignant tumour 
 
7 
  
2 1.9 
Meningitis 
 
1 
  
0 0 
Migraine 
 
2 
 
4 0 0 
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Clinical diagnosis 
G
ib
b
s 
n
=
9
 
H
ar
b
is
o
n
 
n
=
6
4
 
M
cN
ei
l 
n
=
3
4
 
F
o
n
se
ca
 
n
=
8
4
 
T
o
ta
l 
n
 
%
 
Motor neurone disease 
    
0 0 
Movement disorder 
   
1 0 0 
Multiple sclerosis 
    
0 0 
Occluded retinal artery 
    
2 1.9 
Pain 
   
3 1 0.9 
Parkinson's disease 
 
2 
  
3 2.8 
Pentoin toxicity 
  
1 
 
0 0 
Peripheral neuropathy 
 
3 
 
2 0 0 
Peripheral vertigo 
    
2 1.9 
Peripheral vertigo 
   
6 1 0.9 
Postural hypotension 2 
  
14 5 4.7 
Previous stroke/neurological 
deficit 
  
1 2 7 6.5 
Psychological/Psychiatric 2 3 
 
18 1 0.9 
Seizure 
 
6 1 19 5 4.7 
Subarachnoid haemorrhage‡ 
 
1 
  
0 0 
Subdural haemorrhage‡ 
 
5 
  
1 0.9 
Syncope/pre syncope 
   
8 2 1.9 
Temporal arteritis 
  
1 
 
1 0.9 
Tension headache 
 
2 
  
2 1.9 
Thromboembolism 1 
   
0 0 
Transient global amnesia 
 
1 1 
 
0 0 
Trigeminal neuralgia 
     
0 
Unspecified metabolic disorder 
   
4 
 
0 
Wernicke's Encephalophy 
  
1 
  
0 
 
‡ One study (Harbison et al.) considered sub-arachnoid haemorrhage and sub-dural 
haemorrhage as alternative diagnoses. They were removed from the main analyses 
because the other studies did not report on stroke sub-types by pathological cause
  
 
2
1
6
 
APPENDIX 5: PARAMETERS USED IN THE MODEL  
Table 49: Parameters used within the model and associated candidate distributions for PSA 
Rates were converted into daily transition probabilities using the standard formula (Miller and Homan, 1994).  
Stroke transitions were determined by survival methods (which are independent not multinomial probabilities) and the beta distribution was 
therefore used to implement uncertainty into the hazard rates associated with transitions from TIA to (all) stroke. The Dirichlet distribution 
was used for the remaining multinomial transitions. It should be noted that the implementation of the Dirichlet distribution is challenging in 
this particular model context where there are several independent sources of evidence informing each set of transitions. Implementation 
assumed that it was possible to back transform probability data to determine hypothetical transitions in a cohort of 1000 patients. 
 
Transition Treated Untreated 
Daily transition 
probaility %¥ 
Distribution (se) * Daily transition 
probaility¥ 
Distribution 
TIA - All stroke Based on time-
dependent transitions. 
Constant hazard rate 
within discrete intervals. 
Interval for days 0-7 
Beta (0,1106)  Beta (4,536) 
Interval for days 7-90 Beta (0,1107  Beta (0.540) 
TIA - Major haemorrhage 
 
0.0067  Dirichlet 
α(0.1,2.9,0.2,969.9) 
0.001 Dirichlet 
α(0.003,0.2,999.8) 
  
 
2
1
7
 
Transition Treated Untreated 
Daily transition 
probaility %¥ 
Distribution (se) * Daily transition 
probaility¥ 
Distribution 
TIA - carotid surgery 0.2912 Dirichlet 
α(2.9,0.1,0.2,969.9) 
n/a 
TIA - Other cause death 0.0161  Dirichlet 
α(0.2,2.9,0.1,969.9) 
0.0161 Dirichlet  
α(0.2,0.003,999.8) 
Carotid surgery - Major 
haemorrhage 
0.0067 Dirichlet 
α(0.1,1.5,3.0,0.3,995.2) 
n/a 
Carotid surgery - Ischaemic 
stroke 
0.1205 Dirichlet 
α(1.5,0.1,3.0,0.3,995.2) 
n/a 
Carotid surgery - Haemorrhagic 
stroke 
0.0597  Dirichlet 
α(3.0,1.5,0.1,0.3,995.2) 
n/a 
Carotid surgery - Carotid surgery 
death 
0.3096 Dirichlet 
α(0.3,0.1,1.5,3.0,995.2) 
n/a 
Ischaemic stroke - Fatal 
iscahemic stroke 
0.2993 Normal,  
(0.001) 
As treated 
Haemorrhagic stroke - Fatal 
haemorrhagic stroke 
0.3955 Normal,  
(0.001) 
As treated 
  
 
2
1
8
 
Transition Treated Untreated 
Daily transition 
probaility %¥ 
Distribution (se) * Daily transition 
probaility¥ 
Distribution 
Major haemorrhage - Fatal major 
haemorrhage 
0.0005 Normal,  
(0.001) 
As treated 
TIA mimic - All stroke 0.0001 Dirichlet 
α(0.001,0.003,0.2, 
999.8) 
0.00039 Dirichlet  
α(0.004,0.2,999.8) 
TIA mimic - Major haemorrhage 0.00027 Dirichlet 
α(0.003,0.001,0.2, 
999.8) 
0.0000 None (baseline risk 
assumed nil) 
TIA mimic - Other cause death 0.0161 Dirichlet 
α(0.001,0.003,0.2, 
999.8) 
0.0161 Dirichlet 
α(0.2,0.004,999.8) 
¥ corresponding to the value used in the model (for the Markov model considered here, transition probabilities are the daily probability of the event 
occurring).  
*used in probabilistic sensitivity analysis and required where the normal distribution was chosen. 
Where dirichlet distributions are specified they represent movement to the named health state followed by other possible transitions in order. 
 
For transitions from TIA: 
Major haemorrhage, carotid surgery (true TIA only), all stroke (mimic states only), other cause death and a TIA ‘sunk’ state (used to retain the 
assumption that the cohort must sum to 1000). 
For transitions from carotid surgery: 
Major hameorrhage, haemorrhagic stroke, ischaemic stroke, carotid surgery death and a carotid surgery ‘sunk’ state.
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Table 50: Utilities and Life Expectancy 
 deterministic  se† distribution alpha beta 
Post TIA 0.880 0.035 Beta 22.10 0.04 
Stroke 0.443 0.054 Beta 3.67 0.12 
Major haemorrhage 0.310 0.050 Beta 1.93 0.16 
Post Surgery 0.710 0.049 Beta 10.30 0.07 
TIA Mimic (Minor) 0.880 0.055 Beta 22.10 0.04 
TIA Mimic (Serious pathology) 0.443 0.050 Beta 1.93 0.16 
†Standard errors estimated using the standard confidence interval for a proportion 
se=√(p(1-p) where n is known. (Bland, 2000 p.128) 
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Table 51: Costs and associated candidate distributions 
 
deterministic se
18
 distribution alpha beta 
On treatment (secondary 
prevention agents) 
£0.26 - Not varied - - 
Stroke £7,570.00 375 Gamma 16 
93.7
5 
Major haemorrhage £1,000.00 250 Gamma 16 63 
Post surgery £407.00 102 Gamma 16 25 
GP clinic £43.00 - Not varied - - 
Specialist weekly clinic £246.00 - Not varied - - 
Specialist daily clinic £246.00 - Not varied - - 
Carotid endarterectomy £4,017.00 4,000 Not varied - - 
Dependent after a stroke 
within 90 days 
£57,378 12,900 Gamma 16 3226 
Independent after a stroke 
within 90 days 
£8,415 1,893 Gamma 16 473 
Recovered (GP follow-up) £887 199.50 Gamma 16 49 
Recovered (Specialist follow 
up) 
£1475 331.75 Gamma 16 83 
                                                   
 
18 Standard errors estimated using the binomial approximation se=√p(1-p)/n where n is known. 
(Bland, 2000). 
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APPENDIX 6: MODEL RESULTS (DETAILED VIEW) 
A.6.1. Clinical outcomes 
Table 52: Clinical outcomes for all strategies 
 
N
o
 fu
rth
er ev
en
t 
Isch
aem
ic 
S
tro
k
e 
  H
aem
o
rrh
ag
ic 
stro
k
e 
 C
aro
tid
 S
u
rg
ery
 
M
ajo
r 
h
aem
o
rrh
ag
e 
 O
th
er 
cau
se 
d
eath
 
  Non-
fatal 
Fatal Non-
fatal 
Fatal Non-
fatal 
Fatal Non-
fatal 
Fatal  
GPiT 953.59 11.90 2.78 0.08 0.03 14.47 0.05 2.96 0.00 14.14 
Best 
practice 
945.65 17.44 4.47 0.11 0.04 15.32 0.06 2.87 0.00 14.04 
Current 
practice 
918.73 44.12 12.26 0.29 0.11 8.37 0.03 2.52 0.00 13.56 
GPiT refer 
only high 
risk 
960.85 12.15 2.86 0.08 0.03 6.96 0.03 2.91 0.00 14.14 
GPiT no 
referral 
968.04 11.87 2.77 0.08 0.03 0.00 0.00 3.07 0.00 14.14 
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A.6.2. Scenario analysis for the base-case comparison. 
Table 53: Scenario analysis, base-case, 90 day results (deterministic) 
 
Total 
QALYs/ 
patient 
Total 
costs/ 
patient 
Incremental 
QALYs vs. 
best 
practice 
Incremental. 
costs vs. 
best practice 
Net 
benefit 
at a 
£10,000 
ceiling 
ratio 
Net 
benefit 
at a 
£20,000 
ceiling 
ratio 
Net 
benefit 
at a  
£30,000 
ceiling 
ratio 
Current 
practice 
0.2053 £293 -0.0047 £104 -£150 -£197 -£243 
Best 
practice 
0.2100 £190 
  
   
GPiT 0.2108 £187 0.0009 -£3 £12 £21 £29 
GPiT refer 
only high 
risk 
0.2112 £173 0.0012 -£17 £29 £42 £54 
GPiT no 
referral 
0.2115 £159 0.0015 -£31 £46 £61 £76 
Note: Figures in bold denote the preferred strategy on the basis of maximum net benefit for 
each value of the ceiling ratio.
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Table 54: Scenario analysis, base-case, lifetime  results (deterministic)  
  
Total 
QALYs/ 
patient 
Total 
costs/ 
patient 
Incremental 
QALYS vs. 
best 
practice 
Incremental 
costs vs. 
best 
practice 
Net 
benefit 
at a 
£10,000 
ceiling 
ratio 
Net 
benefit 
at a 
£20,000 
ceiling 
ratio 
Net 
benefit 
at a  
£30,000 
ceiling 
ratio 
Current 
practice 
7.6607 £2,985 -0.1635 £808 -£2,443 -£4,078 -£5,714 
Best 
practice 
7.8243 £2,177           
GPiT 7.8585 £1,160 0.0342 -£1,017 £1,359 £1,702 £2,044 
GPiT refer 
only high 
risk 
7.8600 £1,168 0.0357 -£1,009 £1,366 £1,723 £2,081 
GPiT no 
referral 
7.8594 £1,160 0.0351 -£1,017 £1,368 £1,719 £2,069 
Note: Figures in bold denote the preferred strategy on the basis of maximum net benefit for 
each value of the ceiling ratio.
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Table 55: Scenario analysis, base-case, 90 day results (probabilistic) 
  
Total 
QALYs/ 
patient 
Total 
costs/ 
patient 
Incremental 
QALYG 
vs. best 
practice 
Incremental 
costs vs. 
best 
practice 
Net 
benefit 
at a 
£10,000 
ceiling 
ratio 
Net 
benefit 
at a 
£20,000 
ceiling 
ratio 
Net 
benefit 
at a  
£30,000 
ceiling 
ratio 
Current 
practice 
0.2053  £284 -0.0046 £95 -£173 -£187 -£232 
Best 
practice 
0.2098  £189 0.0000 £0 
   
GPiT 0.2107  £185 0.0009 -£4 £19 £21 £30 
GPiT refer 
only high 
risk 
0.2112  £169 0.0013 -£20 £42 £46 £60 
GPiT no 
referral 
0.2115  £153 0.0017 -£36 £65 £70 £87 
Note: Figures in bold denote the preferred strategy on the basis of maximum net benefit for 
each value of the ceiling ratio.
 225 
 
 
 
Table 56: Scenario analysis, base-case,  lifetime results (probabilistic) 
  Total / 
patient 
Total 
costs/ 
patient 
Incremental 
QALYG vs. 
best 
practice 
Incremental 
costs vs. 
best 
practice 
Net 
benefit 
at a 
£10,000 
ceiling 
ratio 
Net 
benefit 
at a 
£20,000 
ceiling 
ratio 
Net 
benefit 
at a  
£30,000 
ceiling 
ratio 
Current 
practice 8.8890 £2,083 -0.2573 £560 -£3,132 -£5,705 -£8,278 
Best 
practice 9.1462 £1,523 
     
GPiT 
9.2003 £968 0.0540 -£555 £1,095 £1,635 £2,176 
GPiT refer 
only high 
risk 
9.2008 £974 0.0546 -£549 £1,095 £1,640 £2,186 
GPiT no 
referral 9.2015 £968 0.0553 -£555 £1,108 £1,661 £2,213 
Note: Figures in bold denote the preferred strategy on the basis of maximum net benefit for 
each value of the ceiling ratio.
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A.6.3. Scenario analysis results for the secondary comparison 
Table 57: Scenario analysis, secondary comparison, 90 day results (deterministic) 
  Total 
QALYs/ 
patient 
Total 
costs/ 
patient 
Inc. 
QALYS 
vs. 
current 
practice 
Inc. 
costs vs. 
current 
practice 
Net 
benefit at 
a 
£10,000 
ceiling 
ratio 
Net 
benefit at 
a 
£20,000 
ceiling 
ratio 
Net 
benefit at 
a  
£30,000 
ceiling 
ratio 
Current 
practice 0.2053 £293           
Best 
practice 0.2100 £190 0.0047 -£104 £104 £197 £243 
GPiT 
0.2108 £187 0.0055 -£107 £162 £217 £273 
GPiT refer 
only high 
risk 
0.2112 £173 0.0059 -£120 £179 £238 £297 
GPiT no 
referral 0.2115 £159 0.0062 -£134 £196 £257 £319 
Note: Figures in bold denote the preferred strategy on the basis of maximum net benefit for 
each value of the ceiling ratio.
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Table 58: Scenario analysis, secondary comparison, lifetime results (deterministic)  
  Total 
QALYs/ 
patient 
Total 
costs/ 
patient 
Inc. 
QALYS 
vs. 
current 
practice 
Inc. 
costs vs. 
current 
practice 
Net 
benefit 
at a 
£10,000 
ceiling 
ratio 
Net 
benefit 
at a 
£20,000 
ceiling 
ratio 
Net 
benefit 
at a  
£30,000 
ceiling 
ratio 
Current 
practice 
8.8870 £2,055           
Best 
practice 
9.1439 £1,477 0.2569 -£578 £3,147 £5,717 £8,286 
GPiT 9.1977 £926 0.3107 -£1,129 £4,236 £7,343 £10,450 
GPiT refer 
only high 
risk 
9.1979 £932 0.3109 -£1,123 £4,232 £7,341 £10,450 
GPiT no 
referral 
9.1982 £925 0.3112 -£1,130 £4,242 £7,354 £10,467 
Note: Figures in bold denote the preferred strategy on the basis of maximum net benefit for 
each value of the ceiling ratio.
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Table 59: Scenario analysis, secondary analysis, 90 day results (probabilistic) 
 Total 
QALYs/ 
patient 
Total 
costs/ 
patient 
Inc. 
QALYS 
vs. 
current 
practice 
Inc. costs 
vs. 
current 
practice 
Net 
benefit at 
a 
£10,000 
ceiling 
ratio 
Net 
benefit at 
a 
£20,000 
ceiling 
ratio 
Net 
benefit at 
a  
£30,000 
ceiling 
ratio 
Current 
practice 
0.2053 £284 
     
Best 
practice 
0.2098 £189 0.0046 -£95 £173 £187 £232 
GPiT 0.2107 £185 0.0055 -£99 £192 £208 £263 
GPiT refer 
only high 
risk 
0.2112 £169 0.0059 -£115 £215 £233 £292 
GPiT no 
referral 
0.2115 £153 0.0063 -£131 £238 £257 £319 
Note: Figures in bold denote the preferred strategy on the basis of maximum net benefit for 
each value of the ceiling ratio.
 229 
 
 
Table 60: Scenario analysis, secondary comparison, lifetime results (probabilistic) 
  Total 
QALYs/ 
patient 
Total 
costs/ 
patient 
Inc. 
QALYS 
vs. 
current 
practice 
Inc. 
costs vs. 
current 
practice 
Net 
benefit at 
a 
£10,000 
ceiling 
ratio 
Net 
benefit at 
a 
£20,000 
ceiling 
ratio 
Net 
benefit at 
a  
£30,000 
ceiling 
ratio 
Current 
practice 8.8890 £2,083 
     
Best 
practice 9.1462 £1,523 0.257 -£560 £3,132 £5,705 £8,278 
GPiT 
9.2003 £968 0.311 -£1,115 £4,228 £7,341 £10,454 
GPiT refer 
only high 
risk 
9.2008 £974 0.312 -£1,109 £4,227 £7,345 £10,464 
GPiT no 
referral 9.2015 £968 0.313 -£1,115 £4,240 £7,366 £10,491 
Note: Figures in bold denote the preferred strategy on the basis of maximum net benefit for 
each value of the ceiling ratio.
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A.6.4. Sensitivity analysis results across all strategies 
Results presented are deterministic.  
Table 61: Results for alternative assumption regarding accuracy of GP diagnosis 
(PPV=75%), 90 days 
  Total 
QALYs/ 
patient 
Total 
costs/ 
patient 
Inc. 
QALYS 
vs. 
current 
practice 
Inc. 
costs vs. 
current 
practice 
Net 
benefit at 
a 
£10,000 
ceiling 
ratio 
Net 
benefit at 
a 
£20,000 
ceiling 
ratio 
Net 
benefit at 
a  
£30,000 
ceiling 
ratio 
Current 
practice 
0.2014 £303           
Best 
practice 
0.2084 £147 0.0070 -£155 £155 £295 £365 
GPiT 0.2097 £143 0.0083 -£160 £243 £326 £409 
GPiT refer 
only high 
risk 
0.2102 £122 0.0088 -£181 £269 £357 £445 
GPiT no 
referral 
0.2107 £101 0.0093 -£202 £294 £387 £479 
Note: Figures in bold denote the preferred strategy on the basis of maximum net benefit for 
each value of the ceiling ratio.
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Table 62: Results for alternative assumption regarding accuracy of GP diagnosis 
(PPV=75%), lifetime horizon 
  Total 
QALYs/ 
patient 
Total 
costs/ 
patient 
Inc. 
QALYS 
vs. 
current 
practice 
Inc. 
costs vs. 
current 
practice 
Net 
benefit at 
a 
£10,000 
ceiling 
ratio 
Net 
benefit at 
a 
£20,000 
ceiling 
ratio 
Net 
benefit at 
a  
£30,000 
ceiling 
ratio 
Current 
practice 
8.6703 £2,531           
Best 
practice 
9.0557 £1,664 0.3854 -£867 £4,721 £8,575 £12,429 
GPiT 9.1364 £1,057 0.4661 -£1,474 £6,135 £10,796 £15,457 
GPiT refer 
only high 
risk 
9.1362 £1,059 0.4659 -£1,471 £6,131 £10,790 £15,449 
GPiT no 
referral 
9.1377 £1,056 0.4674 -£1,475 £6,149 £10,823 £15,498 
Note: Figures in bold denote the preferred strategy on the basis of maximum net benefit for 
each value of the ceiling ratio.
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Table 63: Results for alternative assumption regarding accuracy of GP diagnosis 
(PPV=25%), 90 days 
  Total 
QALYs/ 
patient 
Total 
costs/ 
patient 
Inc. 
QALYS 
vs. 
current 
practice 
Inc. 
costs vs. 
current 
practice 
Net 
benefit at 
a 
£10,000 
ceiling 
ratio 
Net 
benefit at 
a 
£20,000 
ceiling 
ratio 
Net 
benefit at 
a  
£30,000 
ceiling 
ratio 
Current 
practice 
0.2092 £284 
     
Best 
practice 
0.2115 £232 0.0023 -£52 £52 £98 £122 
GPiT 0.2119 £231 0.0028 -£53 £81 £109 £136 
GPiT refer 
only high 
risk 
0.2122 £224 0.0030 -£60 £90 £120 £149 
GPiT no 
referral 
0.2122 £217 0.0031 -£67 £98 £128 £159 
Note: Figures in bold denote the preferred strategy on the basis of maximum net benefit for 
each value of the ceiling ratio.
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Table 64: Results for alternative assumption regarding accuracy of GP diagnosis 
(PPV=25%),  lifetime horizon 
  Total 
QALYs/ 
patient 
Total 
costs/ 
patient 
Inc. 
QALYS 
vs. 
current 
practice 
Inc. 
costs vs. 
current 
practice 
Net 
benefit at 
a 
£10,000 
ceiling 
ratio 
Net 
benefit at 
a 
£20,000 
ceiling 
ratio 
Net 
benefit at 
a  
£30,000 
ceiling 
ratio 
Current 
practice 
9.1036 £1,579           
Best 
practice 
9.2321 £1,290 0.1285 -£289 £1,574 £2,858 £4,143 
GPiT 9.2590 £795 0.1553 -£784 £2,337 £3,890 £5,443 
GPiT refer 
only high 
risk 
9.2595 £804 0.1558 -£775 £2,333 £3,892 £5,450 
GPiT no 
referral 
9.2587 £795 0.1550 -£784 £2,335 £3,885 £5,436 
Note: Figures in bold denote the preferred strategy on the basis of maximum net benefit for 
each value of the ceiling ratio.
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Table 65: Results for alternative assumption about prognosis of non true TIA on 
adverse events (major haemorrhage) [two fold increase in both events in mimic 
population], 90 days 
  Total 
QALYs/ 
patient 
Total 
costs/ 
patient 
Inc. 
QALYS 
vs. 
current 
practice 
Inc. 
costs vs. 
current 
practice 
Net 
benefit 
at a 
£10,000 
ceiling 
ratio 
Net 
benefit 
at a 
£20,000 
ceiling 
ratio 
Net 
benefit 
at a  
£30,000 
ceiling 
ratio 
Current 
practice 
0.2053 £293           
Best 
practice 
0.2100 £190 0.0047 -£104 £104 £197 £243 
GPiT 0.2108 £187 0.0055 -£107 £162 £217 £273 
GPiT refer 
only high 
risk 
0.2112 £173 0.0059 -£120 £179 £238 £297 
GPiT no 
referral 
0.2115 £159 0.0062 -£134 £196 £257 £319 
Note: Figures in bold denote the preferred strategy on the basis of maximum net benefit for 
each value of the ceiling ratio.
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Table 66: Results for alternative assumption about prognosis of non true TIA on 
adverse events (major haemorrhage) [two fold increase in events in mimic 
population], lifetime horizon 
  Total 
QALYs/ 
patient 
Total 
costs/ 
patient 
Inc. 
QALYS 
vs. 
current 
practice 
Inc. 
costs vs. 
current 
practice 
Net 
benefit at 
a 
£10,000 
ceiling 
ratio 
Net 
benefit at 
a 
£20,000 
ceiling 
ratio 
Net 
benefit at 
a  
£30,000 
ceiling 
ratio 
Current 
practice 
8.8870 £2,055           
Best 
practice 
9.1439 £1,477 0.2569 -£578 £3,147 £5,717 £8,286 
GPiT 9.1976 £926 0.3106 -£1,129 £4,236 £7,342 £10,449 
GPiT refer 
only high 
risk 
9.1976 £932 0.3106 -£1,123 £4,229 £7,335 £10,441 
GPiT no 
referral 
9.1976 £925 0.3106 -£1,130 £4,236 £7,343 £10,449 
Note: Figures in bold denote the preferred strategy on the basis of maximum net benefit for 
each value of the ceiling ratio.
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Table 67: Adjustment for poor outcomes following carotid surgeries not performed in 
Current practice and GPiT alternative 2 (no referral to a specialist), 90 days 
  Total 
QALYs/ 
patient 
Total 
costs/ 
patient 
Inc. 
QALYS 
vs. 
current 
practice 
Inc. 
costs vs. 
current 
practice 
Net 
benefit at 
a 
£10,000 
ceiling 
ratio 
Net 
benefit at 
a 
£20,000 
ceiling 
ratio 
Net 
benefit at 
a  
£30,000 
ceiling 
ratio 
Current 
practice 0.2053 £293           
Best 
practice 0.2100 £190 0.0047 -£104 £104 £197 £243 
GPiT 
0.2108 £187 0.0055 -£107 £162 £217 £273 
GPiT refer 
only high 
risk 
0.2112 £173 0.0059 -£120 £179 £238 £297 
GPiT no 
referral 0.2115 £159 0.0062 -£134 £196 £258 £319 
Note: Figures in bold denote the preferred strategy on the basis of maximum net benefit for 
each value of the ceiling ratio.
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Table 68: Adjustment for poor outcomes following carotid surgeries not performed in 
Current practice and GPiT alternative 2 (no referral to a specialist), lifetime horizon 
  Total 
QALYs/ 
patient 
Total 
costs/ 
patient 
Inc. 
QALYS 
vs. 
current 
practice 
Inc. 
costs vs. 
current 
practice 
Net 
benefit at 
a 
£10,000 
ceiling 
ratio 
Net 
benefit at 
a 
£20,000 
ceiling 
ratio 
Net 
benefit at 
a  
£30,000 
ceiling 
ratio 
Current 
practice 
8.8870 £2,055           
Best 
practice 
9.1439 £1,477 0.2569 -£578 £3,147 £5,717 £8,286 
GPiT 9.1977 £926 0.3107 -£1,129 £4,236 £7,343 £10,450 
GPiT refer 
only high 
risk 
9.2002 £955 0.3132 -£1,100 £4,232 £7,365 £10,497 
GPiT no 
referral 
9.2098 £1,040 0.3228 -£1,015 £4,244 £7,472 £10,701 
Note: Figures in bold denote the preferred strategy on the basis of maximum net benefit for 
each value of the ceiling ratio.
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Table 69: Adjustment for variation in utility values used (van Exel et al., 2004)), 90 
days 
  Total 
QALYs/ 
patient 
Total 
costs/ 
patient 
Inc. 
QALYS 
vs. 
current 
practice 
Inc. 
costs vs. 
current 
practice 
Net 
benefit 
at a 
£10,000 
ceiling 
ratio 
Net 
benefit 
at a 
£20,000 
ceiling 
ratio 
Net 
benefit 
at a  
£30,000 
ceiling 
ratio 
Current 
practice 0.1779 £293           
Best 
practice 0.1801 £190 0.0022 -£104 £104 £148 £171 
GPiT 
0.1805 £187 0.0026 -£107 £133 £159 £185 
GPiT refer 
only high 
risk 
0.1807 £173 0.0029 -£120 £149 £178 £207 
GPiT no 
referral 0.1809 £159 0.0030 -£134 £165 £195 £225 
Note: Figures in bold denote the preferred strategy on the basis of maximum net benefit for 
each value of the ceiling ratio.
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Table 70: Adjustment for variation in utility values used (van Exel et al., 2004), 
lifetime horizon 
  Total 
QALYs/ 
patient 
Total 
costs/ 
patient 
Inc. 
QALYS 
vs. 
current 
practice 
Inc. 
costs vs. 
current 
practice 
Net 
benefit at 
a 
£10,000 
ceiling 
ratio 
Net 
benefit at 
a 
£20,000 
ceiling 
ratio 
Net 
benefit at 
a  
£30,000 
ceiling 
ratio 
Current 
practice 
7.6358 £2,055           
Best 
practice 
7.8175 £1,477 0.1817 -£578 £2,395 £4,212 £6,029 
GPiT 7.8555 £926 0.2197 -£1,129 £3,326 £5,524 £7,721 
GPiT refer 
only high 
risk 
7.8565 £932 0.2207 -£1,123 £3,330 £5,537 £7,744 
GPiT no 
referral 
7.8559 £925 0.2201 -£1,130 £3,330 £5,531 £7,731 
Note: Figures in bold denote the preferred strategy on the basis of maximum net benefit for 
each value of the ceiling ratio.
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Table 71: Variation in lifetime cost of stroke (50% increase in all long-term care 
costs), 90 days 
  Total 
QALYs/ 
patient 
Total 
costs/ 
patient 
Inc. 
QALYS 
vs. 
current 
practice 
Inc. 
costs vs. 
current 
practice 
Net 
benefit at 
a 
£10,000 
ceiling 
ratio 
Net 
benefit at 
a 
£20,000 
ceiling 
ratio 
Net 
benefit at 
a  
£30,000 
ceiling 
ratio 
Current 
practice 
8.8870 £4,109           
Best 
practice 
9.1439 £2,953 0.2569 -£1,156 £3,725 £6,295 £8,864 
GPiT 9.1977 £1,851 0.3107 -£2,258 £5,365 £8,472 £11,579 
GPiT refer 
only high 
risk 
9.1979 £1,863 0.3109 -£2,246 £5,355 £8,464 £11,573 
GPiT no 
referral 
9.1982 £1,850 0.3112 -£2,260 £5,372 £8,484 £11,596 
Note: Figures in bold denote the preferred strategy on the basis of maximum net benefit for 
each value of the ceiling ratio.
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Table 72: Varying the discount rate (Undiscounted costs and benefits), lifetime 
horizon 
  Total 
QALYs/ 
patient 
Total 
costs/ 
patient 
Inc. 
QALYS 
vs. 
current 
practice 
Inc. 
costs vs. 
current 
practice 
Net 
benefit at 
a 
£10,000 
ceiling 
ratio 
Net 
benefit 
at a 
£20,000 
ceiling 
ratio 
Net 
benefit at 
a  
£30,000 
ceiling 
ratio 
Current 
practice 10.6198 £2,441           
Best 
practice 10.9268 £1,754 0.3070 -£686 £3,757 £6,827 £9,897 
GPiT 
10.9911 £1,100 0.3713 -£1,341 £5,054 £8,766 £12,479 
GPiT refer 
only high 
risk 
10.9913 £1,107 0.3715 -£1,334 £5,049 £8,764 £12,479 
GPiT no 
referral 10.9917 £1,099 0.3719 -£1,342 £5,061 £8,780 £12,499 
Note: Figures in bold denote the preferred strategy on the basis of maximum net benefit for 
each value of the ceiling ratio.
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Table 73: Varying the discount rate (6% costs and benefits), lifetime horizon 
  Total 
QALYs/ 
patient 
Total 
costs/ 
patient 
Inc. 
QALYS 
vs. 
current 
practice 
Inc. 
costs vs. 
current 
practice 
Net 
benefit at 
a 
£10,000 
ceiling 
ratio 
Net 
benefit at 
a 
£20,000 
ceiling 
ratio 
Net 
benefit at 
a  
£30,000 
ceiling 
ratio 
Current 
practice 
6.6409 £1,824           
Best 
practice 
6.8329 £1,311 0.1920 -£513 £2,433 £4,353 £6,273 
GPiT 6.8730 £822 0.2322 -£1,002 £3,324 £5,645 £7,967 
GPiT refer 
only high 
risk 
6.8732 £827 0.2323 -£997 £3,320 £5,643 £7,966 
GPiT no 
referral 
6.8734 £821 0.2326 -£1,003 £3,328 £5,654 £7,980 
Note: Figures in bold denote the preferred strategy on the basis of maximum net benefit for 
each value of the ceiling ratio.
 243 
 
 
Appendix 7: Application of the CHEERS checklist to the GPiT model. 
CHEERS checklist reproduced from Husereau (2013). 
Section/item 
Item 
No Recommendation 
Reported 
on page 
No 
Title and abstract 
Title 1 Identify the study as an economic 
evaluation or use more specific terms such 
as “cost-effectiveness analysis”, and 
describe the interventions compared. 
p.80 
Abstract 2 Provide a structured summary of 
objectives, perspective, setting, methods 
(including study design and inputs), results 
(including base-case and uncertainty 
analyses), and conclusions. 
Abstract 
Introduction 
Background and 
objectives 
3 Provide an explicit statement of the 
broader context for the study. 
pp.80-82 
Present the study question and its 
relevance for health policy or practice 
decisions. 
 
Methods 
Target population 
and subgroups 
4 Describe characteristics of the base-case 
population and subgroups analysed, 
including why they were chosen. 
pp. 85-7 
Setting and 
location 
5 State relevant aspects of the system(s) in 
which the decision(s) need(s) to be made. 
pp. 85-7 
Study perspective 6 Describe the perspective of the study and 
relate this to the costs being evaluated. 
pp.89-90 
Comparators 7 Describe the interventions or strategies 
being compared and state why they were 
chosen. 
 
Time horizon 8 State the time horizon(s) over which costs 
and consequences are being evaluated 
and say why appropriate. 
p.90 
Discount rate 9 Report the choice of discount rate(s) used 
for costs and outcomes and say why 
appropriate. 
p.90 
Choice of health 
outcomes 
10 Describe what outcomes were used as the 
measure(s) of benefit in the evaluation and 
their relevance for the type of analysis 
performed. 
p.96 
Measurement of 
effectiveness 
11a Single study-based estimates: Describe 
fully the design features of the single 
effectiveness study and why the single 
study was a sufficient source of clinical 
effectiveness data. 
n/a 
11b Synthesis-based estimates: Describe fully pp.102-122 
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Section/item 
Item 
No Recommendation 
Reported 
on page 
No 
the methods used for identification of 
included studies and synthesis of clinical 
effectiveness data. 
    
Measurement and 
valuation of 
preference based 
outcomes 
12 If applicable, describe the population and 
methods used to elicit preferences for 
outcomes. 
pp.122-3 
Estimating 
resources and 
costs 
13a Single study-based economic 
evaluation: Describe approaches used to 
estimate resource use associated with the 
alternative interventions. Describe primary 
or secondary research methods for valuing 
each resource item in terms of its unit cost. 
Describe any adjustments made to 
approximate to opportunity costs. 
 
13b Model-based economic 
evaluation: Describe approaches and data 
sources used to estimate resource use 
associated with model health states. 
Describe primary or secondary research 
methods for valuing each resource item in 
terms of its unit cost. Describe any 
adjustments made to approximate to 
opportunity costs. 
p.125 
Currency, price 
date, and 
conversion 
14 Report the dates of the estimated resource 
quantities and unit costs. Describe 
methods for adjusting estimated unit costs 
to the year of reported costs if necessary. 
Describe methods for converting costs into 
a common currency base and the 
exchange rate. 
pp.125-8 
Choice of model 15 Describe and give reasons for the specific 
type of decision-analytical model used. 
Providing a figure to show model structure 
is strongly recommended. 
p.88; p.91-3 
Assumptions 16 Describe all structural or other 
assumptions underpinning the decision-
analytical model. 
p.90-6 
Analytical methods 17 Describe all analytical methods supporting 
the evaluation. This could include methods 
for dealing with skewed, missing, or 
censored data; extrapolation methods; 
methods for pooling data; approaches to 
validate or make adjustments (such as half 
pp.105-135; 
pp.135-152 
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Section/item 
Item 
No Recommendation 
Reported 
on page 
No 
cycle corrections) to a model; and methods 
for handling population heterogeneity and 
uncertainty. 
Results 
Study parameters 18 Report the values, ranges, references, 
and, if used, probability distributions for all 
parameters. Report reasons or sources for 
distributions used to represent uncertainty 
where appropriate. Providing a table to 
show the input values is strongly 
recommended. 
pp.215-9 
Incremental costs 
and outcomes 
19 For each intervention, report mean values 
for the main categories of estimated costs 
and outcomes of interest, as well as mean 
differences between the comparator 
groups. If applicable, report incremental 
cost-effectiveness ratios. 
pp.167-9; 
p.176 
Characterising 
uncertainty 
20a Single study-based economic 
evaluation: Describe the effects of 
sampling uncertainty for the estimated 
incremental cost and incremental 
effectiveness parameters, together with the 
impact of methodological assumptions 
(such as discount rate, study perspective). 
n/a 
20b Model-based economic 
evaluation: Describe the effects on the 
results of uncertainty for all input 
parameters, and uncertainty related to the 
structure of the model and assumptions. 
pp.178-189 
Characterising 
heterogeneity 
21 If applicable, report differences in costs, 
outcomes, or cost-effectiveness that can 
be explained by variations between 
subgroups of patients with different 
baseline characteristics or other observed 
variability in effects that are not reducible 
by more information. 
n/a 
 
Discussion 
Study findings, 
limitations, 
generalisability, 
and current 
knowledge 
22 Summarise key study findings and 
describe how they support the conclusions 
reached. Discuss limitations and the 
generalisability of the findings and how the 
findings fit with current knowledge. 
Discussion 
chapter  
pp. 192-207 
Other 
Source of funding 23 Describe how the study was funded and 
the role of the funder in the identification, 
Preface 
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Section/item 
Item 
No Recommendation 
Reported 
on page 
No 
design, conduct, and reporting of the 
analysis. Describe other non-monetary 
sources of support. 
Conflicts of interest 24 Describe any potential for conflict of 
interest of study contributors in accordance 
with journal policy. In the absence of a 
journal policy, we recommend authors 
comply with International Committee of 
Medical Journal Editors recommendations. 
Preface 
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